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Chapter 1
The role of testosterone and luteinizing
hormone (LH) in subjective memory
complainers (SMC)
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1.1 Background
Alzheimer’s disease (AD), is the most common cause of dementia in the elderly and is
characterized by a progressive memory decline, impairments in language and visualspatial skills, impairments in behaviour, results in a loss of independence, reduction of
quality of life, and ultimately death. Although our knowledge and understanding of the
disease continues to grow, currently there are no effective treatments for reversing or
even stabilizing the process of the disease. AD remains perhaps the most devastating
disease of older people and constitutes a large social and economic burden to both the
families and society as a whole. Currently there are 30 million individuals worldwide
with dementia (Ferry, C.P et al., 2005) and some predictions indicate as much as a 4
fold increase in the prevalence of AD by 2050 (Brookmeyer et al., 2007). Thus, there is
an urgent need for better tools for diagnosis, prevention, and treatment to avoid this
upcoming epidemic.
Age is the most important known risk factor of AD. As people age, there is a normal
decline in the physiological functions of their body, in particular the hormonal
deficiency following reproductive senescence known as menopause in women and
andropause in men. A number of studies involving postmenopausal women have shown
a correlation between decreasing levels of estrogen and increased levels of beta amyloid
(A), the major component of the neuritic plaques found in the AD brain. Although the
role of testosterone in men has received less attention, it has been shown to share a
similar action to that of estrogens on the generation of the Aβ . Therefore, it has been
suggested that testosterone may have a similar role to estrogen in the relation to AD.
At present, a number of studies in the AD field focus on testosterone levels in men and
its effects on the nervous system. While the results are preliminary and the role of
androgens in the aged-related cognition is still poorly understood compared to those
studies of estrogen, it has been proposed that testosterone therapy may delay the onset
of AD in elderly men.
Luteinizing hormone (LH), one of the pituitary gonadotropin hormones, is synthesized
and secreted under the regulation of gonadotropin-releasing hormone (GnRH), pituitary
factors and gonadal hormone feedback which collectively are termed the
Hypothalamus-Pituitary-Gonadal (HPG) axis. LH is secreted in a pulsatile manner from
2

pituitary into the peripheral circulation which eventually affect target organs expressing
the LH receptor (LHR). In the gonads, LH stimulate gonadal hormone production, such
as testosterone, estrogen, progesterone, activin, and inhibin. LHR is highly expressed in
the hippocampus; a brain region involved in memory function and which is severely
affected in AD (Barron, A.M et al., 2006). Several studies also confirmed that the brain
may also be a target organ for LH (Lei, Z et al., 1993; Al-Hader, A.A et al., 1997).
However, the regulation of LHR in the brain has been largely unexplored.
In aging men, changes of LH levels have been reported with the levels of serum LH
shown to be two to three times higher than men in their mid-20s (Neaves, W.B et al.,
1984). Recent studies by Short et al., 2001

showed that high levels of LH, are

associated with AD. However, whether LH plays a direct role in AD pathogenesis still
remains unclear. Recent studies have linked testosterone depletion and perhaps LH
elevation with increased risk for the development of AD in men. It is unclear whether
the altered actions of both testosterone or LH contribute to the pathogenesis of AD. It is
unlikely that any one of the hormones from HPG axis plays a single and predominant
role in the reproductive system but rather it may be a combination of hormones acting in
concert.
This chapter will review the current understanding of the characteristics and pathogenic
mechanisms of AD, focussing on the relationship between testosterone, LH and AD. In
addition, the review will also discuss the benefits of testosterone and LH suppression in
AD.

1.2 Alzheimer’s Disease : Epidemiology and Clinical Characteristics
Alzheimer’s disease AD) is the most prevalent form of dementia, accounts for about
50-60% of all dementia cases, compared to other types of dementia, such as vascular
dementia (15-20% of the cases), Lewy body dementia (up to 20% of the cases) and
fronto-temporal dementia (approximately about 10% which is associated with a younger
age of onset) (Schulz, R., Noelker, S Linda., Rockwood, K., Sprott, R, 2006). The
number of cases with dementia as well as AD world-wide will increase as the
population grows, affecting approximately 4-5 million people in the United States and
around 15 million people worldwide (Hebert et al., 2003). Other developed countries
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such as Australia and Canada will undergo a similar pattern. Although AD is known to
be a major problem in developed countries, it already poses a great problem in
developing countries, predominantly in Asian countries where the impact of this disease
is predicted to be catastrophic if effective prevention measures are not implemented in
the near future (Ferri et al., 2005). Moreover, in Indonesia, as a developing country with
a high rate of population growth, AD cases are projected to have 295% increment
between 1990 and 2030 (Draper and Brian, 2004). The decline in fertility and
improvements in life expectancy have contributed to the aging population in Indonesia.
As seen in western countries there is a predominance women compared to men in the
older age groups which may contribute further to the dementia epidemic. Furthermore
there is a greater degree of aging in rural areas and taken together with the large rural
population in Indonesia and its associated lower socio-economic status the prevalence
of this disease will be considerable. The absolute number of people in Indonesia has
increased from 4.9 million in 1950 to 16.3 million in 2000. By 2050, it is estimated that
one in four Indonesian would be classified as an elderly person compared to one in ten
at present, resulting in 73.6 million in this population group (Fletcher Robert., 2010).
Currently there are very few facilities for the treatment and care of people with
Alzheimer’s disease and the government is poorly aware of the magnitude of this
problem and is thus unprepared to deal with the looming dementia epidemic and no
initiatives have yet been taken to develop early diagnostic and prevention programs to
combat the consequence of this devastating disease.
AD was first described in 1907 by Alois Alzheimer, a German physician who described
the neuropathology in the brain of a 51 year old woman named Augusta D. After her
death, an autopsy revealed dense deposits outside and around nerve cells in her brain,
and twisted strands of fibre inside dead neurons, which were later known as
neurofibrillary tangles and neuritic plaques, respectively. AD is characterized clinically
by the insidious onset and progressive decline of mental functions affecting long-term
episodic memory (Henderson, 1997). However, AD cannot be definitively diagnosed
until post-mortem examination of the brain for the neuropathological hallmarks of AD.
(Mirra et al., 1991). It was later discovered that the major component of neuritic plaques
is beta amyloid (Aβ), a peptide proteolytically derived from the larger amyloid
precursor protein (APP) (for review see Nunan and Small, 2000, Glenner and Wong,
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1984; Masters et al., 1985). Although more than a century has passed since Alois
Alzheimer’s findings and research has been carried out for decades around the world,
there is still many questions directed at understanding the pathogenesis of AD and there
is no effective treatment.
AD attacks several different regions of the brain including the cerebral cortex, which is
involved in conscious thought and language; the basal forebrain, which is important in
memory and learning; and the hippocampus, which is fundamental to memory storage.
AD can be divided into two forms based on the age of onset, i.e. early onset (EOAD;
the age of onset before 65 years old) and late onset (LOAD; the age of onset after 65
years old). EOAD is the more severe form but is less common and accounts for ~5-10%
of the cases. In some cases, EOAD is caused by autosomal dominant, inherited
mutations identified in three different genes, the amyloid precursor protein (APP) gene
(Goate et al., 1991; Murrell et al., 1991), the presenilin-1 (PS1) gene (Sherrington et al.,
1995) and presenilin-2 (PS2) gene (Levy-lahad et al., 1995; Rogaev et al., 1995); and
characterized by the increased production of Aβ, in particular the longer form and more
toxic Aβ42 (for review see Kowalska, 2003).
On the other hand, LOAD is the most common form of the disease, which accounts
~95% of the cases, and is characterized by several risk factors including age, the
presence of Apolipoprotein E 4 allele (APOE4) (Strittmatter et al., 1993; Martins et
al., 1995; Scheuner et al., 1996), brain trauma, diet (i.e. high levels of choleseterol), low
levels of testosterone and estrogen (Corder et al., 1993; Haskell, Richardson and
Horwitz, 1997; Short et al., 2001) and more recently increased levels of gonadotropins
i.e. luteinizing hormone (LH) and follicle stimulating hormone (FSH) (Bowen et al.,
2002; Short et al., 2001 ).
Each of the major neuropathological hallmarks of AD, namely the senile plaques,
neurofibrillary tangles, neuronal atrophy or neuronal death, and cerebral amyloid
angiopathy, (Dickson, 1997; Braak, H., and Braak, E., 1991; Poirier, 2005) will be
described below.
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Senile plaques
Senile plaques (SP) or amyloid plaques are composed of beta amyloid protein (Aβ) in
the central core surrounded by reactive astrocytes and microglia found in the brain of
Alzheimer’s disease and normal aging (Figure 1.1). As people get older, from the age of
60 years, the proportion of the people with plaques increase linearly. In AD, amyloid
plaques develop in vulnerable regions of the brain, such as hippocampus, which plays
an important role in the formation of short and long-term memory. Amyloid plaques
have variable shape and size but are on the average 50µm (Franke, M., 1976). In
addition, Amyloid plaques also spreads over time in a variety of directions into the
cerebral cortex, the area that is involved in processing of sensory input and learning
(Rodgers, 2003).
According to the amyloid hypothesis (Selkoe,D.J & Hardy,J., 2007) which was
proposed over 25 years ago, accumulation of beta amyloid in the brain is the primary
cause of AD pathogenesis. But recently, it is currently unclear whether amyloid plaques
are actually the primary cause of Alzheimer's disease (AD) or the result of an another
initiating factor. Evidence in support of this notion includes the observation that dense
plaques accumulate with age, even in people who have no cognitive impairment.
Furthermore, plaques do not correlate with disease severity (Robert,D et al.,1991). In
addition, Aβ is also deposited in the exterior of neurons in several unrelated disorders.
On the other hand, the strongest evidence in support of Aβ playing a key role in the
onset of AD may be found in the genetic studies of families with autosomal mutations
that cause AD and are all shown to result in increased production of Aβ. Interestingly it
has been suggested that smaller aggregates of Aβ (ie oligomers) and not the amyloid
plaques per se play the major role in the damaging effect on dendrites (Moolman et al.
2004;Gandy, S et al., 2010; Selkoe, D.J, 2000). Furthermore, while amyloid plaques per
se do not correlate with the severity of the disease there is strong evidence to
demonstrate that soluble Aβ levels, which lead to the development of the amyloid
plaques do correlate with disease severity. Additional genetic evidence for the role of
amyloid in AD is found in patients with Down syndrome (trisomy 21) and it is proven
that most people with Down syndrome will go on to develop AD (Wisniewski et al.,
1985).
6

Neurofibrillary tangles
Neurofibrillary tangles (NFT) are intracellular lesions composed of abnormal insoluble
filaments which is paired helical filaments and straight filaments of abnormally
phosphorylated tau protein accumulates within the neuron (Goedert et al., 2002). Tau is
a microtubule associated protein found in neuronal axons throughout the central and
peripheral nervous systems and to a lesser extent in glial cells. Tau protein is a potent
promoter of tubulin polymerisation and microtubule stabilisation, thus serving an
important role of neuronal outgrowth and morphology (Lovestone and McLoughlin,
2002). There are six isoforms of tau in CNS, differing by possession of N-terminal
inserts of unknown function and by possession of three or four imperfect repeats that
bind to microtubules (Goedert et al., 1996). NFTs are found predominantly in neuronal
cell bodies surrounding SPs. But NFTs also may occur without SPs (Shukla and
Bridges, 1999). The number and distribution of NFTs shows a moderate correlation
with the severity of AD (Schonheit et al., 2004).
The hyperphosporylation of tau has not only been associated with AD but also with a
number of other neurological diseases such as fronto-temporal dementia, Pick’s disease,
cortico-based degeneration, and progressive supranuclear palsy (Goedert et al., 2006)
However, the mechanism that trigger the tau hyperphosporylation are still unclear.
As mutations in tau give rise to tangles but mutations in APP give rise to both plaques
and tangles, it follows that Aβ must, biochemically, precede tau pathology in AD. This
is consistent with the studies on Down’s syndrome brain where it was shown that
amyloid deposition preceded tangle aggregation REFS. The relative importance of Aβ
deposition and neurofibrillary tangles in the onset of dementia in AD has been a subject
of intense debate between amyloid and tau proponents, known as “baptists” and
“tauists” respectively (Hardy and Selkoe, 2002). However, recently there are some in
vitro and in vivo findings which suggested that both Aβ and tau play important roles in
AD (LaFerla, F.M, 2008; Wilson, D.M and Binder, L.I, 1997; Eckert, A et al., 2010).
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Figure 1.1 : Senile plaque and neurofibrillary tangle. Image courtesy of
www.maryjosephfoundation.blogspot.com

Cerebral amyloid angiopathy (CAA)
Cerebral amyloid angiopathy (CAA) is an accumulation of amyloid in cerebral and
meningeal blood vessels. CAA is observed in more than 80% of AD brains (Attems et
al., 2007). However, some level of CAA can also be found in the brains of nondemented elderly. There is now considerable evidence that CAA is a major factor in the
pathogenesis of AD (Fryer et al., 2005; Martins et al., 2006 (Maia et al., 2007)

1.2.1 Aβ and Alzheimer’s disease
Aβ is the major protein component of neuritic plaques in the brain of AD patients. Aβ,
a 4kDa small oligopeptide, is generated from the proteolytic processing of its much
larger, 100-130 kDa parent molecule, the amyloid precursor protein (APP) (Glenner and
Wong, 1984, Masters et al., 1985), the gene for which is located on chromosomes 21,
expressed in brain and in several peripheral tissues such as testis, ovary, liver, kidney,
spleen, pancreas, and salivary gland (Johnson-Wood et al., 1997); Beer, J et al., 1995;
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Bates et al., 2009). Aβ which varies in length from 39 to 42 residues is not the result of
abnormal or pathological APP processing, as was originally believed, but it is secreted
constitutively by normal cells in culture (Haas et al., 1992; Shoji et al., 1992) and can
be detected in plasma and CSF of healthy humans (Seubert et al., 1992).
Aβ generated in intracellular organelles can be secreted into the extracellular space.
The most common isoforms are Aβ40 and Aβ42; the shorter form is typically produced
by cleavage that occurs in the endoplasmic reticulum, while the longer form is produced
by cleavage in the trans-Golgi network. The Aβ40 form is the more common of the two,
but Aβ42 is the more fibrillogenic and is thus associated with disease states. The major
species of secreted Aβ is the soluble Aβ40 found in the CSF at low nano-molar
concentrations (Vigo-Pelfrey, et al., 1993). Although Aβ is soluble in biological fluids
and tissue at physiological concentrations (Mulnard et al., 2000 ; Shumaker et al.,
2003), at higher concentrations it aggregates to form extracellular deposits found in AD
plaque (Lenner and Wong, 1988) . Aβ42 is dominantly found in amyloid plaques of AD
brains and is thought to seed the deposition of Aβ40. These amyloidogenic proteins
have characteristics such as being insoluble in water and having a high β-sheet
secondary structure that is associated with a tendency to aggregate or polymerize.
Ultrastructurally the deposits are mainly fibrillar and show characteristic apple-green
birefringence when viewed under polarized light after Congo red staining (AsamiOdaka et al., 1995; Wisniewski, and Frangione, 1992; Goodenough, Engert and Behl,
2000).
Aβ is secreted from CNS into the extracellular space via transport through the bloodbrain barrier (BBB) and/or via the ISF bulk flow, allowing its detection in the CSF and
plasma (for review see Zlokovic, 2004) and its oligomers are stable molecules that can
exist for long periods in the brain prior to conversion to fibrillar structures (Chromy, et
al., 2003). It is of particular interest to understand which form of Aβ is toxic to neurons.
A study by Dodart et al., 1999 showed that it is not the number or the concentration of
Aβ plaques that predict the extent of memory deficits but the levels of soluble Aβ
peptides. In addition, soluble Aβ peptide are also implicated in spatial learning deficits
in APP transgenic mice (Koistinaho et al., 2001).

9

The fundamental mechanisms underlying the neuronal toxicity of Aβ are complex and
not well understood yet. Aβ toxicity may be induced by two proposed pathways : the
first pathway implies that Aβ directly causes injury to the cell by membrane damage
(Mark, et al., 1997) while in the second pathway Aβ acts indirectly by enhancing
neuronal vulnerability to neurotoxic insults, such as excitotoxicity, hypoglycaemia,
oxidative stress or metabolic impairment (Arias et al., 2002; Matson et al., 1992). These
different pathways may result from the action of different forms of Aβ. This is
consistent with not only the aggregated forms of Aβ being neurotoxic (Lorenzo, et al.,
1994), but also the overwhelming evidence in support of soluble oligomeric forms
being neurotoxic (Roher, et al., 1996; Etcheberrigaray, E et al., 1994, Walsh et al.,
2002; Wang et al., 2002).
Aβ not only possesses neurotoxic properties but is also shown under specified
conditions to exhibit neurotrophic properties (Rismann et al., 2002). Aβ is not toxic to
undifferentiated neurons regulated by cyclin dependent kinase 5 (Cdk-5) but toxic to
differentiated neurons (Koo, et al., 1993; Koo et al., 1994). In addition, recent findings
by Verdile et al (personal communication) indicates that Aβ production increases only
in the late event of the neuronal cell cycle.

1.2.2 The Amyloid Precursor Protein (APP)
APP is an integral membrane protein, with a small intracellular domain and a large
extracellular domain; it is hypothesized that the extracellular domain mediates cell-cell
signalling, while the intracellular domain relays those signals to the rest of the cell. APP
has an important role in helping neurons grow and survive and also may help damaged
neurons repair themselves, especially after brain injury (Rodgers, 2003). It also plays a
role in cell adhesion, apoptosis, cell signalling, and as a cell surface receptor (for review
see Zheng and Koo, 2006). APP is widely expressed in cells throughout the body where
the amount produced is influenced by the developmental and physiological state of the
cells. There are 10 isoforms of APP ranging from 563 to 770 amino acids. Of these
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isoforms APP 695 is the most abundant form in the brain, produced mainly by neurons
(Matson, M.P., 1997).
The generation of Aß from APP is complex, as the APP protein is cleaved several times
in the cell. APP is normally cleaved by three secretase genes, called α, β, or γsecretase.The proteolytic cleavage of APP, a type I transmembrane protein, is
metabolized by two competing pathways which are the amyloidogenic and the nonamyloidogenic pathways (Figure 1.2). In the non-amyloidogenic pathway, APP is
processed by an α-secretase that cleaves within the Aβ region (thus precluding its
formation), resulting in the release of a soluble ~110–120 kDa N-terminal APP
fragment (sAPPα) from the cell surface. This pathway also releases a C-terminal
fragment (CTF) that is 83 amino acids in length (C83) which remains in the cell
membrane with a relative long half life and can be detected to different extents in
metabolically labelled cells (Oltersdorf et al., 1990). The C83 fragment can also be
cleaved by a γ-secretase to release a small, non-toxic 3 kDa fragment known as p3.
(Siman, R., Mistretta, S., Durkin, J.T., et al., 1993). Cleavage of APP by α-secretase is
the major proteolytic pathway, and there are candidates for α-secretase such as
ADAM10, ADAM17, ADAM 19, and TACE (Sangram, S.S et al., 2007). Although
recent studies suggest that the constitutively active α- secretase is ADAM 10
(Lichtenthaler, 2011).Only a small fraction of the total APP is cleaved by α-secretase in
most cell types, resulting in the intact of APP (Strooper and Annaert, 2000). Cholesterol
is thought to modulate the APP processing pathways. When cholesterol levels are low
APP is preferentially metabolized via the non-amyloidogenic pathway where it is
cleaved by α-secretase whilst at high cholesterol levels APP is metabolized by βsecretase (BACE) and γ-secretase through the amyloidogenic pathway (Kojro, E et al.,
2001).; Ian, J.M et al., 2009).
In the amyloidogenic pathway, APP is cleaved first at the N-terminus of the Aβ peptide
sequence by β-secretase (BACE) releasing an APPβ fragment and leaving a 99 amino
acid CTF embedded in the membrane (C99). The C99 fragment is then subsequently
cleaved by γ-secretase, within its intra-membrane region to release the Aβ peptide and
AICD . The result is the generation of Aβ40 and Aβ42. BACE has been identified as the
protein that contains β-secretase activity and homologues to the pepsin family of
11

aspartyl proteases (Vassar, R et al., 1999). The BACE-1 protein appears to be the major
enzyme in the amyloidogenic pathway and is highly expressed in neurons (Fluhrer, R et
al., 2002).
γ-secretase is a protein complex within the lipid bilayer that cleaves within one of the
transmembran regions of the APP, which is the C-terminal end of the Aβ sequence and
it is formed by presenilins (PS), nicastrin, Aph-1 and Pen-2 (Francis, R et al., 2002).
The participation of PS in the pathogenesis of AD can be seen in many cases of familiar
AD (FAD) (see review of Davis, J.N et al., 1997). The cellular sites of γ-secretase
activity remain controversial. Study by Kaether et al., 2006 found that intracellular
generated by γ-secretase is at the plasma membrane and/or early endosomes (Kaether et
al., 2006).

Figure 1.2 : Schematic representation of APP processing. The proteolytic cleavage
of APP resulted in two pathways : the amyloidogenic and non-amylodogenic pathways
(kngreen.googlepages.com)
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Changes in the activity of the secretase proteins can impact on Aβ genesis. If αsecretase activity decreases, or β-secretase activity increases, more Aβ will be formed.
As expected, several mutations in these secretases have been found in human AD
patients that affect secretase activity. In addition, mutations in APP itself can favor the
generation of the Aβ42 product, which is more pathogenic than the Aβ40 product.
Interestingly, α and γ cleavage appears to occur extracellularly, while BACE and γ
cleavage occurs entirely in the endosomal-lysosomal compartment (Kaether et al.,
2006). Some studies also show that the mis-sense mutations in PS1 and PS2 genes,
which can often be found in families with early onset AD, result in the increased
production of Aβ42 peptide as opposed to the less amyloidogenic Aβ40 form of the
peptide (Selkoe, 1998). In the Alzheimer’s Disease & Frontotemporal Dementia
Mutation Database by July there are 25 pathogenic mutations in APP, 155 in PS1, and
10 in PS2 (Cruts and Rademarkers, 2006; http://www.molgen.ua.ac.be/ADMutations/).

1.3 ApoE and Alzheimer’s disease
Human apolipoprotein E (apoE [protein], APOE [gene]) is located on the long arm of
chromosome 19q 13.2 ( Olaisen, Teisberg and Gedde-Dahl, 1982; Das et al., 1985;
Strittmatter et al., 1993) with a molecular mass 34.2 kDa and is synthesized mainly in
the liver, and the brain, as well as circulating

cells

including macrophages and

monocytes (Siest, G, et al., 1995). ApoE plays an important role in the periphery as a
mediator of lipoprotein metabolism and lipid clearance. In the central nervous system its
importance is underscored by the low abundance of other apolipoproteins and plays a
role in the redistribution of lipid and cholesterol during membrane repair and believed
to be important for maintaining synaptic plasticity especially after neuronal injury. One
of the first indication that apoE might be involved in AD came from the
immunochemical localization of apoE in extracellular amyloid plaques and in neurons
containing neurofibrillary tangles (Wisniewski, T et al.,1992).
ApoE serves as a ligand for low density lipoprotein receptor (LDLR and LDLRP). The
three major isoforms of APOE : E2, E3, and E4, are encoded by distinct alleles ε2, ε3,
and ε4 and therefore have six phenotypes (Utermann et al., 1980); Zannis et al., 1982.
They differ in having cysteine (Cys) or arginine (Arg) at amino acid positions 112 and
13

158 and vary in their metabolic properties (Mahley, 1988). ApoE2 (Cys112, Cys158)
binds defectively to low density lipoprotein (LDL) receptors. ApoE3 (Cys112, Arg158)
binds normally to LDL receptors and is associated with normal lipid metabolism.
ApoE4 (Arg112, Arg158) has a relative stronger affinity than apoE3 for LDL receptors
and is associated with elevated cholesterol levels ( for review see Raber, 2004). This
isoform was first shown to be a risk factor and an increased risk for AD since 1993
(Strittmatter et al., 1993), enhanced Aβ aggregation, increased Aβ deposition, and
reduces Aβ clearance (Schemechel, D.E et al., 1993; Berr, C et al., 1994), whereas
APOE2 has a protective effect (Corder et al., 1993) compared to APOE3 (the most
common isoform).
Since it was reported that the apoEε4 allele is overpresented in AD patients,
(Strittmatter et al., 1993) several studies have examined the relation of apoE alleles to
AD pathology. Studies have shown that apoE associates with high avidity to soluble A
(Wisniewski et al., 1993; Raber et al., 2004). ApoE is also known to co-localise with
A plaques (Holtzman, 2002), and APOE 4 is associated with increased plaque density
and size (Schmechel et al., 1993; Holtzman, 2002). In clinical studies of AD,
testosterone levels in subjects without the APOE 4 allele were lower in AD cases than
in controls (Hogervorst et al., 2002). This study also found that cognitively normal
APOE 4 carriers had lower testosterone levels than individuals without the allele
(Hogervorst et al., 2002), suggesting that APOE status can affect testosterone levels.
The mechanism whereby apoE4 promotes AD is not yet established, perhaps by
accelerating plaque formation or by its association with poor neuronal repair.
Considerable evidence supports both mechanisms. In vitro study showed all apoE
isoforms inhibit Aβ aggregation with apoE4 less effectively than apoE3 (Ma et al.,
1994, Moir et al., 1999, Sanan et al., 1994), suggesting a way in which ε4 may increase
amyloid deposition. In addition, transgenic amyloid-producing mice expressing apoE4
develop less Aβ deposition than apoE knockout mice (Bales et al., 1997). These
observations consistent with an effect of apoE isoforms on Aβ aggregation in AD. AD
patients with at least one ε4 allele tend to have more amyloid deposition than do
subjects without APOE ε4 (Beffert and Poirier, 1996; Beffert et al., 1999).

14

With regard to AD development, the effect of APOE ε4 while dose-dependent, in terms
of increased risk is not definitely deterministic of developing AD. (Corder, E.H et al.,
1993). At present, the exact mechanism by which APOE ε4 affects the pathophysiology
of AD is not clear.
Plasma apoE is primarily derived from liver parenchymal cells and from macrophages
throughout the body (in a much lesser extent) whilst apoE in the CNS is known to be
derived exclusively from the brain (Linton, M.F et al., 1991). According to several
studies, Aβ is directly bound by apoE as demonstrated in vitro (Whittemore, E. R., Loo,
D. T. and Cotman, C. R, 1994; Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., et
al.,1993; Wisniewski, T, Frangione, B,1993) and has been shown to co-localize with Aβ
in AD plaques (Wisniewski, T. and Frangione, B, 1992; Namba, Y., Tomonaga, M.,
Kawasaki, H., Otomo, E. and Ikeda, K, 1991). There are conflicting reports over the
effects of apoE isoform specific differences on interactions with Aβ. Strittmater et al.,
1993 reported that apoE4 binds Aβ40 more rapidly than apoE3. In contrast, LaDu et al.,
1995 reported the opposite binding preference of apoE in HeK-293 cells, with an
apoE3-Aβ40 complex occuring more readily than the apoE4-Aβ40 complex over a wide
pH and concentration range. Subsequent studies by several groups including our own
have validated and extended the finds of LaDu et al demonstrating that apoE2 and
apoE3 binds avidly to Aβ while apoE4 binds poorly if at all under native conditions
where apoE is fully lipidated unlike the original experiments of Strittmater et al.,1993
Though many studies have examined the relation of ε4 to AD pathology, the exact role
of of apoE is yet to be elucidated.
It is not yet known whether different isoforms of apoE have different clearance
activities. One of the expectations is that apoE4 may have a significantly reduced
clearance activity when compared to others apoE isoforms. Yang et al., 1993 first
demonstrated that under in vitro conditions apoE cleared Aβ in an isoform specific
manner such apoE2 was most efficient in clearing Aβ followed by apoE3 with apoE4
showing virtually no clearance. Subsequently Sharman et al., 2010 shows that APOE
genotype significantly altered the peripheral clearance of Aβ42 in transgenic mice. ,
indicating that apoE isoforms may impact on clearance of Aβ from the brain.
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1.3.1 Cholesterol and Alzheimer’s Disease
The brain must synthesize its own cholesterol de novo, since cholesterol cannot pass the
BBB (Papadopoulos, 1993; Bjorkhem et al.,2006). Therefore, regulation of cholesterol
synthesis and metabolism in the brain is largely independent of changes in the periphery
(Bjorkhem et al., 2006). Nevertheless, there is increasing evidence from clinical,
epidemiological, and laboratory studies showing that changes in cholesterol metabolism
play a role in the pathogenesis of AD and that brain cholesterol as well as plasma
cholesterol metabolites may act as clinically relevant biomarkers (Bjorkhem et al.,
2006).
Cholesterol metabolism also appears to play an important role in the biology of APP
and Aβ production (Simons et al., 1998). Interestingly, elevated plasma cholesterol
levels were reported in individuals carrying APOE4 (Sing and Davignon, 1985;
Ehnholm et al., 1986), which is the major genetic risk factor for AD (Corder et al.,
1993; Poirier et al., 1993). However, Wolozin et al., 2006 concluded that the link
between AD and APOE4 was not directly related to cholesterol but the overall literature
indicates a close relationship between apoE4, cholesterol metabolism and the risk of
AD. In conclusion, AD may represent an interaction between several different factors
that together, contribute to its ultimate phenotype. More recently sex hormones such as
testosterone have been shown to alter Aβ production and mediate alterations in
cardiovascular risk factors particularly cholesterol metablolism. The following section
outlines age-related changes in testosterone and gonadatropins and describes
mechanisms by which these hormones contribute to AD pathogenesis.

1.4 Testosterone and its role in Alzheimer’s disease risk and pathogenesis.
1.4.1 Testosterone
Testosterone is the predominant androgen in males. Though its a hormone originally
associated with the modulation of reproductive function and secondary sexual
characteristics, testosterone is now recognized to also have a potent function in the
structure and function of the brain as well as behaviour and cognitive function. More
than 95% is secreted by the testis, which produces approximately 6-7 mg per day, about
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2500 mg each year. The normal range of plasma testosterone in males is debateable
(Carruthers et al, 2007), and varies between populations, but is generally taken to be
260 to 1080 ng/dl2 or 8.8-36.7 nmol/L which declines by age 80 to 50% of the average
value of age 20. In females, the circulating testosterone levels are typically about 10%
of those observed in men (Coffey, 1988).

Figure 1.3 : Male Hypothalamus-Pituitary-Gonadal (HPG) Axis
(http://www.homefertility.comhypothalamus.jpg)

In the normal male, testosterone is produced as follows (Figure 1.3). Gonadotropinreleasing hormone (GnRH) is secreted from the hypothalamus. This hormone acts on
the pituitary to secrete Luteinizing hormone (LH) and Follicle-stimulating hormone
(FSH). LH then stimulates the testicular Leydig cells to produce testosterone in a
pulsatile manner with a peak in the morning and lowest level in the evening.
Testosterone itself negatively inhibits GnRH release from the hypothalamus, whilst
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FSH stimulates the testicular Sertoli cells and seminiferous tubules to promote
spermatogenesis. A Sertoli cell produced hormone to reduce FSH secretion known as
inhibin. Testosterone production increases rapidly at the onset of puberty, but starts to
drop as a man approaches 30 years of age. This is further discussed discussed in section
1.4.3
In young males, testosterone acts on a number of other organ systems besides the testes,
including muscle, bone, central nervous system, prostate, bone marrow, (see review of
Tenover J.L, 1994). Testosterone within the bloodstream occurs in two forms : free and
bound. Roughly 2% of total testosterone is made up of free testosterone, which is the
most bioavailable form, and can be transported across the BBB into the CNS . The
majority is bound to sex hormone-binding globulin or SHBG (44%) and albumin (44%)
(Bates et al., 2005). Free testosterone diffuses passively through the cell membranes
into the target cell, where it binds to the specific androgen receptor (AR). The serum
free testosterone and the testosterone that binds to albumin are readily available for
biological action. As a matter of fact, albumin-bound testosterone dissociates during
tissue transit, whereas the strong binding of testosterone to SHBG will usually not allow
for substantial dissociation during the tissue transit time (Tenover J.L, 1994). The
combined free and albumin-bound testosterone (the non-SHBG bound testosterone) is
often reffered to as the “bioavailable testosterone”. However, the testosterone that is
actually available for biological action may vary according to the tissue and
pathophysiological condition, and at present a reliable androgen marker is still lacking.
Although testosterone binds to the nuclear AR in target cells, its activity is significantly
less than the more active androgen, dhydrotestosterone (DHT), and is not included in
the fraction of testosterone which can be aromatized into estradiol in tissues expressing
P450 aromatase enzyme. Hence, testosterone activity is determined by testosterone
concentrations, α-reductase and aromatase activity in the amount of available tissue
such as adipose tissue that converts it to estrogen, together with the level of expressions
of the androgen receptor (AR) (Janowsky, J.S, 2006).
Male aging is associated with a gradual, progressive decline in serum levels of total
testosterone, bioavailable testosterone, and free testosterone in an approximate 1%
annual decline after age 30. In cross-sectional and longitudinal studies of men aged 30
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or 40 years and above, total, bioavailable and free testosterone concentrations fall with
increasing age with a steeper decline in bioavailable and free testosterone compared
with total testosterone concentrations ( Harman et al., 2001; Feldman, H.A, 2002; Liu et
al., 2007).
Androgen receptors (AR) are found in brain regions involved in memory and cognition,
particularly the hippocampus and the frontal regions. The hippocampus has been
studied extensively as it is vulnerable to the course of aging and essential to successful
spatial navigation performance in animals and humans (see review Driscoll et al.,
2005). The hippocampus is a target structure for gonadal steroids with a relatively high
concentration of androgen receptors, suggesting a likely relationship between AR and
hippocampus-dependent cognition.

1.4.2 Testosterone synthesis (Steroidogenesis).
The conversion of cholesterol into androgens takes place in Leydig cells. Although
Leydig cells are of major importance for the generation of circulating androgenic
hormones, the adrenal cortex also contributes to this production. The production of
steroids (steroidogenesis) is not limited to endocrine glands only, but in very small
amounts can also be produced in brain cells (Baulieu, 1997). Although the contribution
of cells in the nervous system to circulating hormone is very small, local production of
steroids can be physiologically very important (King et al., 2002) especially when
transport and clearance are low.
The initial step in steroidogenesis is the conversion of cholesterol to pregnenolone
(PREG) on the inner mitochondrial membrane by the enzyme cytochrome P450 side
chain cleavage (P450scc). The amount of P450scc protein can be regulated directly by
hormone-dependent phosphorylation. When the amount of P450scc is constant,
cholesterol is being transferred from the outer mitochondrial membrane to the inner
mitochondrial membrane, which is deficient in cholesterol. And then PREG converted
to progesterone (PROG), which is the first biologically important steroid in the
pathway, by the enzyme 3β-hydroxysteroid dehydrogenase-isomerase (3β-HSD) in the
endoplasmic reticulum, or to dihydroepiandrosterone (DHEA) by cytochrome P450c17.
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P450c17 is a key branching point in steroid hormone synthesis, directing pregnenolone
towards the sex steroids (both hydroxylation and cleavage activities of the enzyme), the
glucocorticoids (only hydroxylation) or the mineralocorticoids, if neither of the enzyme
activities is participating The former pathway results in the synthesis of of PROG and
PROG metabolites. The latter pathways results in the formation of testosterone via
conversion of andronestedione by 17β-HSD. Testosterone can in turn be converted into
estradiol via the enzyme P450 aromatase (Figure 1.4).

Figure 1.4 : Steroid hormone synthesis pathways in CNS. All steroid hormones are
synthesized from cholesterol and the end products can be classified according to their
principal effects; mineralocorticoids (aldosterone), glucocorticoids (cortisol in human,
corticosterone

in

rodents),

progestins,

androgens

and

estrogens

(http://herkules.oulu.fi/isbn951426844X/html/graphic99.png).

Brain steroid synthesis proceeds in the following manner. First, glutamate is released
from the presynapse induces a Ca
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2+

influx through the NMDA receptors. The Ca

2+

influx drives STAR or peripheral benzodiazepine receptor (Papadopoulos, 1993) to
transport the cholesterol to the mitochondria. The following process of steroidogenesis
is similar to that in Leydig cells.
1.4.3 Testosterone and Aging
Age-related changes occur in numerous physiological systems. Research indicates that
in both human and non-human animals gonadal function is compromised in aged
individuals. Unlike the marked changes in the sex hormones that accompany
menopause in females, the analogous process in males, termed andropause or partial
androgen deficiency in the aging male (PADAM), is characterized by a subtle and
generally gradual decline in circulating testosterone levels. It has been estimated that
testosterone levels decrease on average at a rate of 1% yearly after 30 years of age (
(Rajfer, Jacob,2003) but with variations between individuals and reflecting their state of
health. This reduction in hormone levels has a number of physiological and
psychological effects. It can manifest in the aging male as sexual dysfunction, loss of
muscle and bone mass, increased frailty, depression, and cognitive impairment (Bates et
al., 2005). Eventually, it will lead to an increased risk of developing AD. It has been
reported that the primary site of decreasing testosterone in aging is its biosynthesis in
Leydig cells ( Rajfer, Jacob, 2003). The rate limiting step of testosterone biosynthesis is
transfer of the cholesterol to the inner membrane of mitochondria to start the
steroidogenic process as mentioned above.
In a recent study by Thilers and colleagues (1995), a significant correlation between
circulating testosterone levels and cognitive function in aged man was found. Lower
testosterone levels were related to reduced cognitive performance. Low levels of
testosterone may also be associated with AD where lower free testosterone levels are
observed when compared to age-matched controls (Hogervorst et al., 2004). In addition,
blood plasma testosterone levels from a large longitudinal study of men age 32-87 years
has shown that low free testosterone levels can be detected 5 years prior to AD
diagnosis (Moffat et al., 2004). However, Geerlings et al., 2006 showed that
endogenous testosterone levels were not associated with risk for cognitive decline in a
group of men aged 71–93 yrs over the 6 years of this latter study.
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In order to elucidate the relationship between circulating levels of testosterone and
cognition in aging men, the understanding of bioavailable testosterone and total
testosterone in plasma or serum was needed. There is a curvilinear relationship observed
between sex steroid levels and cognitive functions (see review by Bates et al., 2005).
Studies in humans concerning the relationship between endogenous androgen levels and
cognitive performance have produced inconsistent results, although there do exist
striking sex differences in spatial abilities (Kimura, D., 1996). These inconsistent results
could be explained in part by the fact that each study employed different preparations
and doses of testosterone, and participants were treated for various durations, and the
selection criteria for each target population was different.
The relationships between aging and a decline of sex steroid levels remains to be fully
elucidated, particularly when it applies to age-related disorders such as AD and the
effects in the brain, an androgen-responsive tissue. Evidence indicates that the brain is a
steroidogenic organ, with the ability to synthesize steroid hormones from cholesterol.
The steroids produced in the brain and accumulate in the nervous system are termed
neurosteroids (Mellon, S.H et al., 2001; Plassart-Schiess E. and Baulieu E.E, 2001). In
the brain, testosterone can be metabolized to dhydrotestosterone (DHT) and bind to
androgen receptors (AR). Or it can be converted to estradiol by the enzyme aromatase.
Both androgen receptor (AR) and aromatase are found in regions of the brain involved
in memory and learning, including the hippocampus and amygdala (Janowsky, J.S,
2006; McEwan,I.J, 2004).
Testosterone inhibits generation of Aβ in the rat brain (Ramsden, M, 2003), reduces Aβinduced neurotoxicity in culture (Pike, C.J., 2001), prevents hyperphosphorylation of
tau (Papasozomenos, S.C, and Shanavas, A, 2002), and protects against oxidative stress
(Ahlbom, E, et al., 2001). Moreover, testosterone supplementation in aged rats reduces
glial fibrillary acidic protein (GFAP) expression (Day, J.R., 1998) commonly observed
in the aging brain in association with inflammatory cytokine. Gouras and colleagues,
2000 showed that treating cells with testosterone reduced Aβ secretion by promoting
the non-amyloidogenic processing of APP and stimulating the production of αAPPs,
which has been shown to have neurotrophic and neuroprotective properties These in
vitro and in vivo studies indicate the beneficial role for testosterone supplementation in
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the aging organism and some mechanisms by which testosterone may exert its effects
on the brain.

1.4.3.1 Testosterone replacement therapy
The earliest study of hormone replacement therapy (HRT) and Alzheimer’s disease was
published in 1984 by Heyman et al. Previous epidemiological studies concerning
gender differences in AD have often resulted in conflicting data (Fratiglioni et al, 1997;
Letteneur et al., 1994), yet most studies support the high prevalence and incidence for
AD in women (McGonigal et al., 1993 ; Rocca et al, 1991). Because of this genderspecific reason for AD and not to other dementias, research has been going on in
focusing on the role of sex steroids estrogen and testosterone in the pathogenesis of the
disease. In contrast to the considerable work done on estrogen replacement therapy
(ERT), clinical trials with testosterone replacement therapy (TRT) for AD have been
relatively scarce and these studies involved small samples of participants.
The relationships between aging and lower testosterone levels have led to increased
interest in the use of TRT with the aim of delaying the aging process. TRT has been
shown to be effective and beneficial for andropausal men (Matsumoto, A.M.2002;
Matsumoto, A.M.2003; Gruenewald, D.A, Matsumoto, A.M. 2003). In addition TRT
has the ability to increase bone density, muscle strength and lean body mass in
hypogonadal man (Thilers, PP et al., 2006).It has also been reported that aged man
receiving TRT exhibited increased muscle mass and strength and improvements in
cognitive performance (reviewed in Cherrier, MM, 200; Morley, J.E., 2000; Tenover,
J.S., 1992). Furthermore, an emerging area of research demonstrates that low levels of
androgen may play a role in the onset and progression of AD (Rosario, E.R et al., 2004;
Moffat, S.D et.al., 2004).
Despite nearly a half century of research on aging and sex steroids in men, answers to
key questions that would allow us to confidently assess risk to benefit ratios for
testosterone replacement in older men with hypogonadism remain uncertain. Although
it is now reasonably clear that a significant percentage of healthy older man have
decreased testosterone levels consistent with hypogonadism, the clinical implications of
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this change remain uncertain. Testosterone replacement therapy which is approved by
FDA as a treatment for male hypogonadism, has been found to be effective in
ameliorating a number of symptoms associated with low testosterone. However, there
have been fewer studies, particularly placebo controlled randomized trials, in population
of middle aged or older men who do not meet all the clinical diagnostic criteria.
Furthermore, studies of testosterone therapy in older men generally have been of short
duration, involving only a small number of participants, and often lacking adequate
controls. In its review from the literature Free Executive Summary about testosterone
and aging : clinical research directions, 2004, the reviewers identified only 31 placebocontrolled trials of testosterone therapy in older men with the largest sample size
involved 108 participants and the duration of therapy in 25 of 31 trials was 6 months or
less. There is only one study placebo-controlled trial lasted longer than a year.
Studies that have assessed more specific domains of cognitive function in older men
have produced mixed results. In a long-term longitudinal study, 407 elderly men aged
50–91 years at baseline were assessed for cognitive status and testosterone levels. Tests
of cognitive function and behaviour included verbal and visual memory, mental status,
visuomotor scanning and attention, verbal knowledge/language, visuospatial ability and
symptoms of depression. Overall, an increased free testosterone index was associated
with improved scores on visual and verbal memory, visuospatial function and
visuomotor scanning. There is a strong biological rationale to support the potential
protective effects of testosterone against the age-related cognitive decline and the
development of dementia in men. Cognitive impairment has been observed in men with
prostate cancer undergoing chemical castration, further indicating that testosterone may
play an important part in cognitive function. Low serum testosterone levels have been
associated with low performance in cognitive tests and at least one large longitudinal
study has demonstrated that low testosterone levels are often present up to 10 years
prior to the onset of AD. In older healthy men, lower levels of endogenous testosterone
may be associated with poor performance on at least some cognitive tests. Lastly, the
results of randomized, placebo-controlled studies indicate that testosterone substitution
may have moderate positive effects on selective cognitive domains in older men with
and without hypogonadism. Similar results have been found in studies conducted in
patients with existing AD or MCI.
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Animal research demonstrated a link between reduction in testosterone levels, the
production of Aβ, and the extent of this change is influenced by the APOEε4 genotype.
As described above, several studies showed a decline in testosterone correlates with
aging in men. Some researchers proposed a relationship between the development of
AD and the reductions of testosterone. Should this hypothesis be true, links should exist
between AD, aging, cognitive decline, and reduction of testosterone and also between
testosterone replacement therapy and cognition in elderly AD men.
It is well known from the animal literature that the effects of testosterone mediated
through the androgen receptors are widespread but complex, and as such may have
specific effects on certain aspects of cognition. However, studies of exogenous
testosterone administration in men have provided mixed results. Also, there have been
relatively few studies examining the relationship between sex steroids and cognition in
older people. Many of the studies are associative in nature. The possibility remains that
low testosterone levels are an outcome of age-related cognitive decline and AD
pathology rather than a marker for the disease. It also remains unresolved whether
normal levels of testosterone are required for optimal performance on gender and age
sensitive tests, and further whether its effects are direct or occur through the conversion
of testosterone to dihydrotestosterone or estradiol. Even though most results support the
facts that testosterone can enhance cognition in older men, much research is needed to
be done before recommendations for clinical practice can be made. The results,
although by no means conclusive, indicate a role for testosterone in cognitive
processing and suggest a further investigation and replication in larger samples. There
are quite a lot of reviews about the attention that testosterone is gaining in cognition and
aging research They all recognize that before we can fully understand the
neurocognitive effects of steroid hormones, it is imperative to characterize the neural
and cognitive effects of testosterone loss and its subsequent supplementation. Both
human and non-human animal studies are needed in order to further our understanding
of the genetic and environmental effects as well as the processes that may be
influencing variability in behavior and its functional outcome with aging. An important
feature of animal models of aging and animal models in general, is that they closely
mimic the characteristics of human conditions and that they are sensitive to individual
differences. But even more imperative is to keep in mind the lessons learned from the
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animal research as we enter the decade where it is important to translating the discovery
power of neuroscience to improve the diagnosis and treatment of mental disorders.
There are lessons to be learned not only from the non-human animal studies but also the
literature investigating the effects of hormone replacement therapy in women which is
much more extensive compared to that available on men. Although the Women’s Health
Initiative Memory Study (WHIMS) (Shumaker, S.A, 2003) was terminated early as it
seemed to contradict the previous promising observations regarding HRT and the
overall health risks were unexpectedly found to outweigh the benefits, this now much
criticised trial raised awareness regarding the possible role for hormones in aging and
cognition. Now that estrogen is no longer seen as the silver bullet for AD and agerelated cognitive decline as many had hoped, the focus has shifted somewhat to
testosterone and the andropause,. But still we have to be aware that although recent
findings from observational studies and small-scale testosterone trials in elderly men are
promising, additional studies on a much larger scale are required before any conclusions
and recommendations for clinical practice can be reached for the use of testosterone in
preventing or ameliorating AD.
Information based on clinical trials as mentioned above has added to evidence for
benefits and side effects of testosterone replacement in hypogonadal patients and animal
models. In general, most researchers agree with short term safety of testosterone
replacement therapy but long term safety is still unknown. In this regard, larger longterm studies are needed. It has been estimated that approximately 5000-10000 men need
to be randomized and treated for 5-7 years to assess long term safety that if found t be
successful would serve as a general recommendation for all men (Bhasin, S.,
Buckwalter, J.G, 2001)
The discussion above outlines the importance of reductions in testosterone in AD risk
and pathogenesis and the potential of testosterone in ameliorating the cognitive decline
and neurodegeneration in AD. However, evidence from the original findings of Bowen
et al., 2000 and Short et al., 2001 and subsequent findings from our lab and others have,
implicated another hormone within the HPG axis, luteinizing hormone (LH), in AD risk
and pathogenesis. Below, I review the literature providing evindence implicating LH in
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AD risk, cognitive impairment and modulating Ab levels and discuss lowering LH
levels as a potential therapeutic strategy for AD.
1.4.4 Regulation of testosterone by LH
The hormones of the hypothalamic–pituitary–gonadal axis include gonadotropinreleasing hormone, luteinizing hormone (LH), follicle-stimulating hormone, estrogen,
progesterone, testosterone, activin, inhibin, and follistatin. Each of these hormones is
involved in regulating reproductive function by participating in a complex feedback
loop that is initiated by the hypothalamic secretion of gonadotropin-releasing hormone
(Genazzani et al., 1992). LH and its receptor are present in increased quantities in brain
regions susceptible to degeneration in AD with the most abundant in hippocampus and
known to cross the blood-brain barrier (Bowen R.L, Smith M.A, Harris P.L, et al.,
2002). LH is also known to be mitogenic, and could therefore initiate the cell cycle
abnormalities known to be present in AD-affected neurons. Therefore, it is thought that
LH plays a role in the pathology of AD. In this regard, there are epidemiological data
supporting this notion. Paralleling the female predominance for developing AD (Rocca,
et al.,1991; Jorm, et al.,1987), LH levels are significantly higher in females than males
(Zandi et al., 2002), in post-menopausal women, and are still higher in individuals who
have AD ( Short et al., 2001) Like epidemiological data, experimental data also
indicates a role for LH in AD. In this regards, experiment in cell culture showed that LH
increases amyloidogenic processing of amyloid beta protein precursor (Bowen et al.,
2004), and in animal models of AD, pharmacologic suppression of LH and FSH reduces
plaque formation, a selective GnRH agonist (leuprolide acetate) in AβPP transgenic
mouse has been shown to reduce LH to undetectable levels compared to aged matched
controls (Casadesus et al., 2006). Given the evidence supporting a pathogenic role for
LH in AD, a trial of leuprolide acetate, which suppresses LH release, has been initiated
in patients. A recently completed phase II clinical trial shows stabilization in cognitive
decline

in

a

subgroup

of

(http://clinicaltrials.gov/ct/show/nct00076440?orden=6).

These

AD

patients

promising

findings

support the importance of LH in AD and gives way for an alternative therapeutic
approach to target this insidious disease.
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LH and FSH are required for the development and maintenance of testicular functions.
LH is the most important hormone for control of Leydig cell functions and number. LH
acts on Leydig cells via LH receptors. The importance of LH receptor and its functional
properties has been learned from many studies dealing with receptor’s mutation (see
review by Themmen and Huhtaniemi 2000 , Ascoli et al., 2002).

Figure 1.5 : GnRH neurons and the hypothalamic-pituitary-gonadal axis. (A)
Gonadotropin releasing hormone (GnRH) are discharged from hypothalamic central
nervous system to stimulate the function of gonadotrophs in pituitary gland. (B) The
HPG axis. In response to gonadotropins (FSH, LH) the gonads synthesize and secrete
sex steroids (http://www.cellscience.com/Reviews5/Nunemaker5.gif).

Epidemiologic and biochemical evidence suggests that dysregulation of the
hypothalamic-pituitary-gonadal (HPG) axis with menopause/andropause may be the
common mechanism driving degenerative changes in the aging brain. This
dysregulation leads to the decline in the production of sex steroids and inhibin. The
subsequent loss of negative feedback by these hormones on the hypothalamus and
pituitary leads to increases in serum activins, increased release of hypothalamic
gonadotropin releasing hormone (GnRH), and increased synthesis and secretion of
gonadotropins. The increased secretion of GnRH that results from increased activin
signaling with the loss of gonadal inhibin (Bilezikjian, et al., 2004) and the loss of
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negative feedback by the sex steroids results in a 3- to 4-fold and a 4- to 18-fold
increase in the concentrations of serum luteinizing hormone (LH) and folliclestimulating hormone (FSH), respectively, in women. Likewise, men also experience a
greater than 2-fold, and 3-fold, increase in LH and FSH (Bowen RL, Atwood CS.
2004).
Experimental studies for the loss of sex steroids in promoting Alzheimer’s disease has
come primarily from studies demonstrating an increase in Aß deposition following
menopause/andropause and ovariectomy/castration which suppress the sex steroid
concentration, and by the influence of sex steroids to the modulation of AßPP
processing and Aß generation in vitro. Testosterone have also been shown to alter
neuronal AßPP processing toward the non-amyloidogenic pathway both in vitro and in
vivo. Testosterone treatment with 200nM to 2000 nM of mouse neuroblastoma cells
and rat primary cerebrocortical neurons increased secretion of sAßPPa and decreased
the secretion of Aß (Gouras GK, Xu H, Gross RS, et al.2000). The same result was also
observed in human cell lines and primary cultures of rat and human embryonic
cerebrocortical neurons (Petanceska et al., 2000; Chang et al., 1997).
Recent study by Tianbing Liu et al., 2007 tested whether LH modulate steroid synthesis
in the brain. The result of this study is LH induces neuronal pregnenolone production by
modulating the expression of the LH receptor (suppression of serum LH in young rats
treated with leuprolide acetate for 4 months increased LH receptor in the brain),
increasing mitochondrial cholesterol transport (increased in the expression of
steroidogenic acute regulatory protein / STAR), and increasing P450scc-mediated
cleavage of cholesterol for pregnenolone synthesis. Other hormonal changes in aging
males report a small increase in LH until age 70 and then increases significantly partly
due to the reduced responsiveness to GnRH down-regulation. These changes result in
the loss of the diurnal rhythm variation of testosterone secretion (Morely, J.E, Kaiser,
F.E et al., 1997 ; Lamberts, S.W et al., 1997). Overall studies suggest that in addition to
sex steroids, LH also modulates Aβ generation. Taken together the studies mentioned
above offer significant evidence to indicate a role for LH in neurosteroidogenesis,
cognitive functioning, and modulating Aβ production. Thus, lowering LH levels using
the GnRH analogue, leuprolide, has been evaluated as therapeutic strategies for AD.
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1.5 GnRH agonist and antagonists as a therapeutic strategy for AD.
1.5.1 GnRH
The neuropeptide gonadotropin-releasing hormone (GnRH, also referred to as
luteinizing hormone releasing hormone, LHRH,) serves as both a hormone and a
neurotransmitter, and it has multiple actions on reproductive physiology and behaviour.
At least seven different molecular forms of GnRH have evolved, and nearly all
vertebrates studied express at least two different forms of GnRH: chicken GnRH II, and
a second form that varies across classes (Muske, E Linda, 1993). GnRH is a small
decapeptide that plays a role in the connection between the neural and endocrine
systems. This oligopeptide is synthesized and stored in the medial basal hypothalamus.
It acts on anterior pituitary gonadotrope cells, which express GnRH receptors, to signal
both the synthesis and secretion of gonadotropin hormones : luteinizing hormone (LH)
and follicle stimulating hormone (FSH) into the circulation (Conn, P.M, 1994).

1.5.2 Leuprolide and its effect on LH
After the discovery of GnRH in 1971, analogs that have agonistic and antagonistic
effects have been used widely in experimental and clinical research. In men, GnRH
analogs are the most frequently used treatment for locally advanced or metastatic
prostate cancer ( Frydenberg et al., 2000) . Leuprolide acetate is the most used GnRH
agonist compared to the other GnRH agonists such as goserelin, nafarelin, triptorelin,
histrelin, buserelin, and deslorelin (www.leaddiscovery.co.uk). It is a potent suppressor
of Luteinizing Hormone (LH) (Ferin, M. et al, 1984; Ravivarapu, Moyer and Dunn,
2000) and preliminary data has indicated that it may offer therapeutic benefits against
AD.
Leuprolide or leuprolide acetate is a synthetic gonadotropin-releasing hormone agonist
(GnRH agonist) that has been designed to mimic the actions of GnRH to improve the
cognitive function and slow the progression of Alzheimer's disease (AD). It is a potent
suppressor of Luteinizing Hormone (LH) (Ferin, M. et al, 1984; Ravivarapu, Moyer and
Dunn, 2000).
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Figure 1.6 : Chemical structure of leuprolide
(www.drugs.com/ingredient/leuprolide.html)

In order for suppression of LH to be successful leuprolide needs to be administered
continuously at a sustained level. Mode of action of this drug is by causing constant
stimulation of the pituitary GnRH receptors. Short term exposure to leuprolide
stimulates production of LH resulting in increased testicular androgen production.
However long term continuous administration of leuprolide will soon decrease pituitary
secretion (down-regulation) of luteinizing hormone (LH) and desensitization of the
pituitary – gonadal axis, which will be followed by suppression of sex hormone
production (Chrisp and Sorkin, 1991, Parmar et al., 1990) . Adequate desensitization is
usually achieved when there is no significant difference between basal and peak LH
levels in response to exogenous GnRH. This agonist analog is more potent than natural
GnRH and appears to be capable of occupying pituitary GnRH receptors. This results in
a "down-regulation" of

receptor activity and gonadotropin release, ultimately

decreasing serum testosterone levels to those seen following castration. Numerous
studies have demonstrated the effect of leuprolide on LH suppression. Like other
GnRH agonists, leuprolide is commonly used to treat hormone related conditions such
as prostate cancer, breast cancer, and estrogen-dependent conditions (endometriosis and
uterine fibroids) (Wilson, A.C et al., 2007).
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Bowen et al., 2004 showed that LH modulates the processing of AβPP and the
generation of Aβ. However in castrated or ovarectomised animals following treatment
with leuprolide acetate decreased brain Aβ was not observed. (Xu, et al., 1998; Gouras,
G.K et al., 1998). On the other hand suppression of gonadotropins with leuprolide
acetate has been shown to improve cognitive performance and decreases Aβ deposition
in transgenic mice carrying the AβPP Swedish mutation (Casadesus, G, Ogawa, O,
Bowen, R.L, et al., 2003). This results shows us that treatment with leuprolide acetate
effectively lowered serum levels of the gonadotropins, luteinizing hormone and folliclestimulating hormone, through gonadotropin releasing hormone receptor desensitization..
Reduction in the levels of these gonadotropins resulted in a 3.5- and 1.5-fold reduction
in total brain Aβ40 and Aβ42 concentrations, respectively, in C57Bl/6J mice (Bowen et
al., 2004).
Phase II clinical trials conducted by Voyager Pharmaceutical Corporation leuprolide
treatment showed stabilization in cognitive decline in a subgroup of AD patients..
(ALADDIN Study - Phase III, 2007). Basically, female AD patients treated with high
doses of leuprolide acetate showed stabilization in cognitive function and activities of
daily living (http://www.secinfo.com/d14D5a.z6483.htp, pages 56-64). Based on the
above findings leuprolide acetate is strong candidate for the treatment of AD.
1.5.3 Naltrexone and its effects on LH
Naltrexone also is a suppressor of LH. However, unlike leuprolide, it is a pure opioid
antagonist which has a high affinity for opiate receptor sites, that is used for blocking
effects of opioid agonist promptly and completely (Gauthier and France, 1999), This
receptor antagonism varies between receptor types with the μ-type receptors being most
selectively antagonized as measured by PET (Lee et al., 1988). Since naltrexone has
high receptor affinity, it blocks virtually all of the effects of opioids such as heroin. The
two opioid antagonists most widely used are naltrexone and naloxone. Naltrexone has
far greater therapeutic usefulness than the other opioid antagonist naloxone. First, unlike
naloxone which is administered intravenously, naltrexone retains much of its efficacy
when administered orally. Secondly, the duration of action of naltrexone is more than
24 hours after moderate doses, unlike naloxone which has a relatively short half-life
(Martin et al., 1973).
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Figure 1.7 : Chemical structure of Naltrexone
(www.drugs.com/ingredient/naltrexone.html)

An opioid is a chemical that works by binding to opioid receptors, which are found
principally in the central nervous system and the gastrointestinal tract. Opioid peptides
are found throughout the central nervous system, and have profound effects on neuroendocrine function. The widespread occurrence of opioid peptides and their receptors in
brain and the periphery correlates with a variety of actions elicited by opioid agonists
and antagonists on hormone secretion. Interestingly opioid receptor antagonists can
influence attention and memory. Furthermore, according to study by Zubieta, J.K and
Roberts E, 1999, it has been hypothesised to be potential therapeutic value in
Alzheimer’s Disease.
Narcotic drugs and endogenous opiate peptides inhibit the production of luteinizing
hormone (LH) by the hypothalamic-pituitary axis in the male and female of several
mammalian species (Azizi, et al., 1973; Mirin, et al., 1976 ; Cicero, T.J et al., 1976;
Van Vugt, et al., 1983; Grossman et al., 1981). The administration of opiate-receptor
antagonists alone significantly increase the pulsatile mode of LH release, with increases
in the frequency and peak amplitude of both immunoactive and biologically active LH
pulses ( Veldhuis et al., 1983; Delitala et al., 1983; Ellingboe, J et al., 1982). In
addition, the negative feedback actions of androgen and estrogen can selectively
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influence either the frequency or the amplitude of the LH pulse. However, whether there
is any relationship, between these inhibitory actions of sex steroid hormones and the
suppressive effects of endogenous opiates is not known. Recent investigations in the rat
have suggested that endogenous opiates may participate in testosterone and estrogen's
suppressive effects on LH secretion (Van Vugt, et al., 1983; Leadem, C.A. et al., 1985
; Cicero, T.J et al., 1979). However, whether functional coupling between these two
major inhibitory systems exists in man and is integrated specifically via mechanisms
that control one or more distinct properties of pulsatile LH release has not been
elucidated.
Several clinical studies of naltrexone effects in women showed that treating women
with naltrexone restores menstrual cycles in amenorrheic and/or anovultory women
with high serum LH levels (Lanzone et al., 1993; Genazzani et al., 1995., Remorgida et
al., 1990; Wildt et al., 1993; Armeanu et al., 1993; Couzinet et al., 1995) . In addition,
long term naltrexone treatment in females with polycystic ovary syndrome (PCOS) has
been shown to reduce the amount of LH released. Furthermore the BMI in obese PCOS
women were reduced (Fruzzetti et al., 2002), together with insulin levels (Fulghesu et
al., 1998; Villa et al., 1997).
Naltrexone also has been used in a small studies to evaluate its potential therapeutic
benefits for AD (Hyman et al., 1985; Pomara et al., 1985; Knopman et al., 1986)
although with an inconclusive results. However, the major limitations of these earlier
studies are the very small sample sizes, in each study with 10 or less dementia patients,
and particularly the short duration of treatment which was usually administered for 2-3
weeks. Therefore, in this study, Naltrexone will be used in order to mimic situations of
low levels of LH in an in vivo model which will allow us to assess the effect of LH
levels and testosterone hormone therapy on Aβ production.

1.6 Role of Glia in Hormonal Signalling
Glial cells are non-neuronal cells that provide support and nutrition, maintain
homeostasis, form myelin, and participate in signal transmission in the nervous system.
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Glial cells are classified in two main groups : microglia and macroglia. Microglia is
macrophage-like cells that play important roles in responses of the brain to injury or
infection. Macroglia are subdivided in four specialized cell types : ependymal cells,
Schwann cells, ologodendroglia, and astroglia. Of these cell types astroglia exhibit
GFAP expression (see review Luis, M., Garcia-Segura, 2004)
Over the last several decades research has focused largely on the effects of hormones on
neuronal metabolism, with relatively little attention given to glial cells. Glial cells
greatly outnumber neurons in the brain, they express many of the genes linked to AD.
Together with neuronal cells they share expression of a number of hormone receptors.
These include receptors for melatonin, thyroid, vasopressin, oxytocins, leptin, and
steroid hormones and likely targets for steroid hormones (Prevot, 2002), and are
subjected to many of the same environmental conditions as are neurons. Studies of AD
patients and of animal and cell culture models of AD have demonstrated altered glial
expression of a number of AD associated proteins. It is thought that Aβ plays a role in
inducing many of these alterations (McGeer et al., 2002).
In AD, activated microglia congregate around the amyloid plaques and degenerating
neurons and may produce toxins and inflammatory cytokines that contribute to
neurodegenerative processes (review by Mattson, M.P, 2004). In response to cytokines
or other hormones these glial cells produce a number of proteins particularly glial
fibrillary acidic protein as well as steroid hormones. For example, the expression of
glial GFAP is strongly regulated by gonadal hormones in brain areas including the
hypothalamus and hippocampus, and the promoter region of GFAP gene contains
hormone responsive elements (HRE) (see overview Cynthia L.Jordan, 1999). Finlay and
Kritzer, 1999 presented the first in vivo evidence that glia express androgen receptors
by examining the cortices of adult rhesus monkeys. Several studies also has
demonstrated that glial cells express steroid and thyroid hormone receptors ( BarakatWalter, et al., 1999; Gudino-Cabrera and Nieto-Sampedro, 1999; Garcia-Segura, et al.,
1999; Vardimon, et al., 1999). Given the evidence that glia in the brain express steroid
receptors, steroid could potentially alter neuronal function by exclusively regulating a
variety of glial mechanisms.
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Integration of hormonal signalling by glial cells occurs in at least two fundamental
ways. The first is that the hormone acts directly on the glia, which in turn acts on the
neuron to modulate its function (Garcia-Segura,1999).. The second way is the hormone
acts first on the neuron, which then releases a substance to target the glia, which then
presumably signals back to that and other neurons (Garcia-Segura, 1994).
Garcia-Segura and colleagues were among the first to show that natural fluctuations in
estrogen levels stimulate a coordinated and dramatic reorganization of synapses and glia
(Olmos, et al., 1989). For example, in the arcuate nucleus of the hypothalamus, an area
that is sexually dimorphic in its synaptic connectivity, the pre-ovulatory surge in
estrogen affects glia to increase their GFAP expression. (Garcia-Segura, 1994). As
estrogen levels decline, glia withdraw their extended process. Exogenous estrogen
produces these same effects in ovariectomized adult females. In addition, estrogen does
not induce similar morphological changes in the arcuate nucleus of adult males
(Horvarth, et al.,1997). However, it is still not clear whether estrogens act directly on
glia or neurons to alter synaptic connectivity. Research regarding testosterone effects in
glia is still lacking and needs to be explored further.
Several studies show that steroids regulate the reactive state of astrocytes and microglia
(Garcia-Segura, et al., 1999; Mor, et al., 1999; Nichols, 1999). As reviewed by Nichols,
1999 activation of astrocytes and microglia is a well-known marker of brain aging.
Importantly, glial activation associated with normal aging, can occur in the absence of
neuronal degradation. Nichols found that while adrenalectomy induced a marked
increase in GFAP gene expression in the brains of non aged rats, adrenalectomy had no
effect on GFAP gene expression in aged rats.
In summary, although there is still much to be learned on the role of glial cells in
neuroendocrine regulation and hormonal signalling, we know that glial cells are able to
respond to hormonal and neuronal signals and can produce local active hormonal
metabolites whenever and whereever they are needed under physiological, pathological
conditions and their association with aging.
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1.7 Summary and project rationale
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive
memory loss, impairments in behaviour, language and visuo-spatial skills and is
ultimately fatal. In the majority of cases, AD onset occurs after the age of 65 (late onset)
and is sporadic in origin. Only approximately 5-10% of cases have a disease onset
before the age of 65 (early onset). These are often familial forms but only a few that are
caused by autosomal dominant mutations in certain AD linked genes. One of the major
pathological hallmarks of AD is the presence of neuritic plaques in the brain. These
plaques are formed from the build-up of a peptide known as beta-amyloid (Aβ). There is
now evidence to show that sex hormones play an important role in reducing Aβ levels
and so has the potential to protect individuals against developing the disease.
Our laboratory was the first to demonstrate clinically that a reduction in testosterone
levels following chemical castration resulted in increased plasma beta Aβ levels and
subsequently showed that in elderly men a decrease in testosterone levels was
associated with increased plasma abeta levels. However, the question remains whether
changes in plasma testosterone result in changes in Aβ in the CSF and the brain. In
addition, recent research has shown that high levels of the gonadotropin, Luteinizing
Hormone (LH), are associated with AD and modulate Aβ production. However, the
relative contribution of LH and testosterone in the pathogenesis of AD remains to be
elucidated.
In order to determine whether testosterone modulates Aβ in the brain I have investigated
the effects of its removal and replacement on the levels of this peptide in castrated male
guinea pigs. LH was also investigated in this model by either its chemical suppression
and through implants.
The efficacy of testosterone on cognition in high risk men by employing a randomized
placebo controlled double blind study has been assessed and correlated with a number
of key blood and brain biomarkers. These findings will serve as the basis for the
establishment of a larger, multicentre trial for the prevention of AD.
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1.7.1 Significance of the Study
This study will extend our understanding of the role of testosterone on Aβ metabolism
in an animal model. It will also investigate the potential roles of testosterone and LH on
Aβ metabolism and AD pathogenesis in a human clinical trial . The outcome of this
study has the potential to influence the development of an effective approach for the
prevention and/or treatment for AD. While there is a high incidence of AD in Indonesia,
which is double the incidence of AD in Australia, no clinical trials have been conducted
on AD in the Indonesian population to date. Therefore, the current project will directly
benefit Indonesia as it will investigate the role of testosterone in the local population.
Furthermore the findings generated has the potential of benefitting the global
community world-wide.

1.7.2 Hypotheses
- LH increases brain Aβ levels in guinea pigs
- Testosterone regulates blood and brain Aβ levels in guinea pigs
- Suppression of LH and testosterone decrease brain Aβ levels in guinea pigs
- Testosterone treatment in men reduces plasma Aβ levels
-Testosterone treatment in men improves cognition in vivo
- Testosterone treatment in men alters brain metabolites
- Efficacy of Testosterone treatment in men is determined by baseline hippocampal
volume.

1.7.3 Objectives
- To investigate whether testosterone regulates blood and brain Aβ levels in guinea pigs
- To investigate whether LH decreases brain Aβ levels in guinea pigs
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- To investigate whether suppression of LH and testosterone supplementation alter brain
Aβ levels
- To investigate whether testosterone treatment in men reduces plasma Aβ levels
- To investigate whether testosterone treatment in men improves cognition in vivo
- To investigate whether testosterone treatment in men alters brain metabolites
- To investigate whether hippocampal volume determines efficacy of testosterone
treatment in men.
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Chapter 2
Materials and Methods
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2.1 Materials
2.1.1 Participants
The clinical study was undertaken at the Siloam Hospital in Lippo Karawaci,
Tangerang, Indonesia. Human ethics approval was obtained from the Independent
Human Ethics Committee, Faculty of Medicine from the University of Indonesia as well
as Edith Cowan University, Western Australia prior to commencement of the study. The
participants were recruited from all areas surrounding Jakarta and Tangerang, Indonesia,
including patients from Siloam Hospital, Lippo Karawaci, Indonesia and the nursing
homes from those areas. All participants were screened based on the eligibility criteria
(details on Chapter 2 Section 2.1.1.1) prior to the commencement of the study. Only
male subjects who had provided written informed consent and met the eligibility criteria
were included in either short term study or the long term double blind randomized
placebo-control clinical trial.

2.1.1.1 Eligibility Criteria
The following eligibility criteria were used: 1) Male 50 years of age or older; 2)
Subjects were selected based on their MMSE assessment. A score of 24 or above
determined eligibility of inclusion in the trial. Final decision of inclusion was
determined jointly by a neurologist, neuropsychologist, and the researchers in charge of
the project; 3 ) Participants must have a testosterone level of less than 300 ng/dL (~10..4
nmol/L). 4) must have normal range of prostate-specific antigen (PSA), 5) Blood
pressure must be within normal limits ) must not have diabetes mellitus, 7) must have
normal liver and kidney enzyme function and 8) must have not suffered from major
head injury. The screening test, included a testosterone measurement, Mini Mental State
Examination (MMSE), and clinical interview about subject’s medical record (i.e.
whether they have had any medication such as donepezil or rivastigmine), were also
carried out to decide the eligibility of the subjects. All participants in this study had at
least 6 years of education.
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2.1.1.2 Biochemistry Laboratory Tests

2.1.1.2.1 Collection of Samples
Blood samples collected from participants at each visit using venipuncture underwent a
full blood count performed by the diagnostic laboratory of Siloam Hospital, Karawaci..
Blood samples ( 45 ml) were collected using serum separating tubes (SST) that include
a gel and blood clot activator), EDTA, and heparin collection tubes. Blood in SST
collection tubes were centrifuged at 2500 rpm for 10 minutes

to separate the serum.

The serum was removed, then aliquoted ~ 1ml to which 10ul (Xug/ml) of protein
inhibitor was added (aprotinin - Sigma) was added. Blood in EDTA and heparin
collection tubes were centrifuged at 1000 rpm for 10 minutes at RT, to separate the
plasma, leucocytes, and blood. Plasma was removed and further centrifuged at 2500
rpm for 10 minutes to harvest platelets. The resulting supernatant (plasma) was
aliquoted ~ 1-5 ml and 10µl protein inhibitor (aprotinin - Sigma) was added to each ml
of plasma.
The platelets were washed in 5 ml of saline and then centrifuged at 2500 rpm for 10
minutes, to remove saline. The platelets were resuspended in 200 – 250 µl of saline
prior to aliquoting to a fresh tube.
For harvesting leucocytes, whole blood was centrifuged at 2200 rpm for 5 minutes, the
leucocytes added to another tube with 3-4 ml ice cold Ficoll and centrifuged again at
1100 rpm for 15 minutes. The Ficoll was removed and leucocytes were washed with 10
ml of saline (0,9% NaCl) and centrifuged at 2500 rpm for 10 minutes. This step was
repeated to remove residue Ficoll or plasma . Leucocytes were preserved in 1ml Fetal
Bovine Serum (FBS – Invitrogen) containing 10% Dimethyl sulfoxide (DMSO - Sigma)
for APOE genotyping. All blood products were stored at -80oC prior to shipment to
Perth. Leucocytes were collected for APOE genotyping (see below section 2.1.1.2.2)
2.1.1.2.2 Blood Biochemistry
Serum samples underwent a full blood biochemistry at the Path West Diagnostic
laboratories (Perth, Western Australia) to be measured of the following hormones : LH,
estradiol, and insulin, SHBG, albumin, glucose, and PSA levels were also measured.
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Lipid profile such as HDL, LDL, triglyceride, and cholesterol levels were also
performed in plasma heparin samples. Testosterone and DHT levels were measured in
serum samples by gas chromatography-mass spectrometry (GC-MS) at the ANZAC
Research Institute, Sydney. Plasma and CSF underwent analysis for Aβ 42 and Aβ 40
levels using ELISA as described in section 2.2.5 and was performed in Professor
Martins laboratory.

2.1.1.2.3 APOE genotyping
All the leucocytes were thawed and spun at 4,000 rpm for 3 minutes to separate the
leucocytes pellet from FBS mixture. The pellet was washed in 1ml 0.9% NaCl and spun
at 4,000 rpm for 3 minutes to remove all the excess FBS mixture. The washing step was
repeated twice in order to get a clear pellet. The pellet was gently resuspended in 550l
TES buffer (10mM Tris-HCl, 100mM NaCl, 1mM EDTA, pH 8), then added 60l of
20% (w/v) SDS and 20l of proteinase-K. The mixture was incubated overnight with
movement in a 37oC incubator. An equal volume of phenol (~600l) was then added
into the mixture and mixed. An addition of phenol resulted in cloudy mixture. After
centrifugation at 13,000 rpm for 8 minutes, the mixture was separated into 3 layers, i.e.
(from top to bottom): DNA layer, phenol and cell debris at the bottom of the tube. This
phenol purification step was repeated with 300l phenol to ensure the purification of
DNA from protein and cellular debris. DNA was transferred into a clean DNAse-free
tube with 50l of 3M sodium acetate (NaC2H3O2) and 1ml of 100% alcohol (cold) was
added to the DNA. The DNA mixture was then gently shaken until the white DNA
thread is visible. After centrifugation at 13,000 rpm for 15-25 minutes. A DNA pellet
appeared on the bottom of the tube and the supernatant was discarded. One ml of cold
100% alcohol was then added to the pellet and centrifuged at 13,000rpm for 5 minutes.
The DNA pellet was then washed with 1ml cold 70% ethanol and spun at 13,000 rpm
for 5 minutes. The excess 70% ethanol was discarded and the DNA was air-dried for 5
minutes to totally remove any residual ethanol. DNA-free water (200-300l) was then
used to resuspend the DNA pellet prior to APOE genotyping. DNA concentration was
measured using Nanodrop which requires sub-microlitre volumes for assessment at
260nm and 280nm.
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APOE genotyping were determined by observing migration patterns of DNA on
polyacrylamide gels from each individual following PCR. 1.1l DNA was mixed with
14l of the master mix contains the following:
Solution

1 reaction
(l)

DMSO

1.5

10x polymerase buffer

1.5

2mM dNTPs

1.5

MgCl2

1.2

Primer 1 (5’ – TCCAAGGAGCTGCAGGCGGCGCA – 3')

1.2

Primer 2 (5' – GAATTCGCCCCGGCCTGGTACACTGCCA – 3')

1.5

AmpliTAQ gold

0.075

ddH20

5.35

One drop of paraffin oil was then added on the top of the mixture to avoid evaporation
during PCR (polymerase chain reaction). The mixture was then amplified using PCR
cycle. The first cycle was the initial denaturation (1X), i.e. 94oC – 5min, 65oC – 30sec,
70oC – 90sec. The cycle was then continued with 35 repetitive cycles, i.e. 94oC – 30sec,
65oC – 30sec, 70oC – 90sec and finished with the chase cycle (1X), i.e. 94oC – 30sec,
65oC – 30sec, 70oC – 10min, 4oC – 1min. The PCR products were then digested using
HhaI enzyme and resulted in restriction fragments which were then separated based on
their length by gel electrophoresis. The process is known as restriction fragment length
polymorphism (RFLP) genotyping. HhaI enzyme (New England Biolabs) was diluted in
NEBuffer4 to 5U/l. Onel of HhaI enzyme was added into each PCR product and
incubated at 37oC overnight. The digested product was then run in the 8%
polyacrylamide gel (10ml of 8% acrylamide mixture, 20l of 25% Ammonium
persulfate – APS, and 15l TEMED). Ten l of samples were mixed with 2l loading
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buffer (1.5gram Ficoll, 0.02gram bromophenol blue, 0.02gram xylene cyanol in 10ml
TBE buffer) prior to loading. For the DNA marker, 10l of DNA-free water was mixed
with 2l PUC19 DNA marker and 2l loading buffer. The gels were then
electrophoresed at 110 Volt for 1.5 hours using TBE buffer (10.8gram Tris-HCl pH 8.3,
5.5gram boric acid, 0.94gram Ethylenediaminetetraacetic acid (EDTA) in 1 litre of
ddH2O. The gels were washed in 50ml ddH20 with 1l etidium bromide (EtBr) with
shaking for 5 minutes. Three washing steps were followed using 50ml ddH20. The
visualization of the APOE bands was performed under GelDoc BioRad system.

2.1.1.3 Neuropsychological Testing

In the neuropsychological component of the study, the matched groups of participants
were assessed at three different time points :1) baseline and treatment period (week 024) 2) washout period (week 24-28) 3) cross-over period (week 28-52), as shown in
figure 2.2.

The following neuropsychological assessments were implemented: 1)

MMSE, a simple test to screen for mental impairment for 5-10 minutes , 2) the Rey
Auditory Verbal Learning Test (RAVLT) for 35-45 minutes_. The application in this
study of parallel forms of the RAVLT (matched for equal difficulty) ensured that
retesting could be conducted over time without the memory data being potentially
confounded by practice effects. In addition to these cognitive assessment protocols, a
questionnaire to self-assess the health status of the participant (SF36) was also applied.
The three related negative emotional states of depression, anxiety and stress were
assessed using Geriatric Depression Scale (GDS) and Depression, Anxiety and Stress
Scales (DASS) questionnaires. These questionnaires provided information on the
emotional states of participants when they underwent the cognitive assessment as
depression, anxiety and stress have been known to be associated with cognitive status
(Insel, 2002;Jorm, 2000).
2.1.1.4 Brain Imaging
In addition to the medical examination and neuropsychological testing participants also
underwent brain imaging which included Magnetic Resonance Imaging (MRI) and
Magnetic Resonance Spectroscopy (MRS). MRI was used in the long-term study to
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determine whether the use of testosterone therapy is influenced by hippocampal volume
ie individuals with reduced hippocampal volume may obtain less benefit. For the MRI
data, we have done the Medial Temporal lobe Atrophy (MTA) scale, starting from
rating 0 to 4 in which the higher the scores indicate more atrophy (Korf et al., 2004)
measured by three of our experienced radiologist. All of the MRI imaging data (T1,T2)
is stored in DICOM format with 7mm thickness slice (TR = 4802, TE=120).
While MRI uses anatomical images to localize regions of interest with high resolution,
MRS is a non-invasive, sensitive tool for measuring the concentration of metabolites in
the brain, such as N-acetyl aspartate (NAA), Myo-inositol (MI), choline (Cho) and
creatine (Cr) levels (Firbank, 2002)..1H MRS in this study (TR=1500, TE=272) will
enhance the diagnostic accuracy of MRI and provide additional information of the brain
metabolites changes, such as NAA, Cho and Cr, which can be seen in the form of a
graph with specific peaks for each metabolites e.g 2 ppm for NAA (Figure 2.1).

Figure 2.1 1H MRS with 5 different spectroscopic points in 1,5T Gyroscan Intera
Phillips
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We are using two dimensional MR spectroscopy (2D CSI) which enable us to acquire
multiple small voxels which gives better information to determine the region of interest
(ROI) and the spectroscopic points. We are using 5 spectroscopic points :
1) in the right hippocampus
2) in the left hippocampus
3) in the right medial temporal lobe
4) in the left medial temporal lobe
5) brain area which have normal spectroscopy
The voxel information from the spectroscopic points can be used to calculate metabolite
ratios to creatine-containing compounds. The creatine signal is usually stable over time
and therefore is often used as an internal standard to which other metabolites resonance
intensities are normalized.Therefore, from this study we would like to determine :
1) NAA/Cr ratio (which is found to be lowered in AD)
2) Cho/Cr ratio (which some found to be elevated in AD)
MRI and MRS were performed on all participants, with or without testosterone
treatment, three times i.e.: at the beginning (baseline), at the end of the initial 24-week
treatment period and at the end of the study (see figure 2.2 for the detail), using the
Gyroscan Intera 1.5T (Phillip Medical System) at Siloam Hospital Karawaci by the
original team of radiographers following strict standardized procedures MRI image
acquisition and data handling.

2.1.2 Animal Trial
2.1.2.1 Animals and Treatment Groups
Animal care and experimentation in this study were carried out in accordance with
ethical guidelines published by NH&MRC (National Health and Medical Research
Council) Statement on Animal Experimentation and approved by the UWA Animal
Ethics Committee and Edith Cowan University.
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Adult male guinea pigs weighing 500 grams (± 6-8 weeks old) were obtained from the
BSAU animal care unit at UWA (Perth, WA, Australia). Animals were kept in a 1:1
light and dark cycle room at the BSAU animal care unit with free access to water and a
soy-free diet (in order to eliminate any phytoestrogen intake) obtained from Glenforrest
Stockfeeders (Perth, WA). The composition of soy-free diet were formulated from
casein (300g/kg), as the protein source, sucrose, glucose and starch, as a carbohydrate
sources, cellulose (150g/kg) as a fibre source, refined vegetable oils (100g/kg) as lipid
source and vitamin, and mineral supplements. As guinea pigs can not produce vitamin
C, a supplementation of vitamin C was also added to their water. Prior to
experimentation, all the animals were caged for a week in order for them to adapt to the
environment.

2.1.2.2 Hormone treatment pellets and the dosage
The treatment groups are outlined in table 2.1. All the treatments given in guinea pigs
were in the form of 40-day slow release pellets manufactured by Innovative Research of
America, USA. The active ingredients and dosages used in this study are shown in
table 2.2.
Table 2.1. The summary of treatment groups
Treatment Group

Administration of

Day of Sacrifice

hormone pellets
Testosterone treatment

Peripherally

18

and

36

days

administration

post
of

testosterone pellets.
LH treatment

Peripherally and cortical 18
placement - brain

and

36

days

(peripherally); 15 and 28
days (cortical placement)
post administration of LH
pellets.
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Leuprolide and testosterone Peripherally

18

and

36

days

post

treatment

administration of leuprolide
and testosterone pellets.

Naltrexone and testosterone Peripherally

18

and

36

treatment

administration

days

post
of

naltrexone and testosterone
pellets.

Table 2.2 A summary of all pellet dosages used in the animal study
Pellets

Dosage

Placebo

20 mg /kg BW/day

Testosterone

2.5 mg /kg BW/day (Low)
5 mg /kg BW/day (Medium)
20 mg /kg BW/day (High)

Luteinizing Hormone (LH)

2.25 g /kg BW/day
(~11.25 IU/kg BW/day)

Leuprolide

0.02 mg /kg BW/day

Naltrexone

8 mg /kg BW/day

2.1.3 Consumables
2.1.3.1 Chemicals
All chemicals used in the study, generally, were of the highest purity and purchased
from Sigma Chemical Co. (St. Louis, Missouri, USA), BDH Chemicals Australia Pty.
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Ltd (Victoria, Australia) or BioRad (Irvine, California, USA) unless otherwise
specified.
2.1.3.2 Antibodies
The human-specific APP antibody, C1/6.1, directed against the last 20 residues of APP
was kindly provided by Dr. Paul Matthews (Nathan Kline Institute, NY, USA).

The mouse monoclonal antibody WO2 was kindly provided by Professor Colin Masters
(University of Melbourne, Vic, Australia). This antibody, is directed against the amino
acid sequence 5-8 of the human A The 6E10 antibody (Covance) was used as a
capture antibody for either A40 or A42, and recognizes residues of the N-terminus of
A and R208 as detection antibody (kindly provided by Dr. Pankaj Mehta) .

For detecting GFAP (glial fibrillary acidic protein), the mouse monoclonal GFAP
antibody (Sigma chemical Co., Missouri, USA) was used. The polyclonal goat apoE
antibody (Millipore) was used to detect the apoE levels by western blot. The polyclonal
rabbit anti-cytochrome P450 side chain cleavage enzyme (P450scc – Milipore) was
used to detect the levels of P450scc neurosteroid enzyme by western blot. The loading
control protein, actin, was also examined using mouse monoclonal actin antibody
(Sapphire Bioscience Pty Ltd, Redfern, NSW, Australia).

Two major secondary antibodies were used in this study, a sheep anti-mouse IgG
horseradish-peroxidase (HRP) antibody (GE Healthcare, Buckinghamshire, UK) and a
polyclonal rabbit anti-goat IgG-HRP antibody (Dako Co, CA, USA).

73

2.2 Methods
2.2.1 Clinical Study Design
The testosterone used in the clinical study was applied in the form of a cream
(Andromen,® 5% Forte) , which was obtain from Lawley Pharmaceuticals (Perth,
Western Australia).
Prior to commencing the main “long-term” study, a pilot “short term” study was
performed to determine the optimal site to apply the testosterone cream.

2.2.1.1 Short-term (Pilot) Human Study

Short-term (Pilot) Human Study 1
Four male participants were recruited for the pilot study .Before admission of this study,
the participants were instructed to fast overnight. At admission, the male participants
were underwent a medical examination [height, weight, and body mass index (BMI)
were measured]. For this study, the participants were recruited and admitted into
hospital for a period of 36 hours. The blood sample were drawn at a baseline (time
zero), 2, 4, 8, 12 hour prior to the application of testosterone cream. Testosterone (100
mg in the form of Andromen® 5% FORTE cream) was then immediately applied via
transdermal route (topically). According to the manufacturer’s information, a once off
daily dose of 100 mg [4 cm applied to the trunk (side of body above hips)] will increase
serum testosterone concentrations in healthy testosterone deficient men into the midnormal range. The participants were bled again at 2, 4, 6, 8, 10, 12, 16, 20 and 24 hours
post application. The level of serum testosterone and LH were measured for all the
blood samples taken.
Short-term (Pilot) Human Study 2
As the preliminary result of the first pilot study indicated that application of testosterone
cream on the side of the trunk (above hip) had a variable effect on increasing blood
testosterone levels, the pilot study was repeated. In this second pilot study, testosterone
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(50 mg in the form of Andromen® 5% FORTE cream) was applied on the scrotum to
maximise the absorption of the testosterone cream on the skin, as this is an area which
contains minimal body fat, has thin skin and a good blood supply [insert refs].
The same male participants were instructed to fast overnight and admitted into hospital
for a period of 28 hours. At admission in the morning, the participants were underwent a
medical examination [height, weight, and body mass index (BMI) were measured] and
were bled for a baseline (time zero), and 4 hours later prior to treatment. Testosterone
(50 mg in the form of Andromen® 5% FORTE cream) was then immediately applied via
transdermal route (topically to the scrotum). The participants were bled again at 2, 4, 6,
8, 10, 12, 16, 20, and 24 hours post-application. The level of serum testosterone, SHBG,
(Sex Hormone Binding Globulin) albumin and plasma Aβ levels were measured.

Table 2.3 Comparison between Short-term Human Study 1 and 2
Pilot Study 1

Pilot Study 2

Duration of Study

28 hours

(36 hours)
Blood taken prior to the At baseline (time zero), 4, At baseline (time zero) and
application of testosterone

6, 4, 8, 12 hour prior to the 4
application of testosterone

hour

prior

to

the

application of testosterone

The site for testosterone On the trunk (side of body On the scrotum, topically
application

above

hips),

topically (transdermal route)

(transdermal route)

Blood taken post to the At 2, 4, 6, 8, 10, 12, 16, 20, At 2, 4, 6, 8, 10, 12, 16, 20,
application of testosterone

and

24

application

hours

post- and

24

hours

post-

application
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2.2.1.2 Long-term Human Study

A randomized, crossover, placebo controlled and double-blind study was undertaken to
study the effectiveness of testosterone (a transdermal formulation) treatment in
hypogonadal male subjects. Of the potential participants that were screened, 44 eligible
males were recruited and assigned to one of the two parallel groups; placebo (n=22) or
testosterone (n=22) treatment. Assignment was random using stratification to ensure
each arm of the study was balanced, in terms of individual memory performance at
baseline. The study design (shown in Fig 2.2) was such that participants received
testosterone treatment or placebo for a period of 24 weeks, followed by a washout
period of 4 weeks, after which time, the participant groups were “crossed over”, such
that the placebo group received testosterone and vice versa for a further 24 weeks. For
all participants, there were a total of 11 clinic visits to Siloam

Hospital, Lippo

Karawaci, within the 52-week study period.
During the first visit, the participants’ blood pressure, height, weight, body fat
percentage and body mass index (BMI) were checked and blood drawn for a baseline
reading of blood counts, chemistries, serum testosterone level, LH and SHBG, DHT
(dihydrotestosterone) and estradiol, cholesterol, lipid concentrations and plasma Aβ
levels (as described in section 2.1.1.2.2). The participants’ APOE genotype was also
determined. The baseline neuropsychological testing, brain imaging (MRI/MRS) and a
CSF sample (for those participants who consented) were collected. CSF samples were
collected by lumbal puncture (as described below).
The patient was placed in the lateral decubitus position lying on the edge of the bed and
facing away from operator. Patient’s position is in a knee-chest position with the neck
flexed. The patient’s head is rested on a pillow, so that the entire cranio-spinal axis is
parallel to the bed. Then the operator found the posterior iliac crest and palpated the L4
spinous process, and marked the spot. The skin was anaesthetized using 1% lidocaine in
the 5 ml syringe. Then a spinal needle was inserted and once the needle was properly
positioned, CSF pressure was measured and the CSF samples were collected. When the
CSF begins to flow from the needle, the first few drops were discarded. CSF was not
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supposed to be aspirated, because a nerve root might be trapped against the needle and
risking the possibility of injury. After 3-5 ml CSF were collected, the needle was
withdrawn and the puncture site was dressed with a bandage. The patient was rested in
bed for a few hours.
For the testosterone treatment group (n=22), testosterone (50 mg in the form of
Andromen® FORTE cream) was applied daily on the scrotum via transdermal route
(topically) for a period of 24 weeks. For the placebo group (n=22) the same amount of
the cream base [dl- tocopherol acetate (vitamin E), without the active ingredient,
testosterone] was applied at the same frequency. Since Aβ produces hydrogen peroxide,
which is a toxic free radical, and antioxidants such as vitamin E have been shown to
reduce the amount of damage to brain cells by Aβ brain {Butterfield, 1999 #50}, the
placebo group is important to ascertain what effect, if any, the cream base, may have on
reducing Aβ levels and enhancing memory performance. At each of the six remaining
clinic visits i.e. at 4, 8, 12, 16, 20 and 24 weeks during the first treatment period, blood
pressure, weight, body fat percentage and body mass index (BMI) were checked and
blood drawn for blood counts, chemistries, measurement of serum testosterone, LH,
SHBG, albumin, PSA, DHT, estradiol, insulin, cholesterol, lipid and glucose
concentrations and plasma Aβ levels, while neuropsychological testing were only
included at 8, 16 and 24 weeks. At the end of 24 weeks a second CSF sample was
collected (from those participants that consented) and MRI/MRS performed, followed
by a 4-week washout period.
During the 4-week washout period, the participants were given an equivalent amount of
cream base containing no active ingredients with the same route of administration. They
were also clinically examined and assessed neuropsychologically and blood collected
for analysis as described above. At the end of the washout period, neuropsychological
testing (as described in section 2.1.1.3) was performed. The placebo and testosterone
treatment arms of the study were then crossed-over for a further 24-week treatment
period. During this period, the participants were examined every eight weeks (three
bleeds in total i.e. at weeks 8, 16 and 24 of the cross-over period); blood collected for
analysis as described above and neuropsychological testing performed on all occasions.
At the end of the 24-week cross-over period (i.e. week 52 overall, the completion of the
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trial) a third CSF sample was collected (from those participants that consented) and
MRI/MRS performed.

Testosterone treatment

Cross-over period
Week

0

4

8

12

16

20

24

28

36

44

52

Washout period
 Every 4 weeks for 0-28 weeks and every 8 weeks for cross-over period, participants were
bled for measuring testosterone,DHT,SHBG, LH,estradiol,lipid profile,PSA,insulin and Aβ
levels
 Their cognitive status were evaluated using RAVLT,MMSE,GDS and SF36 every 8 weeks
At these time points, MRI and MRS were performed and a CSF sample was
collected for measuring Aβ levels

Figure 2.2 : The summary protocol for long-term human study

2.2.2 Animal Trial Design
Guinea pigs were either left intact (non-castrated) or surgically castrated, to mimic the
loss of testosterone following andropause in men. All hormone treatments given to the
animals were in the form of slow release pellets (Innovative Research of America,
USA) and administered either peripherally (subcutaneuous insertion into the dorsal neck
fat pad of the guinea pig) or cortical placement on the dura above the left and right
parietal cortex. The pellets were designed to slowly release the active ingredients over a
period of 40 days for the hormone treatments or 50 days for the hormone suppression
treatments (leuprolide and naltrexone).
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2.2.2.1 Surgical procedures

All surgical procedures used in this study were performed at the surgery room of BSAU
animal care unit at UWA (Perth, WA, Australia).

Anaesthesia

All surgical procedures applied to the guinea pigs were performed under halothane
anaesthesia by inhalation. Animals were anaesthesized with 3-4% of halothane mix and
O2/N2 mixture followed by 1-2% of halothane mix in order to maintain anaesthesia
during the surgical procedure. However, cortical pellet implantation was performed
under atropine-diazepam-hypnorm anaesthesia. Atropine at a dose of 0.05 mg/kg body
weight (BW) was given subcutaneously. The 5 mg/kg BW diazepam was then injected
intraperitoneally after 5 minutes. After the sedation about 15-20 minutes, the 1 ml/kg
BW hypnorm was given intramuscularly. This procedure provided deep anaesthesia for
about 45 minutes. If the guinea pigs showed signs of awakening before the surgery was
completed, a further 10% of initial dose of diazepam and 25% dose of hypnorm, were
given via the same delivery routes. Immediately after the surgery, the analgesic,
buprenophine (0.05 mg/kg BW, subcutaneous) was given and the animals were kept in a
warm place to recover.

Surgical castration

Two hundred and thirty five guinea pigs were allocated for surgical castration and
weighed prior to the castration. The surgical castration was performed by Dr. David
Gardner (veterinary surgeon). Halothane anaesthesia was induced with (3-4%
Halothane) and anaesthesia maintained during the surgical castration (1-2% Halothane).
All the castrated animals were caged for a week to allow all the endogenous testosterone
to be cleared from the body prior to the pellet implantation.
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Pellet implantation
Intact or castrated animals were treated with either testosterone, LH, hormone
suppression analogues (leuprolide or naltrexone) or a placebo in the form of slowrelease pellet (IRA, USA) and administered by the use of two different approaches. The
first is peripherally (subcutaneous insertion into the dorsal neck fat pad of the guinea
pig) (Wahjoepramono et al., 2008) and the second is cortical placement on the dura
above the left and right parietal cortex (Rapisarda et al., 1977; Wahjoepramono et al.,
2011). The pellets were designed to slowly release the active ingredient over a period of
40 days for the hormone treatment or 50 days for the hormone suppression treatments.
A summary of the experimental treatments is provided in Table 2.4.
For peripheral insertions, smaller pellets were administered subcutaneously using a
stainless steel reusable precision trochar with regular medical point needle for easy
implantation of small pellets up to 8 mm in diameter as illustrated in Figure 2.3. Since
the trochar can only be used for the small pellets up to 8 mm in diameter, the bigger
pellets were administered surgically. The animals were anaesthetized under halothane
anaesthesia and the pellets were placed in a small subcutaneous pocket above the
scapula. The pockets were then surgically sutured closed and the animals were kept
warm and allowed to recover from anaesthesia. For the double-pellet implantation
groups, i.e. leuprolide or naltrexone (as the first pellet) and testosterone (as the second
pellet) group, a 10-day separation period was included between the first and the second
administered pellet to let the levels of both testosterone and LH decrease to negligible
levels. A jugular bleed was performed to measure baseline levels of LH and A prior to
the implantation of the second pellet, i.e. testosterone pellet. In the absence of LH, the
effect of increased doses of exogenous testosterone on A levels was observed in these
groups. All the peripheral pellet insertions were performed by Kevin Taddei and Dr
Gardner.
The administration of the pellet in the brain (either LH or placebo) was performed using
atropine-diazepam-hypnorm anaesthesia. Briefly, guinea pigs were placed in a
stereotaxic head holder and a burr hole drilled in the left and right parietal bones to
expose the underlying dura. A pellet were placed in the burr hole on either side of the
brain, and held in place on the dura by Gelfoam® and dental cement. All animals were
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given the analgesic, buprenorphine (0.05 mg/kg BW subcutaneous) immediately post
surgery, and kept in a warm place to recover.

Figure 2.3 : Pellet implantation procedures using a trochar (Innovative Research of
America, USA).

2.2.2.2 Animal sacrifice and tissue collection

At the the conclusion of each time point, i.e. day 7, 18 or 36; and day 14 or 28 for the
cortical placement group, blood, cerebrospinal fluid (CSF) and the tissues, i.e. brain,
liver and kidney were collected. All animals in the control group (baseline) were
sacrificed immediately (at time zero) and used to obtain baseline readings of all
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parameters for the normal (control) guinea pigs. For each terminal point, the animals
were anaesthetised prior to the final bleed. Blood was collected via cardiac puncture for
maximal blood collection and CSF was collected by puncture of the cisterna magna.
The animals were then euthanized with sodium pentobarbitone immediately following
the CSF sample collection. The whole blood and the CSF were then spun at 3500 rpm
for 15 minutes at 4oC to collect the plasma and remove the blood cells, respectively. For
the tissues collection, all animals were cardiac-perfused with cold saline containing
1000U/ml heparin. The brain was removed and snapped frozen in liquid N2 for Western
immunoblotting and ELISA. All the tissues were then stored in -20oC freezer until used.
2.2.2.3 Preparation and Homogenisation of Brain tissue

Guinea Brains were removed from storage at -20oC and thawed on ice. The brain was
then dissected into the following brain regions: frontal cortex, hippocampus and
cerebellum. The tissues were then weighed and homogenized using a Teflon-glass
homogenizer in 3 ml/g of phosphate buffered saline (PBS) pH 7.4 (mixed powder from
Fisher Biotec, Perth, WA) containing a commercially protease inhibitor cocktail
(Roche, Basel, Switzerland) prior to the analysis to measure A and AD related protein
levels in the tissue. Some of the total brain homogenates (180l) were spun by airfuge
160,000 x g for 15 minutes to obtain brain extract for APPs level measurement. Three
hundred and ten l (310l) of brain homogenates were then processed for ELISA
measurements (refer to Section 2.2.4). The remainder was aliquoted and stored at -80oC
until use for western immunoblotting.

2.2.3 Western immunoblotting
Western immunoblotting was used to measure semi-quantitative levels of AD related
proteins in plasma, CSF and tissue homogenates. This analysis included sample
preparation and determination of protein concentration, loading of samples
,electrophoresis, and immunoblotting AD related proteins.
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2.2.3.1 Preparation and determination of protein concentration
The protein concentration in each region of the brain was estimated using the Micro
BCA protein assay kit (Pierce, IL, USA). All homogenates were diluted 1:600, in PBS
pH 7.4 and loaded in duplicate into 96-well microtitre plate (100l/well). Protein
extracts used to measure soluble α-APPs were diluted 1/100.

Equal amount of

standards solutions, made by diluting stock BSA solution (2 mg/ml ddH2O) to a
working dilution of 80 g/ml (6, 8, 10, 12, 14, 16, 18, 20, 40, 80 g/ml), and blank
(PBS pH 7.4) were also loaded in duplicate in the same manner. One hundred l of the
colorimetric detection mixtures were then added to each well. The plates were then
incubated at 60oC for 15 minutes. A BioRad model 3550 plate reader was used to read
the absorbance at 595 nm and the protein concentration determined by reference to a
standard curve (generated using MCM Plate Manager, BioRad, CA, USA). Each
homogenate sample containing 25 g of total protein was then resuspended in 4X Tris
Tricine sample buffer (4g SDS, 2g glycine and 5mg phenol red dissolving in 8.3ml of
1M Tris, pH 6.8) with the addition of double-distilled water [DDW]) containing 0.1M
dithiotreitol (DTT) and brought to a final volume of 50 µl. Samples were then stored in
-80oC until underwent electrophoresis..

2.2.3.2 Polyacrylamide gel electrophoresis
Tris tricine polyacrylamide gel was used to run all the AD-related proteins. The gel
contained a bottom layer of 12% resolving gel (5 cm deep), then an 8% resolving gel (2
cm deep) and a 4% stacking layer to form the wells. For P450scc, the gel contained only
the bottom layer of 10% resolving gel (7cm deep) and a 5% stacking layer. The samples
and the internal control (IC), which is pooled samples from the rest of the brain, were
mixed in sample buffer and together with molecular weight markers (MW) were then
vortexed, centrifuged and heated to 95oC for 10 minutes prior to the loading. After the
final quick centrifugation, samples, IC , and MW were then loaded and electrophoresed
at 80 volt for 30 minutes and then 120 volt for approximately 2.5-3 hours for all
proteins or 4.5 hours for P450scc, in cathode (1M Tris, 2M Tricine, 1% SDS) and anode
buffer (2M Tric-HCl, pH 8.9) to separate proteins. The gels were removed from the gel
caster and the proteins transferred to nitrocellulose membrane by western,blotting using
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the transfer buffer (25mM Tris, 200mM glycine, 20% methanol), at 250mA, 4oC for
overnight or at 350mA, 4oC for 4 hours.

2.2.3.3 Immunoblotting
The membranes were removed from the transfer tank and stained with a Ponceau stain
(0.1% Ponceau-S in 5% acetic acid) to determine whether equal protein was loaded and
the transfer process was performed well. The picture of these membranes was scanned
using GS-800 scanner (BioRad CA, USA). The membranes were then cut into sections,
based on specific molecular marker, in order to enable probing for different protein of
interest from the same blot. All the sections were then washed in hot PBS several times.
All the incubation and washing steps used in the immunoblotting and detection were
performed at room temperature with gentle rocking .
Non-specific binding sites of protein were blocked using blocking buffer (TBS
containing 5% skim milk) for 1 hour. The blocking buffer was drained, then TBST pH
7.4 (TBS containing 0.05% (v/v) Tween-20) containing 0.05% skim milk were used to
dilute the primary antibodies. All the primary antibodies used to detect proteins of
interest along with the dilutions are listed in Table 2.5.
Table 2.4 Primary antibodies used for western blotting (p denotes polyclonal, m
denotes monoclonal)
Antibody

Protein

Dilution used

Source of
antibody

mC1/6.1
Matthews

by

Dr.

(Nathan

Paul APP
Kline

Institute, NY, USA)

C100

mWO2 by Professor Colin APPs
Masters

(University

1:5,000

Mouse

1:5,000
1:2,000

Mouse

1:10,000

Mouse

of

Melbourne, Vic, Australia)
mGFAP
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(Sigma

chemical GFAP

Co., Missouri, USA)
papoE (Milipore)

apoE

1:10,000

Goat

pP450scc (Milipore)

P450scc

1:1000

Rabbit

1:20,000

Mouse

m-actin(Sapphire Bioscience -actin
Pty

Ltd,

Redfern,

NSW,

Australia).

The membranes were incubated in the primary antibody for 2 hours and then washed 3
times for 10 minutes with TBST pH 7.4. The secondary antibody linked to horseradish
peroxidises (HRP) was then diluted in TBST pH 7.4 containing 0.05% skim milk and
used to incubate the membranes for 1 hour. All the secondary antibodies used in the
western immunoblotting are listed in Table 2.6

Table 2.5 Secondary antibodies used for western blotting (all antibodies are linked
to HRP)
Antibody

Protein

Dilution used

APP, C100, GFAP, APPs

1:5,000

-actin

1:10,000

Rabbit anti-goat antibody

apoE

1:10,000

Donkey anti-rabbit antibody

P450scc

1:5,000

Sheep anti-mouse antibody

The membranes were washed with TBST pH 7.4 (3x10 minutes) and rinsed with TBS.
Finally, the membranes were incubated in Enhanced Chemiluminescence reagent (ECL,
Amersham Biosciences, UK) for 2 minutes with a fast rocking motion and then blotted
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and exposed to ECL hyperfilm (Amersham Biosciences, UK) with different exposure
time in order to get the desired signal intensity. All the film were developed in the dark
room and scanned for semi-quantitative analysis using Quantity One® 1-D Analysis
Software (BioRad, CA, USA).

2.2.4 Brain ELISA sample preparation
Brain homogenate (310l) in PBS containing protease inhibitor was resuspended in
710l of brain ELISA buffer (250mM sucrose, 20mM Tris-HCl, 1mM EGTA [Ethylene
glycol-bis

(2-amino-ethylether)-N,N,N’N’-tetra-acetic

acid],

1mM

EDTA

[Ethylenediaminetetra-acetic acid], pH 7.4,. A volume of 1.1ml cold 100mM NaCl
containing 0.4% diethylamine (DEA) was then added to the brain homogenates and
mixed using a Teflon-glass homogenizer. The homogenate was then centrifuged at
1000.000G, 4oC for 40 minutes for all the treatment group except for groups with LH
and placebo implantation in the brain which were spun at 100,000G, 4oC for 1 hour. A
1.7ml aliquot of supernatant was mixed with 170l of 0.5M Tris-HCl, pH 6.8,and
aliquoted into 4 tubes (~ 440l/tube) and then stored in -80oC until use. Each aliquot
were used to measure A40 and A42 levels by ELISA, as well as the CSF samples.
2.2.5 Enzyme-Linked ImmunoSorbent Assay (ELISA)
The ELISA was used to measure A40 and A42 levels in plasma, CSF (from human and
guinea pigs), and brain homogenates (from guinea pigs) As levels of A in the CSF are
very high (above the highest standards of ELISA), the CSF was diluted in PBS (1:10)
before the analysis. All the frozen samples were thawed on ice prior to the analysis.
The ELISA protocol was as follows: Nunc 96 well plates were coated with 100l/well
of coating primary (6E10) antibody solution (25l of primary antibody in 10ml of
CO3/HCO3 solution [0.26g Na2CO3, 0.21g NaHCO3, pH 9.6 with final volume of 50 ml
was met with addition of DDW]). As guinea pig A is identical to human Aβ (Beck,
1997), the same primary antibody 6E10 was used for both human and guinea pig
samples. The plates were sealed and incubated at 4oC overnight. Plates were then
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washed 3 times with PBST pH 7.4 using the plate washer (BioRad, CA, USA) and
blocked with blocking buffer 200l/well (0.25g of BSA (Bovine Serum Albumin)
diluted in 25ml PBST) at room temperature for 1 hour, followed by 3 washes in PBST.
Samples and standards were then loaded into the wells of the plates (100l/well). The
plates were sealed and incubated at room temperature for 2 hours and then at 4oC
overnight. The next day, the plates were washed 3 times with PBST, then 100l/well of
detection antibody solution (10l of secondary antibody [M40 for Aβ40 or R301 for
Aβ42] diluted in blocking buffer) was added. The plates were sealed and incubated at
room temperature for 1.5 hours, followed by 3 washes with PBST. The neutravidinHRP solution (100l/well) was then added into the wells, and the plates were incubated
at room temperature for 1 hour. The plates were then washed again with PBST prior to
adding TMB/KGP reagent (100l/well). The plates were shielded from the light to
allow the reaction of TMB/KGP to take place until the wells of the last 2-3 highest
standard were distinguishable (usually took between 10-15 minutes). A 1M H3PO4
solution (100l/well) was used to stop the TMB/KGP reaction. The plates were then
read in a BioRad microplate reader at 450nm to provide of a raw OD reading of A
levels. The unit of the A calculation depends on the amount of A detection in each
samples measured (in nanomolar for the brain homogenates samples and picogram or
nanogram for CSF and plasma samples). The A results obtained from calculation of
A standard concentrations by comparing the sample absorbance with the absorbance of
known concentrations of Aβ40 or Aβ42 standards assayed identically on the same plate.
Using the wet weight of the brain in the original homogenate, the final values of A in
brain were expressed as nanomoles / gram wet weight or picogram/ ml and nanogram /
ml.
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Chapter 3
Reduction of CSF and cerebral Aβ levels by
testosterone in castrated guinea pigs
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3.1 Introduction
Studies of estrogen levels and the incidence of AD in women are numerous, and have
shown that hormone therapy around the time of menopause (but not in much older
women) may delay the onset of AD (Brinton et al., 2004) In vitro studies supporting
this effect have shown that estrogen can reduce the production of A in culture, and
promote the secretion of α-APPs , another proteolytic product of APP known to have
neurotrophic properties (Brinton et al., 2004) As in vitro studies have shown that
testosterone can also reduce production of A, promote α-APPs secretion and promote
neuronal viability (Goodenough, 2000 ; Gouras, 2000 ; Pike, 2006), possible links
between testosterone and AD are now being investigated.
Levels of testosterone on average decline in men by approximately 1% every year from
the 3rd - 4th decade of life, and the gradual decline in androgen levels that occurs,
combined with other factors that increase resistance to androgen action, such as rising
sex hormone binding globulin (SHBG) levels with age, causes androgen deficiency
symptoms often referred to as andropause (Haren, 2002 ; Pike, 2006). It has been
suggested that the above-mentioned effects of testosterone do not occur via androgen
receptors (AR), but occur following aromatisation to estradiol which then binds to
estrogen receptors (ER). The use of non-aromatisable dihydroxytestosterone (DHT) in
some of these androgen experiments, and aromatase inhibiting drugs in others, has
confirmed that some (but not all) of the in vivo and in vitro effects of testosterone can be
attributed to AR pathways (Pike, 2006).
An association between low testosterone levels and AD is supported by recent findings
that testosterone levels are inversely correlated with plasma Aβ levels (Gillet, 2003).
Low free testosterone has now been found to be an independent predictor of AD, and
elderly AD cases also appear to have raised levels of gonadotropins (Hogervorst, 2003 ;
Hogervorst, 2004) Another study has found that brain testosterone levels in subjects
with mild neuropathology are similar to levels in subjects with more advanced AD, yet
significantly lower than age-matched controls (Rosario, 2004). In a large longitudinal
study, it was found that low free testosterone levels could even be detected 5-10 years
prior to diagnosis of AD (Moffat, 2004) Not all studies agree with the above findings
(Geerlings, 2006) nevertheless, chemical castration therapy in men with prostate cancer
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results in increased plasma A levels, providing alternative in vivo proof that
testosterone can influence Aβ levels (Gandy, 2001 ; Almeida, 2004). In vivo studies
also contradict some of the in vitro findings, e.g. whereas many cell culture studies have
suggested testosterone effects occur via ER following aromatisation to estrogen, in vivo
studies of castrated animals show the non-aromatisable androgen dihydrotestosterone
(DHT), and not estrogen, influenced A levels (Ramsden, 2003). The aim of this
chapter is to investigate further the role of testosterone in Aβ metabolism in vivo, using
the guinea pig (Cavia porcellus) as an animal model.

In addition to a complete

sequence identity to the human Aβ protein (Beck, 1997), this non-transgenic rodent
model offers the advantage of yielding greater amounts of brain tissue and CSF samples
than can be collected in mice and rats. Further, guinea pigs have a similar cholesterol
metabolism to humans (Luz Fernandez, 2001 ; Zern, 2003 ; Sharman, 2008)., which is
important in synthesis of sex steroids and in AD pathogenesis. As a non-transgenic
animal model, the guinea pig also provides the opportunity to investigate any subtle
effects of hormones or gonadotropins that may be masked by over-expression of APP in
transgenic murine models. A number of other studies have utilized the guinea pig as a
model for investigating AD related proteins (Beck, 1997 ; Fassbender, 2001; Beck,
2003) and evaluating the efficacy of inhibitors and modulators of Aβ production
(Netzer, 2003 ; Lanz, 2005). Guinea pigs have also been used to evaluate the effects of
oestrogen on brain Aβ levels (Petanceska, 2000), where depletion promoted Aβ
accumulation, which was alleviated with supplementation of this hormone. In this
chapter, I describe the effects of testosterone depletion and supplementation on CNS Aβ
levels. Previous findings have reported correlations between testosterone and peripheral
levels of Aβ (Gandy, 2001 ; Gillet, 2003 ; Almeida, 2004) thus I also assessed the
effects of testosterone reduction and supplementation on plasma Aβ and investigated
whether there is a relationship between changes in plasma testosterone levels and
altered CSF and cerebral Aβ levels.
3.2 Aims
The aims of the study were:


To determine if CSF and plasma Aβ levels are altered in the presence of reduced
testosterone levels in gonadectomised (GDX) guinea pigs.
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To determine if testosterone supplemented to gonadectomised (GDX) guinea
pigs restored CSF and plasma levels to that seen in non-gonadectomised (nonGDX) guinea pigs.



To determine if a reduction in testosterone or supplementation of this hormone
alters brain levels of Aβ or APP and its metabolites.

3.3 Methods
Animals
Seventy eight adult male guinea pigs, body weight (BW) 500 gram (± 6-8 weeks old),
were used. During the experiments, animals were kept in a 1:1 light and dark cycle
room with free access to a soy-free diet (Glen Forrest Stockfeeders, Perth, WA) and
water. A summary of the animal groups are described in Figure 3.1.
Twenty three animals were left intact (non-GDX) and 55 animals were then castrated
(GDX) under halothane anaesthesia. One week following castration, 40-day slow
release pellets (Innovative Research of America, Florida, USA) were implanted in the
periphery (subcutaneous insertion into the dorsal neck fat pad of guinea pig), as
described in section 2.2.2.1. The pellets contains placebo (n=12), low testosterone (2.5
mg/kg Body Weight (BW)/day, n=12) or high testosterone (20 mg/kg BW/day, n=12),
The remaining GDX animals were left without any treatment (n=19).

Figure 3.1: A Summary of animal groups used in the study.
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CSF, Plasma and Tissue Collection
The CSF, plasma and tissue collection was performed as described in section 2.2.2.2
and 2.2.2.3. Briefly, at each point of sacrifice, (i.e. 0, 18, 27, 36 days), animals were
anaesthetised with halothane and blood was collected via cardiac puncture. CSF was
collected from the cisterna magna. Processing of whole blood (to collect plasma) and
CSF, prior to analysis of Aβ40 levels is described in section 2.2.2.2. To collect brain
tissue, all animals were cardiac-perfused with heparinized-cold phosphate buffer saline
(PBS) and the brain removed. The brains were dissected into regions, such as frontal
cortex, hippocampus and cerebellum, and homogenized in PBS containing protease
inhibitor. Brain homogenates were used for protein analysis of the APP metabolites
protein, Full length (FL) APP, secreted -APP (s-APP) and APP C-terminal fragment
(APP-CTF) were assessed by western immunoblotting as described in section 2.2.3.3,
A40 levels were assessed by ELISA (as described in section 2.2.5).

Measurement of serum testosterone, plasma and CSF Aβ40 levels.
Serum testosterone was measured by Path Centre (Perth, Australia) and plasma and CSF
A40 levels were measured by sandwich ELISA using 6E10 as capture antibody (antihuman ASignet Laboratories, USA) and R208 as a detection antibody (kindly
provided by Dr. Pankaj Mehta, NYS Institute for Basic Research, New York, USA) (see
chapter 2.2.5).

Statistics
All data that was normally distributed were analyzed using ANOVA at the 0.05
significance level. The levels of testosterone, CSF A levels, FL-APP and its Cterminal fragment were found to be not normally distributed and thus were analyzed
using non parametric Kruskal Wallis analysis of variance.
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3.4 Result
3.4.1 Distinct effects of testosterone reduction or supplementation on CSF and
plasma Aβ40 levels.
Guinea pigs were either left intact (non-GDX), GDX only or GDX and supplemented
with low (2.5 mg/Kg BW) or high (20 mg/kg BW/day) concentrations of testosterone.
The animals were initially sacrificed 18 and 36 days after treatment and serum, CSF and
plasma were collected to measure testosterone and Aβ40 levels, respectively. These
results are shown in Figures 3.2-3.4. Please note that groups of GDX guinea pigs
administered placebo implant were also included. However, all animals in this group
did not show a value for plasma Aβ levels, despite obtaining values for all other groups.
The assay was performed three times without obtaining a value for samples in the GDX
+placebo group. However, serum testosterone and CSF Aβ levels were obtained for the
GDX+ placebo and shown to have similar levels to the GDX only [Testosterone (Mean
± SEM) nmol/L: GDX = 2.74 ± 0.31, GDX+placebo = 2.76 ± 0.17 ; CSF A40 (Mean
± SEM) ng/ml ; GDX = 2.65 ± 0.38, GDX+placebo A40 = 2.54± 0.33] Since the aim
was to determine the effects of testosterone on plasma Aβ and investigate if there is a
relationship with any changes observed in the CSF and brain, results from the GDX
only group were included to represent a reduction in testosterone and comparisons were
made with this group.

To confirm that GDX resulted in a reduction in testosterone concentration and that
supplementation resulted in an increase in concentration, serum levels were measured.
Compared to non-GDX controls, significant reductions in testosterone levels (p<0.05)
were observed following 18 or 36 days GDX (Figure 3.2). This decline was associated
with a significant increase in CSF A40 levels at days 18 and 36 following GDX (see
Figure 3.3). Compared to non-GDX animals, plasma Aβ levels were similar following
18 days GDX, but were significantly increased after 36 days GDX (Figure 3.4).
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Administering the low dose testosterone pellets for 18 days caused a rise in serum
testosterone levels to that seen in non-GDX animals (Figure 3.2). This was
accompanied by a decrease in plasma A40 to levels seen in non-GDX animals, yet
CSF A40 levels were almost as high as in the untreated GDX animals (Figure 3.3). By
day 36, serum testosterone (Figure 3.2) and plasma A40 levels (Figure 3.4) were back
to levels seen in the untreated GDX animals. In contrast, CSF A40 levels were lower
than those seen in untreated GDX animals, closer to A40 levels found in non-GDX
control animals (see Figure 3.4).

The administration of pellets containing high testosterone resulted initially in supraphysiological serum testosterone levels at day 18, reducing to levels found in non-GDX
controls by day 36 (see Figure 3.2). An additional group at which GDX guinea pigs
were administered testosterone for 27 days was included to determine if this reduction
was time dependent. The results show that a gradual reduction in testosterone following
27 and 36 days exposure to the testosterone implant.

Despite these initial supra-

physiological levels of testosterone, A40 levels in CSF at day 18 and day 27 were not
significantly reduced compared to untreated GDX animals. A significant reduction in
CSF A40 levels was only detected on day 36 (p<0.05) (Figure 3.3). On day 18, plasma
A40 levels in the high testosterone group were similar to levels found in the plasma of
untreated GDX animals (on day 18), despite the supra-physiological levels of
circulating testosterone. At day 27 and 36 of treatment, plasma A40 levels increased
significantly above the GDX or Non-GDX guinea pig test group A40 levels (see
Figure 3.4).

Overall reducing testosterone, via castration significantly increased CSF and plasma
Aβ40 levels in experimental guinea pigs. Supplementation of testosterone had distinct
effects on plasma and CSF Aβ40, where levels were reduced in CSF but increased in
plasma. I next determined if brain Aβ40 levels were altered as a response to changes in
testosterone levels and if this was associated with alterations in APP processing.
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Figure 3.2: Serum testosterone levels in non-GDX, GDX and GDX guinea pigs
administered testosterone. Non-GDX animals were sacrificed at baseline (day 0)
GDX only or GDX guinea pigs supplemented with low (2.5 mg/kg BW/day) or high (20
mg/kg BW/day) doses of testosterone were sacrificed at 18 and 36 days following
treatment. An additional group at which GDX guinea pigs were administered a high
dose of testosterone for 27 days was included. All data are shown as mean ± SEM.
T=testosterone and D=day of treatment. * p<0.05, testosterone levels significantly
reduced compared to non-GDX animals.

#

p<0.05, testosterone levels significantly

increased from corresponding untreated GDX animals.

Φ

p<0.05, testosterone levels

significantly reduced from GDX animals supplemented with testosterone for 27 days.
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Figure 3.3: CSF Aβ40 levels in non-GDX, GDX and GDX guinea pigs administered
testosterone. Non-GDX animals were sacrificed at baseline (day 0) GDX only or
GDX guinea pigs supplemented with low (2.5 mg/kg BW/day) or high (20 mg/kg
BW/day) doses of testosterone were sacrificed at 18 and 36 days following treatment.
An additional group of GDX guinea pigs which were administered a high dose of
T=testosterone and D=day of treatment.

*

p<0.05, CSF A40 levels are significantly increased compared to non-GDX animals.

#

testosterone for 27 days was included.

p<0.05, CSF A40 levels are significantly lower compared to untreated GDX animals,
at day 36.
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Figure 3.4: Plasma Aβ40 levels in non-GDX, GDX and GDX guinea pigs
administered testosterone. Non-GDX animals were sacrificed at baseline (day 0)
GDX only or GDX guinea pigs supplemented with low (2.5 mg/kg BW/day) or high (20
mg/kg BW/day) doses of testosterone were sacrificed at 18 and 36 days following
treatment. An additional group at which GDX guinea pigs were administered a high
dose of testosterone for 27 days was included. T=testosterone and D=day of treatment.
*

p<0.05, plasma A40 levels are increased compared to non-GDX animals at day 36. #

plasma A40 levels are significantly increased compared to GDX at day 36.

3.4.2 Effects of testosterone reduction or supplementation on brain Aβ levels and
APP processing.
To determine if testosterone altered brain Aβ40 levels, the frontal cortex, hippocampus
and cerebellum from each experimental group underwent analysis. The results are
shown in Figure 3.5. Compared to non-GDX control animals, Aβ40 levels in the frontal
cortex and cerebellum were not significantly altered 18 days after GDX (Figure 3.5 A
and C). However, a significant reduction was observed following administering a high
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dose of testosterone for 18 days. This reduction was not observed following 36 days of
testosterone treatment. It was noted, however, that compared to non-GDX, GDX led to
a reduction of Aβ40 in the frontal cortex and cerebellum. This may account for the lack
of effect of testosterone at day 36, as levels were already reduced in GDX animals. A
significant increase was observed in the hippocampus of GDX animals, at day 18 which
was significantly reduced below the levels shown in non-GDX animals following
administering testosterone at highest dose used in this study (20mg/kg BW/day) (Figure
3.5 B). Although the effect of GDX was lost at day 36, supplementation of testosterone
resulted in a reduction in Aβ40 levels at this time point.

Testosterone has been shown to impact on Aβ production in vitro and in vivo, through
altering APP processing (Gouras, 20003 ; Pike, 20064) . To determine if APP
metabolism is altered in the GDX guinea pig in the presence or absence of testosterone,
levels of APP and its metabolites (APP-C-terminal fragments (APP-CTF) and secreted
APP (α-APPs) were assessed. (Figure 3.6-3.8). Levels of FL-APP (Figure 3.6) and
APP-CTF (Figure 3.7) were not significantly altered as a result of castration nor
testosterone supplementation. Analysis of sAPPα was performed using tissue from the
frontal cortex. This region provides sufficient material for ultracentrifugation to obtain
supernatant-free of cell debris (as described in section 2.2.2.3). Following Aβ analysis
via ELISA and western immunoblotting analysis of APP, the frontal cortex was the only
region to have sufficient amount of tissue remaining required to perform this analysis.
The sAPPα protein was detected via western immunoblotting and underwent
quantitative analysis. The findings (Figure 3.8) showed that compared to non-GDX
animals, a significant reduction in α-APPs levels was observed in the frontal cortex of
GDX animals. The supplementation of testosterone, either low or high levels, restored
the levels of α-APPs to that seen in non-GDX animals (see Figure 3.8).

Overall the results show that a reduction in testosterone as a result of GDX is associated
with a reduction in α-APPs . The addition of testosterone following GDX restored αAPPs levels to that seen in the non-GDX guinea pigs. Although most prominent in the
hippocampus, testosterone also reduced brain Aβ40 levels. Together, these results
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indicate that testosterone may modulate brain APP processing through the nonamyloidogenic pathway. Parallels were also observed between brain, CSF and plasma
Aβ40 for some of the experimental treatments. In particular, treatment with the highest
dose of testosterone led to reductions in brain and CSF levels but increased plasma
Aβ40.
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Figure 3.5: Aβ40 levels in frontal cortex, hippocampus and cerebellum from nonGDX, GDX only and GDX guinea pigs administered testosterone. Non-GDX
animals were sacrificed at baseline (day 0)

GDX only or GDX guinea pigs

supplemented with low (2.5 mg/kg BW/day) or high (20 mg/kg BW/day) doses of
testosterone were sacrificed at 18 and 36 days following treatment. Homogenates from
the (A) Frontal cortex, (B) Hippocampus and (C) Cerebellum underwent ELISA
analysis for Aβ40. Data is represented as mean Aβ40 levels (nmol/g wet tissue weight)
± SEM. T= administered testosterone pellet. *, p<0.05, Aβ40 levels increased compared
to non-GDX animals. #, p<0.05, Aβ40 levels decreased compared to non-GDX animals.
Φ

, p<0.05, Aβ40 levels decreased from GDX animals.
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Figure 3.6: Full length (FL) APP levels in frontal cortex, hippocampus and
cerebellum from non-GDX, GDX only and GDX guinea pigs administered
testosterone. Non-GDX animals were sacrificed at baseline (day 0) GDX only or
GDX guinea pigs supplemented with low (2.5 mg/kg BW/day) or high (20 mg/kg
BW/day) doses of testosterone were sacrificed at 18 and 36 days following treatment.
(A) Homogenates from the frontal cortex, hippocampus and cerebellum underwent
western immmunoblotting for full length (FL-APP) using antibody C1/6.1 or β-actin.
Three samples from each group are represented on the immunoblots. (B) Quantitative
analysis of all samples revealed no overall significant changes in FL-APP levels in any
of the brain regions analysed. Data is represented as percentage of non-GDX control
and are shown as mean ± SEM.
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Figure 3.7: APP-CTF levels in frontal cortex, hippocampus and cerebellum from
non-GDX, GDX only and GDX guinea pigs administered testosterone. Non-GDX
animals were sacrificed at baseline (day 0) GDX only or GDX guinea pigs
supplemented with low (2.5 mg/kg BW/day) or high (20 mg/kg BW/day) doses of
testosterone were sacrificed at 18 and 36 days following treatment (A) Homogenates
from

the

frontal

cortex,

hippocampus

and

cerebellum

underwent

western

immmunoblotting for APP-CTF using antibody C1/6.1 or β-actin. Three samples from
each group are represented on the immunoblots.

(B) Quantitative analysis of all

samples revealed no overall significant changes in APP-CTF levels in any of the brain
regions analysed. Data is represented as percentage of non-GDX and are shown as
mean ± SEM.
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Figure 3.8: Levels of α-APPs levels in the frontal cortex, from non-GDX, GDX only
and GDX guinea pigs administered testosterone. Non-GDX animals were sacrificed
at baseline (day 0) GDX only or GDX guinea pigs supplemented with low (2.5 mg/kg
BW/day) or high (20 mg/kg BW/day) doses of testosterone were sacrificed at 18 and 36
days following treatment (A) Homogenates from the frontal cortex were western
immmunoblotted for α-APPs using antibody WO2. Immunoblots exhibit 3
representative samples from each group. (B) Quantitative analysis of all samples
revealed a significant reduction in levels of α-APPs in GDX animals, which were
restored to those observed for the non-GDX animals following testosterone treatment.
Data is represented as percentage of non-GDX and are shown as mean ± SEM.
α-sAPP levels are significantly reduced (*, p<0.05, ) from those observed in the intact
control. α-APPs levels are significantly increased in the testosterone treated animals
compared to the castrated GDX animals. (# p<0.05)
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3.5 Discussion

Replacement of testosterone or its metabolite, DHT to mice has been shown to improve
learning and memory and reduce cerebral amyloid accumulation (Ramsden, 2003;
Rosario, 2006 ; Cherrier, 2007). This chapter describes the use of a non-transgenic
animal model to further investigate the benefits of testosterone to reduce Aβ
accumulation. The guinea pig unlike mice, shares Aβ sequence identity and more
closely mimics cholesterol metabolism as well as hormonal changes seen in humans and
has the added advantage of having more available tissue (ie brain, CSF and plasma) for
experimentation. This has enabled the correlation between testosterone and CSF in
particular to be determined Aβ thereby extending the the correlation between
testosterone and plasma Aβ studies performed in mice.

To model testosterone depletion, guinea pigs were castrated and left for 18 or 36 days
prior to analysis of serum testosterone, and Aβ levels in the periphery and CNS. As
expected, serum testosterone levels significantly declined following castration, and this
was associated with increased levels of CSF and plasma A40. Other in vivo studies
have also found that lowering testosterone levels either by orchidectomy or antiandrogen therapy results in increased plasma A levels (Gandy, 2001 ; Almeida, 2004)
or brain A levels (Ramsden, 2003 ; Rosario, 2006). Additionally, the lower
testosterone levels resulting from castration cause a loss of negative feedback of
testosterone on the luteinizing hormone (LH), a gonadotropin, leading to elevated LH
levels, and this has also previously been shown in vitro to favour the amyloidogenic
pathway, increasing Aβ production (Bowen, 2004) The inclusion of plasma LH values
in this study would have provided greater insight into whether changes in the HPG axis
contributed to the effects observed. However, this was not possible as unfortunately
there are no standard assays to measure guinea pig LH levels. The -unit of guinea pig
LH has little or no homology with human or rodent LH, thus appropriate, reliable
immunoassays for measuring guinea pig LH are not available. However, since guinea
pig LH has the highest homology with sheep LH, we attempted to measure the samples
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using a radio-immunoassay for sheep LH but serum values using this assay were
undetectable. Considering that a change in the hormone levels causes a dysregulation of
the HPG axis, it is conceivable that testosterone may alter A levels indirectly through
modulating LH levels.

Androgen receptor (AR) levels in the brain will also have been affected by
gonadectomy and subsequent androgen treatment. Testosterone treatment increases
levels of AR phosphorylation, which has been shown to increase AR transcriptional
activity, whereas in gonadectomised mice, testosterone treatment causes a drop in AR
synthesis, possibly due to AR promotor methylation (for a review see Fuller, 2007). The
testosterone treatment in the current experiments will have induced changes to many of
the above-mentioned components of the hypothalamic-pituitary-gonadal axis, the
complex interaction of which will have produced the detected changes in A levels.

Many in vitro testosterone studies have found that decreasing production of A via the
amyloidogenic pathway is coupled to an increase in the secretion of α-APPs , produced
via the alternative non-amyloidogenic pathway (Goodenough, 2000 ; Gouras, 2000 ;
Pike, 2006), and increased α-APPs levels are thought to be neuroprotective. However
not all in vitro studies have found these pathways to be coupled (Fuller, 1995), and the
negative correlation between A levels and α-APPs levels seen in in vitro androgen or
estrogen studies has not been found in in vivo studies (Petanceska, 2000 ; Ramsden,
2003 ; Pike, 2006). For example, gonadectomised mice have increased brain levels of
A when compared to control mice, and treatment of gonadectomised animals with the
non-aromatisable DHT reduces brain A levels down to levels below that found in
intact animals, yet with no effect on α-APPs (Ramsden, 2003). In this chapter, I have
shown that testosterone reduced CSF and cerebral Aβ levels and restored the reduction
in α-APPs resulting from gonadectomy, indicating that testosterone may modulate APP
processing through the non-amyloidogenic pathway.
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One explanation in the difference between my results and those reported by Ramsden
and colleagues, 2003 may be due to the type of androgen used. The aromatisation of
testosterone to estrogen is thought to be involved in the apparent testosterone induced
secretion of APP, as inhibition of aromatase in the presence of testosterone results in a
reduction in α-APPs (Goodenough, 2000). Furthermore, estrogen itself has been shown
to induce α-APPs secretion (Bi, 2000 ; Manthey, 2001). Thus it is plausible that
testosterone could be altering APP metabolism through estrogen dependent pathways.
However, DHT which does not undergo aromatisation to estrogen may have effects on
APP metabolism and A production which are independent of estrogen or the
enzymatic processing of APP as reported in other studies (Ramsden, 2003 ; Rosario,
2006). Whether DHT or testosterone has independent effects will need to be clarified in
studies that directly compare the effects of these androgens on APP metabolism.

The findings in this chapter show that low dose testosterone decreased A40 levels,
resulting in a negative correlation between plasma A40, plasma testosterone and αAPPs levels. This is similar to results found by others who employed either in vitro,
animal or human studies (Gouras, 2000 ; Gillet, 2003 ; Ramsden, 2003). However, CSF
A40 levels did not mirror the changes seen in blood plasma. If anything, changes in
CSF A40 levels appeared to lag behind changes in plasma testosterone and plasma
A40 levels by a period of 1-2 weeks. This is conceivable if changes in other
components of the hypothalamic-pituitary-gonadal axis control A40 levels in the CSF
(for example, LH levels), as opposed to a more direct action following androgens
binding to androgen receptors. Gonadectomy followed by fluctuating testosterone levels
induced by the experimental treatment would cause ongoing re-equilibration in the
hypothalamic-pituitary-gonadal system, until testosterone returned to a constant low
level. Alternatively, or in addition, CSF A levels are in general much higher than
circulating levels of A, leading us to speculate that our results may reflect slow
clearance of A from the CSF to the bloodstream. The clearance process of A from
brain to bloodstream involves various stages, including and not limited to (1) diffusion
between the interstitial fluid (ISF) and capillaries, (2) the continuous slow removal of
A via the ISF-CSF bulk flow into the bloodstream, (3) mediated clearance processes
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by carrier proteins such as apolipoprotein E, apolipoprotein J, 2-macroglobulin, and
(4) transport of A across the brain-blood barrier regulated by the receptor for advanced
glycation end products and the low density lipoprotein receptor protein-1 (LRP)
(Silverberg, 2003 ; Deane, 2004) [Silverberg, 2003; Deane, 2004]. Once in the
bloodstream, A has a short half-life and is believed to be rapidly degraded by the liver
and kidneys (Hone, 2003).

Feedback mechanisms and components of the hypothalamic-pituitary-gonadal axis
following castration in young male guinea pigs, e.g. AR, LH and follicle stimulating
hormone (FSH) levels and testosterone negative feedback effects, are unlikely to be
identical to those of aging human males with low, but not absent, levels of androgens.
However, this study provides additional evidence of a role for testosterone in A
metabolism, and supports the concept that androgen therapy regulates brain A levels
and hence reduces the risk of AD in men. The high plasma A40 levels in the animals
treated with the higher dose of testosterone are of particular interest. Such high levels
of testosterone would be expected to induce aromatisation to estrogen, which has been
shown to reduce A levels in female rodent brains, and is thought to improve memory
in elderly men (Ramsden, 2003 ; Cherrier, 2007). However, this result does not support
the concept that supra-physiological levels of testosterone will further reduce A levels.
The significant lowering of CSF A40 levels only occurred by day 36, by which stage
circulating testosterone levels were either within the normal range or below normal
levels. The results are in agreement with results by Ramsden et al., 2003. who also
found that changes in brain A40 and A42 levels in male castrated mice were lower
upon treatment with the non-aromatisable dihydrotestosterone (DHT), but were not
affected by treatment with estrogen. In addition, high testosterone caused a significant
increase in plasma A40 levels at days 27 and 36. This could possibly be the result of
clearance of the high brain A40 levels, yet once in the bloodstream, A40 is thought to
be rapidly broken down (Hone, 2003). Studies are needed to establish why changes to
CSF and A levels are so different, and importantly, whether the increased levels are
the result of improved clearance.
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Similarly, brain and plasma levels of A were found to be affected differently by DHT
in experiments by Ramsden et al. 2003. Higher doses of most androgens produce more
aromatisation, as seen with the supra-physiological levels of testosterone reached with
intramuscular injections of testosterone enanthate in studies of cognition in older men.
This treatment doubles estradiol levels in moderate doses, and quadruples them with
large supra-physiological doses (Cherrier, 2007). Only the moderate dosage group
showed improvements in spatial and verbal tests, suggesting an inverted U-shaped
response pattern to both testosterone and estrogens. The route of administration of
testosterone should also be evaluated, as transdermal testosterone administration (as
opposed to intramuscular or by pellet) only raises estradiol levels slightly, while
quadrupling DHT levels, due to 5α reductase enzymes in the skin (Swerdloff, 2000).
The investigation of other APP-related proteins and other hormones and related
proteins, such as apolipoprotein E, LRP, sex-hormone binding globulin, free
testosterone, estrogen, DHT, AR, FSH and LH is required to obtain a more complete
picture of the interactions between components of the hypothalamic-pituitary-gonadal
axis, and to characterise better the effects of these interactions on A metabolism. The
next two chapters analyse the effects of one of these components, LH, at modulating Aβ
metabolism in the guinea pig CNS.

The results presented in this chapter have

highlighted the need to understand the long-term changes brought about by testosterone
treatment on components of the hypothalamic-pituitary-gonadal axis, as short-term
studies provide only a partial understanding of the dynamics of the system. The results
also demonstrate that the measurement of blood plasma A levels, are not sufficient to
monitor the efficacy of androgen therapy for the prevention of AD.
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Chapter 4
CNS administration of human luteinizing
hormone increases cerebrospinal fluid and
cerebral beta amyloid levels in guinea pigs
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4.1 Introduction
Age-associated reductions in sex steroids have been implicated in cognitive impairment,
dementia and the pathogenesis of AD. Results presented in Chapter 3 show that
reductions in serum testosterone increased CNS levels of Aβ in the gonadectomised
guinea pig, providing further evidence for a role of this sex steroid in AD pathogenesis.
However, there is growing evidence to suggest that increased gonadotropin levels
during aging may also contribute to AD pathogenesis. Compared to age-matched
controls, serum levels of gonadotropins have been shown to increase in subjects with
AD (Bowen, 2000;Short, 2001) . Furthermore, findings from our group have shown that
increased serum LH levels are associated with poorer cognitive performance in postmenopausal women (Rodrigues, 2008) and that serum LH levels are associated with
plasma Aβ40 levels in cognitively normal elderly men (Verdile, 2008) .

Initial evidence that LH may be involved in AD pathogenesis was provided by Bowen
and colleagues (2002) who reported an increase in LH immunoreactivity in the
pyramidal neurons of the AD brain compared with age-matched controls. . Coupled
with findings that LH modulates APP processing and A generation in vitro, and that
gonadotropin releasing hormone (GnRH) agonists decrease A levels in mouse brain
(Bowen, 2004 ;Casadesus, 2006) , these findings indicate that the increased
gonadotropins

are a physiologically relevant signal that potentially modulates

neurodegeneration in the aging brain.

The mechanisms by which LH modulates A metabolism remain to be determined.
Earlier studies have shown the presence of pituitary and gonadal hormones in the CSF
of rabbits (Heller, 1968 ;Knowles, 1972) . More recently a small percentage (<1%) of
radio-labelled hCG injected into rats was shown to cross the blood brain barrier into the
CSF and was also detected in the hippocampus (Lukacs, 1995 . In addition, peripheral
administration of the LH analogue, hCG, to rodents, has been shown to impair
hippocampal associated behaviours (Barron, 2010 ;Berry, 2008 ;Lukacs, 1995).
Together, these studies provide evidence that systemic gonadotropins can enter the CNS
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and can impact on memory and learning. There is also evidence that LH is synthesized
in the brain and components of LH receptor signalling, steroidogenic acute regulatory
(StAR) protein and cytochrome P450 side-chain cleavage enzyme (P450scc), have all
been identified in neuronal cells (Bowen, 2002; Liu, 200;Mukai, 2006 ; Murakami,
2006 ;Webber, 2006 ;Wilson, 2006) . The LH receptor itself has been shown to be
expressed in neurons from the hippocampus, an area of the brain involved in memory
formation and severely affected in AD (Lei, 1993). The existence of LH signalling
pathway in neurons is still not well understood. However there is some evidence in
vitro to suggest that modulation of the neuronal LH receptor can impact on
neurosteroidogenesis (Liu, 2007) . Exposure of neuronal cells in culture to LH has been
shown to result in an accumulation of Aβ (Bowen et al., 2004). Further, our group and
others have shown that peripheral administration of hCG, to rodents, increases cerebral
Aβ (Barron, 2010 ;Berry, 2008) . However, whether LH directly alters Aβ metabolism
in the CNS, in vivo, remains to be determined. This chapter investigates whether direct
exposure of LH to the CNS can alter Aβ metabolism in guinea pig brain.

4.2 Aims
The aims of my study were:


To determine if the slow release of LH into the guinea pig CNS increased CSF
and brain Aβ40 levels.



To determine if increased brain Aβ40 levels are associated with changes in
levels of APP and its metabolites.
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4.3 Methods
Animals
A total of 44 adult male guinea pigs, body weight (BW) 500 gram (± 6-8 weeks old)
underwent experimentation. For a set of experiments guinea pigs were either
gonadectomised (GDX) (n=10) under halothane anaesthesia (3-4% induction and 1-2%
maintenance with Halothane) or left non-gonadectomised (non-GDX) (n=10). Another
group of animals (n=24) were GDX as above and left for one week prior to implanting
slow release pellets (Innovative Research of America, Florida, USA) containing either
0.045 mg (equal to 2.25 g/kg BW/day) human LH (MP Biomedicals; n=12) or placebo
(n=12) under combination of atropine-diazepam-hypnorm anaesthesia (0.05 mg/kg BW
atropine, subcutaneously; 5 mg/kg BW diazepam, intraperitoneally and 1 ml/kg BW
hypnorm, intramuscularly). This combination provided deep anaesthesia for about 45
minutes. Once anaesthesia was achieved, guinea pigs were placed in a stereotaxic frame
(David Kopf Instruments) and partial craniotomy was performed to expose the
underlying dura. The dura was incised and a pellet (5 mm in diameter) was placed in the
interhemispheric subdural space of the frontal lobe (stereotaxic coordinate: A 13.0–A
9.0, i.e.: 13 to 9 mm anterior to the frontal zero plane, according to Rapisarda and
Bacchelli, 1977 (Rapisarda and Bacchelli, 1977). After the surgery, the dura was
stitched, the cranium was replaced and the skin was sutured. An analgesic,
buprenophine (0.05 mg/kg BW, subcutaneously) was administered and animals were
kept warm until they recovered. Animals were sacrificed at 14 or 28 days postadministration of the pellets. Six animals treated with placebo and 6 animals treated
with LH were sacrificed at each time point.

CSF, plasma and tissues collection
The CSF, plasma and tissue collection was performed as described in section 2.2.2.2
and 2.2.2.3. Briefly, at each time point, animals were anaesthetised with halothane and
blood was collected via cardiac puncture. CSF was collected from the cisterna magna.
Processing of whole blood (to collect plasma) and CSF, prior to analysis of Aβ40 levels
is described in section 2.2.5 To collect brain tissue, all animals were cardiac-perfused
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with heparinized-cold phosphate buffer saline (PBS) and the brain removed. The brains
were dissected into regions, such as frontal cortex, hippocampus and cerebellum, and
homogenized in PBS containing protease inhibitor. Brain homogenates were used for
identification for APP metabolites. Full length (FL) APP, and APP-CTF were assessed
by western immunoblotting as described in section 2.2.3), A40 levels were assessed by
ELISA (as described in section 2.2.5).

Measurement of serum testosterone plasma and CSF Aβ40 levels.
Serum testosterone was measured in non-GDX and GDX guinea pigs by Path Centre
(Perth, Australia) and plasma and CSF A40 levels were measured by sandwich ELISA
using the monoclonal 6E10 as capture antibody (anti-human ASignet Laboratories,
USA) and the polyclonal R208 as a detection antibody (kindly provided by Dr. Pankaj
Mehta, NYS Institute for Basic Research, New York, USA) (see chapter 2.1.3.2).

Statistical analysis
The student t-test (assuming unequal variance) was used for data comparisons between
non-GDX and GDX animals. All other data were analysed using two-way analysis of
variance (ANOVA) with LSD Post-hoc test at the 0.05 significance levels.
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4.4 Results
4.4.1 CSF and brain Aβ40 levels are altered following LH administration to guinea
pig CNS.
To determine the direct effects of LH on CNS A levels, placebo or LH slow release
implants were administered to the interhemispheric subdural space of the frontal lobe.
As the guinea pigs were GDX prior to pellet implantation, the effect of GDX on CSF,
plasma and cerebral A40 levels were assessed in the GDX animals compared to nonGDX control animals.

As expected GDX led to a reduction in testosterone levels (non-GDX animals = 28.65 ±
6.22; GDX 3.7 ± 0.62 nmol/L, p<0.001). Analysis of CSF Aβ40 levels revealed that
GDX resulted in significant increase in CSF A40 levels compared to the non-GDX
control animals (p<0.05; Figure 4.1A). The addition of the LH implant increased CSF
Aβ40 levels further. Two-way analysis of variance (ANOVA) showed that the LH
treatment (F=34.453; p<0.001) and the duration of treatment (F=26.237; p<0.001) both
significantly impacted on CSF A40 levels. An interaction between the LH treatment
and duration of treatment was also significant (F=7.692; p<0.05). Post-hoc analysis
revealed that there was a significant increase in CSF Aβ40 levels following 14 (p<0.05)
and 28 days (p<0.001) of LH treatment (Figure 4.1B). Overall, these results indicate
that although GDX led to an increase in CSFAβ40 levels, the addition of exogenous LH
led to a further increase, which was dependent on duration of treatment.

I next determined if these effects extended to the periphery by measuring plasma Aβ40
levels from non-GDX, GDX or LH or placebo treated animals. Compared to non-GDX
animals, GDX did not alter Aβ40 levels (Figure 4.2A). Similarly, compared to animals
administered with placebo, plasma A40 levels were not altered in those administered
LH (Figure 2B).
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Figure 4.1: CSF Aβ40 levels from non-GDX, GDX or GDX guinea pigs
administered placebo or LH for 14 or 28 days.
Gonadectomised (GDX) guinea pigs were administered placebo or LH slow release
pellet implants for 14 or 28 and CSF was collected from the cisterna magna. (A) GDX
resulted in increased levels of CSF A40 compared to the non-GDX control animals
(*p<0.05). (B) CSF A40 levels were significantly increased in animals administered
LH at 14 and 28 days pos-treatment compared to guinea pigs administered placebo
(*p<0.05, ***p<0.001). All data are shown in Mean ± SEM.
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Figure 4.2: Plasma Aβ40 levels from non-GDX, GDX or GDX guinea pigs
administered placebo or LH for 14 or 28 days.
Gonadectomised (GDX) guinea pigs were administered placebo or LH slow release
pellet implants for 14 or 28 and plasma was collected. (A) Plasma A40 levels were not
altered as a result of GDX (B) No change in plasma A40 levels were observed in
animals administered placebo or LH. All data are shown in Mean ± SEM.
Having shown that GDX and the direct cerebral exposure to LH resulted in increased
Aβ40 levels in CSF, I next investigated whether brain Aβ40 levels were altered in these
animals. The frontal cortex and hippocampus were isolated and underwent analysis for
Aβ40. The Aβ40 levels within the frontal cortex of GDX animals were similar to those
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observed for non-GDX animals (Figure 4.3A). Administering the LH implant resulted
in an increase in Aβ40 levels within the frontal cortex. Two-way analysis of variance
(ANOVA) showed that there was a main effect of LH treatment (F=12.171, p<0.01;
Figure 4.3B), however there was no effect of duration of treatment (F=0.789, p<0.385).
Post hoc analysis revealed that Aβ40 levels were significantly increased following 28
days (p<0.05), although a trend towards an increase was observed following 14 days of
treatment.
In contrast to Aβ40 levels in the frontal cortex, those observed in the hippocampus of
GDX animals were significantly increased compared to levels from hippocampus of
non-GDX animals (p<0.01; Figure 4.4A). The addition of LH resulted in a further
increase in Aβ40 levels within the hippocampus. Two-way analysis of variance
(ANOVA) exhibited similar findings to that observed in the frontal cortex, there was a
main effect of LH treatment (F=12.116, p<0.01; Figure 4.4B). However there was no
effect of duration of treatment (F=0.478, p<0.499). Post-hoc analysis revealed that
compared to placebo treated animals, hippocampal Aβ40 levels were significantly
increased following 14 or 28 days treatment with Aβ (p<0.05). Overall the results
indicate that the addition of exogenous LH, results in an increase in cerebral Aβ40
levels.
To determine if the increase in Aβ40 levels observed with LH was due to altered APP
processing, brain homogenates underwent western immunoblotting for FL-APP and its
C-terminal fragments (APP-CTF). In frontal cortex tissue, compared with placebo, no
significant changes were observed in FL-APP and APP-CTF following treatment with
LH (Figure 4.5A). Analysis of hippocampal tissue (Figure 4.5B) revealed a main effect
of LH treatment on FL-APP (F=6.762, p<0.05) and APP-CTF (F=9.06, p<0.01) levels,
this was not dependent on duration of treatment. Post-hoc analysis revealed that FLAPP and APP-CTF levels were significantly increased following 28 days of treatment
(p<0.05). The LH associated increase in APP-FL and APP-CTF levels in the
hippocampal tissue, may explain the increased Aβ40 levels observed in this brain
region.
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Figure 4.3: Aβ40 levels from frontal cortex of non-GDX, GDX or GDX guinea pigs
administered placebo or LH for 14 or 28 days.
Cerebral A40 levels were measured in frontal cortex of non-GDX control, GDX
animals and animals administered placebo or LH slow release pellets. (A) There were
no different in frontal cortex A40 levels between non-GDX control and GDX animals.
(B) Compared to placebo treated animals, a trend towards an increase in A40 levels
were observed in the animals treated with LH for 14 days. Following 28 days of
treatment, A40 levels in the frontal cortex were significantly increased in LH treated
animals (*p<0.05). All data are shown in Mean ± SEM.
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Figure 4.4: Aβ40 levels from hippocampus of non-GDX, GDX or GDX guinea pigs
administered placebo or LH for 14 or 28 days.
(A) Gonadectomy (GDX) resulted in increased levels of hippocampus A40 levels in
GDX animals compared to non-GDX control animals (**p<0.01). (B) A significant
increased in hippocampal A40 levels were observed in those animals treated with LH
at day 14 and day 28 compared to non-GDX control animals (*p<0.05). All data are
shown in Mean ± SEM.
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Figure 4.5: Levels of full length APP and its C-terminal fragment in frontal cortex
and hippocampus of GDX guinea pigs administered placebo or LH for 14 or 28
days.
(A) Compared to GDX animals administered placebo, there were no significant changes
observed in FL-APP and APP-CTF levels as a result of LH supplementation at 14 and
28 days LH pellet administration. (B) Hippocampal levels of FL-APP and APP-CTF
levels were significantly increased in homogenates of animals following 28 days of LH
treatments (*p<0.05). All data are shown in Mean ± SEM.
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4.4.2 Increased brain P450scc protein levels following administration of LH to
guinea pig.

Our results above indicate that cerebral Aβ levels were significantly altered in the
frontal cortex and hippocampus of guinea pigs administered LH. We next examined
expression levels of the P450scc enzyme, in the frontal cortex and hippocampus, as an
indicator of the activation of LH signalling. The results show expression of the ~ 49
kDa P450scc enzyme in both brain regions (Figure 4.7A). A similar sized protein band
(49-50 kDa) has been reported in rodent brain (Chia, 2008 ;Kimoto, 2001) . Analysis of
levels of P450scc in the frontal cortex (Figure 4.6A) and hippocampus (Figure 4.6B)
revealed a main effect of LH treatment (F=16.647, p<0.01 and F=16.688, p<0.01,
respectively) where significant increases were observed at day 28 (p<0.01).
Unexpectedly, the levels of P450scc in the hippocampus of the placebo groups were
also significantly decreased from day 14 to day 28 (p<0.05). The experiment was
performed three times and a similar result was achieved on each occasion. Further, βactin levels were shown to be similar in all samples, ruling out the possibility of sample
loading errors. To investigate this further and determine if the dramatic reduction was
due to GDX, another aliquot of hippocampal homogenates from non-GDX, GDX or
GDX animals containing placebo implants underwent western immunoblotting for
P450scc. The results show that compared to non-GDX control guinea pigs, levels of
P450 were significantly decreased in GDX or GDX animals implanted with placebo
pellets (Figure 4.6C), indicating that GDX impacted on hippocampal expression of
P450scc.
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Figure 4.6: Levels of cytochrome P450 cholesterol side-chain cleavage enzyme
(P450scc) in frontal cortex and hippocampus of non-GDX, GDX or GDX guinea
pigs administered placebo or LH for 14 or 28 days.
(A) Compared to placebo treated animals, P450scc levels within the frontal cortex
were significantly increased following 28 days of LH supplementation
(**p<0.01). (B) In the hippocampus, P450scc levels were also increased
significantly at 28 days post LH treatment (##p<0.01). Unexpectedly, the levels
of P450scc in the hippocampus of the placebo groups were significantly
decreased from day 14 to day 28 (*p<0.05). (C) Hippocampal levels of P450scc
were measured in homogenate from non-GDX, GDX and GDX animals
administered placebo for 14 or 28 days. Compared to the non-GDX control
animals, P450scc levels were significantly reduced in all GDX animals
(***p<0.001). Compared to animals administered placebo for 14 days,
hippocampal levels of P450scc were significantly reduced in those animals
treated for 28 days (#p<0.05). All data are shown as the Mean ± SEM.
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4.5 Discussion

Evidence supports the notion that LH promotes the amyloidogenic pathway (Bowen,
2004 ), and that peripheral administration of its analogue, hCG can impair memory and
learning in rodents and result in the accumulation of cerebral Aβ levels (Barron,
2010;Berry, 2008) . However, there is yet no in vivo data to indicate that the direct
application of LH itself to the CNS can alter Aβ metabolism. This chapter addressed
this by implanting slow release pellets in the parietal cortex of the GDX guinea pig
brain.

We have previously shown that plasma and CSF Aβ40 levels were increased following
GDX of male guinea pigs (Chapter 3, Wahjoepramono, 2008) . Although in the current
study plasma Aβ40 levels were unaltered [possibly due to the shorter period of GDX in
this study (14 days) compared with that of [Chapter 3, Wahjoepramono, 2008 (36
days)], increased CSF Aβ40 levels were observed. We have extended these findings to
also show increased cerebral Aβ levels.

However, analysis of Aβ40 levels in the frontal cortex and hippocampus revealed
contrasting results. GDX did not alter levels of Aβ40 within the frontal cortex, whereas
an increase in Aβ40 levels was observed in the hippocampus. Immunohistochemical
analysis of brain tissue from GDX male transgenic mice has shown marked deposition
of Aβ in the subiculum and the CA1 region of the hippocampus (Rosario, 2010
;Rosario, 2006) . However, these studies did not report any changes within the frontal
cortex. The availability of larger quantities of brain tissue from guinea pigs has
provided the opportunity to undertake a quantitative analysis of endogenous Aβ and
indicates that there are regional specific changes in Aβ levels associated with
gonadectomy. Reductions in testosterone as a result of GDX would also lead to a
corresponding increase in peripheral LH levels and evidence exists that this increase
may impact on the hippocampal associated functions. A small percentage of peripheral
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gonadotropins can cross the BBB and impact on hippocampal dependent memory and
behaviour in rodents (Heller, 1968 ;Knowles, 1972;Lukacs, 1995) . Further, peripheral
administration of the more potent analogue of LH, hCG has been shown to impair
working memory in rodents and increase in cerebral Aβ levels (Barron, 2010 ;Berry,
2008) . Studies also suggest that LH is localised to the hippocampus and is the most
likely site of LH signalling in the brain (Bowen, 2002;Liu, 2007 ;Wilson, 2006) .
Together, these findings indicate that the hippocampus may be a major target for
gonadotropins within the brain.

Further evidence for this notion has been presented in the findings in the current chapter
where the addition of exogenous LH, led to differences in levels of Aβ in the
hippocampus and the frontal cortex. Significant increases in Aβ40 levels were observed
in the hippocampus earlier (at day 14- post implanation) compared to the increases
observed in the frontal cortex. Further, there was a significant increase in expression
levels of APP and its C-terminal fragment in the hippocampus as a result of LH
treatment. This increase was not observed in the frontal cortex. Increases in APP
expression have been previously reported when human embryonic stem cells are treated
with hCG (Porayette, 2007) , and the amyloidogenic and non-amyloidogenic processing
of APP have been shown to drive these cells into cell proliferation or differentiaion into
neuronal precursor cells (Porayette, 2009) . In results presented in Figure 4.5, the
increase in APP and its fragments within the hippocampus most likely accounts for the
increase in Aβ40 levels observed in this region of the brain.

Analysis of CSF showed that both LH and duration of treatment impacted on Aβ40
levels, where there was a significant increase following 14 and 28 days treatment. No
changes were observed in plasma Aβ40 levels indicating impaired efflux of Aβ from the
CNS, resulting in the accumulation of Aβ within the CNS. Aβ is known to cross the
BBB into the periphery through a number mechanisms and impaired efflux of Aβ from
the CNS is one mechanism thought to contribute to the accumulation of Aβ in the brain
[reviewed in (Bates, 2009) ]. In chapter 3, data was presented to show that
administering testosterone to GDX guinea pigs results in a reduction in CSF Aβ levels
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and an increase in plasma Aβ levels, suggesting that testosterone may promote
clearance of Aβ from the CNS (Wahjoepramono, 2008).

Although no significant changes in the brain apoE levels with LH administration (data
not shown) was observed,, investigating the effects of LH on other transport proteins
involved in transporting Aβ across the BBB, e.g. RAGE, LRP-1, Aβ degradative
enzymes or microglia would be of interest to confirm and provide further insight into
mechanisms involved in the apparent impairment in Aβ clearance from the CNS.

The results presented in this chapter also show for the first time, in vivo, that the
addition of human LH increases the expression of endogenous brain levels of P450scc.
In gonadal tissues P450scc converts cholesterol to the steroid precursor, pregnenolone,
and it is up-regulated when the LHR signalling pathway is activated in vivo (Scott,
1990)

and (Luo, 2005) ;Rekawiecki, 2005) . Components of the LHR signalling

pathway have been shown to be present in neuronal cells (Bowen, 2002 ;Liu, 2007
;Mukai, 2006 ;Murakami, 2006 ;Wilson, 2006) and in rodent brain (Kimoto, 2001).
While assessing levels of other components in the LH signalling pathway such as StAR,
pregnenolone or other neurosteroids would provide further evidence of activation of LH
signalling, it is probable that the increased levels of P450scc in the frontal cortex reflect
activation of LH signalling.

It is noted, however, that there was a dramatic decrease in P450scc levels in the
hippocampus of animals treated with placebo for 28 days compared to 14-day treatment.
This result was unexpected and the reason for the marked reduction is unclear.
However, compared to non-GDX animals, a similiar reduction in P450scc levels was
observed in the hippocampus of GDX animals (which did not undergo surgical
placement of implant), ruling out the possibility that this was an artefact of the implant
itself.
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This reduction may reflect a down regulation of P450scc synthesis due to prolonged
period of testosterone depletion. While, there is no current evidence for this occuring in
the brain, age related reductions in testosterone in rat leydig cells have been shown to
correlate with reductions in P450scc and StAR mRNA tanscript and protein levels (Luo,
2005) . Although this reduction was observed over months in the Luo et al.,2005 study,
down-regulation of P450scc may be accelerated under conditions of testosterone
depletion. Despite this reduction, the addition of LH resulted in an up-regulation of
P450scc expression, but whether this increase was sustained over a longer period was
not addressed in this study.

Although our results show an LH-mediated up-regulation of P450scc, whether increases
in Aβ levels were associated with activation of LH signalling was not addressed in the
current study. However, findings from a recent study, suggest that the signalling
pathway may play an important role in Aβ accumulation (Lin, 2010) . In this study,
crossing of LHR-/- mice with the AD transgenic model Tg2576 resulted in a reduction
in AD pathology, namely amyloid deposition, astrogliosis and tau phosphorylation (Lin,
2010). Interestingly, while LHR-/- mice are devoid of sex steroids for the duration of
life and show increased peripheral levels of gonadotropins, depletion of sex steroids and
increased accumulation of gonadotropins has previously been associated with
exacerbated AD pathology (Bowen, 2002 ;Rosario, 2006) .

While it is difficult to explain the reason(s) why ablation of LHR prevents Aβ
deposition yet leads to other conditions normally associated with increased AD
pathology, the study by Lin et al (Lin, 2010) is the first to implicate LHR in AD
pathogenesis and provides evidence that LH signalling pathways play an important role
in Aβ metabolism and accumulation. Studies using cell culture models utilising various
LH receptor binding or signalling mutants may address some of the mechanisms
associated with LH mediated modulation of Aβ metabolism (Lee, 2002) . However, it
should also be noted that LH could act through receptor independent mechanisms as is
evident in findings that have shown gonadotropin-mediated effects on non-gonadal
tissue, when LH receptor is absent, in low abundance or dysfunctional (Yarram,
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2003;Allan, 2010) . Overall the findings from my study have provided initial evidence
that direct exposure of the CNS to LH can alter Aβ metabolism. Whether this occurs at
more physiological concentrations of LH, is addressed in the next chapter where LH or
the GnRH agonist (leuprolide acetate) that has been shown to lower endogenous LH,
have been added systemically to the guinea pig.
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Chapter 5
Peripheral administration of human
luteinizing hormone (LH) and leuprolide to
the guinea pig impacts on CNS Aβ levels.
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5.1 Introduction
As described in detail in Chapters 1 and 4, increases in gonadotropin levels,
particularly, luteinizing hormone (LH) during aging, may contribute to AD
pathogenesis (Bowen et al., 2004; Casadesus et al., 2006, 2007, Webber et al., 2007,
Verdile et al., 2008, Berry et al., 2008, Barron et al., 2010, Wahjoepramono et al.,
2011).There is accumulating evidence (both in vitro and in vivo) in support of
exogenous human LH (Bowen et al., 2004; Casadesus et al., 2006; Wahjoepramano et
al., 2011), over-expression of LH (Casadesus et al., 2007) or addition of its more potent
analogue, hCG (Barron et al., 2010;Berry et al., 2008; Lucaks et al., 2005) can
modulate accumulation of cerebral Aβ levels and impair hippocampal associated
behaviours. In the previous chapter, the direct application of LH to the guinea pig CNS
was shown to increase CSF and cerebral Aβ levels. This chapter investigated whether
peripheral administration of LH can modulate CNS levels of Aβ. It also assesses the
efficacy of the GnRH agonist, leuprolide at modulating CNS Aβ levels in the guinea
pig.
Leuprolide (Leuprolide acetate) is currently used for the treatment of endometriosis
(Strowitzkiet al., 2012), prostatic cancer (Trachtenberg, J. 1983; N.J. Wojciechowski,
1986; Leonard,S.M, 2003, and precocious puberty (Kappy et al., 1989 ; Neely et al.,
1992; Clemons et al., 1993). Both GnRH agonists or antagonists are analogues designed
by specific amino acid substitutions to alter efficacy, affinity and prolong their duration
of action (reviewed by Millar et al., 2004). GnRH has a half life of 2-4 minutes
(Jeffcoateet al., 1974) and its analogues have a half life in the range of hours.
Administration of the agonist, leuprolide, results in an initial increase or “flare effects”
in serum gonadotropin secretion for several days which is followed by a precipitous
reduction. This decrease is a result from the loss of GnRH signalling due to the
desensitization of pituitary GnRH receptors which will lead to downregulation of
gonadotropin secretion (Periti et al., 2002).
Administering leuprolide to wild type or APP transgenic mice has been shown to reduce
brain Aβ levels and deposition (Bowen et al., 2004; Casadesus et al., 2006). The use of
a larger, non-transgenic model such as the guinea pig allows regional differences in
141

soluble brain Aβ levels and effects on CSF Aβ levels to be analysed. In addition, the
absence of APP over-expression and robust amyloid deposition, which may mask the
potency of leuprolide at reducing soluble Aβ levels, will be analysed in a more relevant
animal model.
5.2 Aims


To determine the effects of peripherally administering human LH to guinea pigs
on CSF Aβ, and levels of brain Aβ, APP and its metabolites.



To determine if administering leuprolide, reduces CSF and brain Aβ levels.

5.3 Methods
Animals
Peripheral administration of human LH and Leuprolide to guinea pigs
A total of 36 guinea pigs were gonadectomised (GDX) under halothane anaesthesia as
previously described in Chapter 2.2.2.1. One week following GDX, forty-day slow
release pellets: placebo, LH, and leuprolide (Innovative Research of America, Florida,
USA) were implanted in the periphery (subcutaneous insertion into the dorsal neck fat
pad of guinea pigs), as described in section 2.2.2.1. The groups and concentrations of
active ingredients within the slow release pellets are shown in Figure 5.1. Note that,
compared to animals that had undergone GDX only (for period of 18 or 36 days), those
administered slow release implants had undergone GDX 1 week prior to insertion of
implants. Thus, the total time in which guinea pigs exhibited reduced testosterone levels
was 25 and 43 days respectively.
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Guinea pigs
(n=36)

GDX + Placebo
(n=12)

Day 18
(n=6)

GDX + LH
(2.25 g/kg BW/day
(~11.25 IU/kg BW/day); (n=12)

Day 36
(n=6)

Day 18
(n=6)

Day 36
(n=6)

GDX + Leuprolide
0.02 mg/kg BW/day
(n=12)

Day 18
(n=6)

Day 36
(n=6)

Figure 5.1: A summary of animal groups and treatments used.
CSF and tissue collection
At day 18 or 36 post-implant, animals were sacrificed and CSF and brain were collected
to measure the A40 levels, as previously described in chapter 2. All animals were
cardiac-perfused with heparinised-cold PBS. The brain was removed and snap frozen in
liquid N2 for ELISA measurement of A40. Prior to each assay, the brain was dissected
into frontal cortex and hippocampus and was homogenized in cold PBS with protease
inhibitor. APP and its metabolites were examined semi-quantitatively via western blot
as described in chapter 2.2.3. -actin was used as a loading control protein. A sensitive
double-antibody sandwich ELISA assay was used for the detection and measurement of
A levels in tissue homogenates, plasma, and CSF respectively as described in chapter
2.2.5. CSF Aβ levels used in this Chapter and the previous two Chapters were all
measured in the same assay together.
Statistical analysis
Data was analysed using the Statistical Package for Social Sciences (SPSS : version 17;
SPSS Inc., Chicago, Illinois, USA). Experiments were 2x2 factorial designs (presence
or absence of placebo x presence or absence of LH and/or Leuprolide). Analysis of data
were performed by two-way ANOVA at the 0.05 significance level to test for treatment
interactions and main effects. If the data was found to be heterogenous, analysis was
performed using non-parametric Kruskal Wallis analysis of variance. This is noted in
the relevant figure legends below.
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5.4 Results
5.4.1 Guinea pig CSF and brain Aβ levels are altered following peripheral
administration of LH.
To determine the effects of the peripheral addition of exogenous LH on CNS Aβ levels,
slow release implants of LH or placebo were administered subcutaneously to
gonadectomised (GDX) guinea pigs for 18 and 36 days. Aβ40 levels were measured in
the CSF, frontal cortex and hippocampus and results are shown in Figures 5.2, 5.3 and
5.4 respectively. As described in chapter 3, (section 3.4.1), compared to intact controls
(non-GDX), GDX for 18 or 36 days led to a significant increase in CSF Aβ40 levels
(Figure 5.2A). This most likely reflects the reductions in testosterone in these GDX
animals (see chapter 3, Figure 3.2). Administering exogenous LH led to a further
increase (Figure 5.2B). Two-way analysis of variance (ANOVA) showed that there was
a main effect of LH (F=7.934, p<0.01) and an effect on the duration of treatment
(F=4.745, p<0.04)(Figure 5.1B). Pairwise comparison analysis revealed that compared
to placebo treated animals, CSF Aβ40 levels were significantly increased following 36
days of treatment with LH (p<0.05). Overall, these results indicate that although GDX
led to an increase in CSFAβ40 levels, the addition of exogenous LH led to a further
increase, which was dependent on duration of treatment.
To determine if the effects of LH in the CSF reflected that occurring in the brain the
frontal cortex and hippocampus were isolated and underwent analysis for Aβ40. As
reported in chapter 3, 18 days of GDX did not significantly alter Aβ40 levels in the
frontal cortex; however levels were significantly reduced following 36 days GDX
(Figure 5.2A). Administering the LH implant resulted in a reduction in Aβ40 levels
within the frontal cortex. Two-way analysis of variance (ANOVA) showed that there
was a main effect of LH treatment (F=35.645, p<0.01; Figure 5.2B) and duration of
treatment (F=5.514, p<0.029), where Aβ40 levels were significantly reduced following
18 and 36 days of treatment (p<0.05).
In the hippocampus, GDX led to a significant increase in Aβ40 levels (Figure 5.3A).
This effect of GDX was lost at day 36.

In contrast, administering LH led to a

significant reduction in Aβ40 levels. Two-way ANOVA revealed that there was a main
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effect of LH treatment (F=14.801, p<0.001; Figure 5.3B), however there was no effect
of duration of treatment (F=0.789, p<0.385). These results indicate that the addition of
exogenous LH peripherally, negated the effects of GDX on brain Aβ40 levels.
To determine if administering LH altered the levels of APP and its metabolites, brain
homogenates underwent western immunoblotting for FL-APP and its C-terminal
fragments (APP-CTF). Analysis of FL-APP levels in the frontal cortex revealed no
significant impact of treatment (F=0.896, p<0.356) or duration of treatment (F=0.033,
p<0.858). The data for APP-CTF levels was not normally distributed and as such twoway analysis (for normally distributed data) could not be performed. Instead the non
parametric, Kruskal Wallis analysis was performed. Analysis revealed no statistically
significant changes in APP-CTF. Similar results were observed in hippocampal tissue.
Overall, the results indicate that changes observed in cerebral Aβ40 levels due to LH
administration were not attributed to altered levels of APP and its C-terminal fragment.
To further determine if the reductions in cerebral Aβ40 levels were associated with
changes in APP metabolism, levels of α-APPs, were measured in the frontal cortex. As
mentioned in Chapter 3, this region provides sufficient material for ultracentrifugation
to obtain supernatant free of cell debris (as described in section 2.2.2.3). Following Aβ
analysis via ELISA and western blot analysis of APP, the frontal cortex was the only
region to have sufficient amount of tissue remaining required to perform this analysis.
The sAPPα protein was detected via western immunoblotting and underwent
quantitative analysis (Figure 5.6). Analysis by two-way ANOVA showed that there is a
main effect of treatment (F=8.251, p<0.014) and duration of treatment duration of
treatment (F=6.126, p<0.029). Pairwise comparison analysis showed that compared
with placebo, α-APPs levels were significantly increased at day 36 (p<0.05).
Taken together the results indicate that administering LH peripherally, led to increased
CSFAβ40, a similar trend to that seen following direct exposure of LH to the brain (see
Chapter 4, Figure 4.1). However, unlike cerebral exposure to LH, administering the
hormone, peripherally led to a reduction in Aβ levels in the frontal cortex and
hippocampus. The reduction in Aβ40 levels corresponded with an increase in α-APPs in
the frontal cortex.
145

B

CSF A40 Levels (ng/ml)
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GDX Day 36
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18 Days‐post
implant
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Fig 5.2: CSF Aβ40 levels from GDX guinea pigs administered placebo or LH for 18
or 36 days. Gonadectomised (GDX) guinea pigs were administered placebo or LH slow
release pellet implants for 18 or 36 days and CSF was collected from the cisterna
magna.
(A) GDX guinea pigs show increased levels of the CSF A40 compared to non-GDX at
day 18 and 36 following surgery. Data is represented as mean± SEM of 6 animals/
group. *, p<0.05.Values significantly increased from non-GDX.
(B) Compared to the placebo group within the same day of treatment, CSF A40 was
significantly increased in animals administered LH at day 36.Data is represented mean±
SEM. For placebo day 18, n=5, for placebo day 36 n=8, for LH day 18 and 36 n=6 for
each time point.*, p<0.05. Values significantly increased compared to placebo at Day
36.
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Figure 5.3: Aβ40 levels from frontal cortex of GDX guinea pigs administered
placebo or LH for 18 or 36 days. Gonadectomised (GDX) guinea pigs were
administered placebo or LH slow release pellet implants for 18 or 36 days and Aβ40
levels were measured in the frontal cortex.
(A) GDX guinea pigs show increased levels of A40 compared to non-GDX at day 18
and 36 following surgery. Data is represented as mean± SEM of 6 animals/ group. *,
p<0.05, Values significantly reduced compared to GDX at Day 18.
(B) Administering the LH implant resulted in a reduction in Aβ40 levels within the
frontal cortex. Two-way ANOVA and pairwise comparison analysis revealed that
compared to placebo treated animals, Aβ40 levels were significantly reduced following
18 or 36 days of LH treatment (p<0.05). Data is represented mean± SEM. For placebo
day 18, n=5, for placebo day 36, n=8, for LH day 18 and 36n=4 for each group*,
p<0.05.Values were significantly reduced compared to placebo treated animals at both
day 18 and Day 36.
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Figure 5.4: Aβ40 levels from hippocampus of GDX guinea pigs administered
placebo or LH for 18 or 36 days.Gonadectomised (GDX) guinea pigs were
administered placebo or LH slow release pellet implants for 18 or 36 days and Aβ40
levels were measured in the hippocampus.
(A) GDX guinea pigs show increased levels of Aβ40 compared to non-GDX at day 18
and but not at day 36 following surgery. Data is represented as mean± SEM of 6
animals per group.*, p<0.05. Value was significantly increased from non-GDX control.
#, <0.05, Value at day 36 was significantly reduced from day 18 of GDX.
(B) Administering the LH implant resulted in a reduction in Aβ40 levels within the
frontal cortex. Two-way ANOVA and pairwise comparison analysis revealed that
compared to placebo treated animals, Aβ40 levels were significantly reduced following
36 days of treatment. Data is represented mean± SEM. For placebo day 18, n=4, for
placebo day 36 n=8, for LH day 18 and 36 n=5/time point ,*p<0.05. Value is
significantly reduced from 36 day placebo treatment.
148

4

CSF Aβ40 : Frontal cortex
Aβ40 ratio

A

B

3.5

**

**

3
2.5
Placebo

2

LH
1.5
1
0.5
0
18 Days post‐implant

36 Days post‐implant

CSF Aβ40 : Hippocampus
Aβ40 ratio

4
3.5
3
2.5
Placebo

2

LH
1.5
1
0.5
0
18 Days post‐implant

36 Days post‐implant

Figure 5.5 : Ratio of Aβ40 levels in the CSF to those in the frontal cortex (A) and
hippocampus (B) of GDX guinea pigs administered placebo or LH for 18 or 36
days.(A) In the frontal cortex, there was main effect of treatment (F=26.311, p<0.0001).
No effects of duration of treatment (F=0.029, p<0.867) and interaction effect between
treatment and duration of treatment (F=0.08, p<0.781) impacted on rates of Aβ40
clearance. Compared to placebo, LH treatment significantly increased CSF Aβ40 to
frontal cortex Aβ40 in both 18 and 36 days post implant. **p<0.0001 (B) In the
hippocampus, treatment (F=8.336, p<0.011), duration of treatment (F=1.786, p<0.2)
and interaction effect between treatment and duration of treatment (F=1.715, p<0.209)
did not impact on hippocampal Aβ40 levels. LH treatment led to a trend towards
increased CSF Aβ40 to hippocampus Aβ40 ratio in both 18 and 36 days postimplant.Data is represented mean± SEM, for placebo day 18, n=4, for placebo day 36
n=7, for LH day 18 n=5 and LH day 36 n=4 pergroup.
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Figure 5.6 : Levels of full length APP and its C-terminal fragment in frontal cortex
and hippocampus of GDX guinea pigs administered placebo or LH for 18 or 36
days.
Gonadectomised (GDX) guinea pigs were administered placebo or LH slow release
pellet implants for 18 or 36 days and levels of APP and its C-terminal fragment (APPCTF) were assessed by immunoblotting from tissue homogenates of (A) frontal cortex
or (B) hippocampus. No significant changes were observed for FL-APP and its Cterminal fragemt in both the frontal cortex and hippocampus. Note that the data from
APP-CTF in the frontal cortex was not heterogeneous, thus statistical analysis was
performed using the non parametric Kruskal Wallis analysis of variance.Data is
represented as mean± SEM of 6 animals/ group.
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Figure 5.7: Levels of α-APPs in frontal cortex of GDX guinea pigs administered
placebo or LH for 18 or 36 days.
Tissue homogenates from the frontal cortex underwent processing to isolate the soluble
fraction to measure secreted -APP by western immunoblotting(A). Administration of
LH in the periphery increased the levels of α-APPs significantly at day 36 compared to
the placebo groups(B). Two-way ANOVA and pairwise post-hoc analysis revealed that
compared to placebo treated animals, α-APPs levels were significantly reduced
following 36 days of treatment *p<0.05, Value is significantly reduced from 36 day
placebo treatment. Data is represented as mean± SEM of 6 animals/ group.
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5.4.2 Cerebral Aβ levels are significantly reduced in leuprolide treated guinea pigs.
Previous studies in mice administered leuprolide have shown that this GnRH agonist
reduced cerebral Aβ deposition (Bowen et al., 2004; Casadesus et al, 2006). The use of
a larger rodent (non-transgenic) model such as the guinea pig allows regional
differences in soluble brain Aβ levels and effects on CSF levels to be analysed.
GDX guinea pigs were administered a concentration of leuprolide for 18 or 36 days.
Following treatment, animals were sacrificed and CSF and brain Aβ levels were
analysed. The results are shown in Fig 5.7 and 5.8. Compared to animals administered
placebo those treated with leuprolide did not show significantly altered CSF Aβ40
levels. However a trend towards a reduction was observed following 18 days leuprolide
treatment. Two-way ANOVA revealed there was a main effect of duration of treatment
(F=9.589, p<0.005), rather than the treatment itself (F=0.072, p<0.079). This effect was
particularly evident in the leuprolide group where there was a significant increase at day
36, compared to day 18 post-treatment (p<0.012).
Analysis of brain Aβ40 levels revealed changes due to leuprolide treatment, particularly
in the frontal cortex.Analysis of Aβ40 levels in the frontal cortex revealed main effects
of both treatment (F=0.937; p<0.006) and duration of treatment (F= 0.935; p<0.007).
Compared to placebo, leuprolide treatment initially led to a significant increase in Aβ40
levels at 18 days (p=0.031), and then a reduction following 36 days of treatment
(p=0.024) (Figure 5.8 A). However, analysis of hippocampal Aβ40 levels showed no
effects of the treatment (F=1.31, p<0.266) or duration of treatment (F=0.09, p<0.768)
(Figure 5.8B).
Analysis of levels of APP and its C-terminal fragment in both the frontal cortex and
hippocampus

revealed

no

significant

changes

associated

with

leuprolide

treatment(Figure 5.9). However, analysis of α-APPs levels showed that leuprolide
increased the levels of this APP fragment. Two-way ANOVA revealed there were
significant effects of leuprolide treatment (F=28.158,p<0.001) and duration of treatment
(F=9.51,p<0.006). When compared to placebo there was a significant increase
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following 18 (p=0.002) and 36 (p= 0.001)days post-leuprolide treatment(p<0.05)(Figure
5.10).
Overall, the results show the most prominent effects of leuprolide were observed in the
frontal cortex. The levels of Aβ40 initially increased 18 days after treatment then
reduced following 36 days of treatment. Prominent increases in α-APPs were also
observed in the frontal cortex. No leuprolide mediated changes in Aβ40 levels were
observed in the CSF or hippocampus.
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Figure 5.8 : CSF Aβ40 levels from GDX guinea pigs administered placebo or
leuprolide for 18 or 36 days. Gonadectomised (GDX) guinea pigs were administered
placebo or leuprolide slow release pellet implants for 18 or 36 days and CSF was
collected from the cisterna magna. Although not significant, at day 18 compared to
animals administered placebo, those administered leuprolide showed reduced levels of
CSFAβ40. Levels increased in both the placebo and leuprolide groups 36 days after
administering the slow release implants. Data is represented as mean± SEM of 6
animals/group. Please note that CSFAβ40 from 2 samples of the day 18
leuprolidegroup,were not detectable by the ELISA assay.*, p<0.05, Values at day 36
significantly increased compared with animals treated with leuprolide for 18 days.
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Figure 5.9 : Aβ40 levels from frontal cortex and hippocampus of GDX guinea pigs
administered placebo or leuprolide for 18 or 36 days. Gonadectomised (GDX)
guinea pigs were administered placebo or leuprolide slow release pellet implants for 18
or 36 days and Aβ40 levels were measured in the frontal cortex and hippocampus.(A) In
the frontal cortex, treatment and duration of treatment impacted on Aβ40 levels.
Compared to placebo, leuprolide treatment initially led to a significant increase in Aβ40
levels at 18 days, and then a reduction following 36 days of treatment. (B) In contrast to
Aβ40 levels in the frontal cortex, treatment or duration of treatment did not impact on
hippocampal Aβ40 levels. Data is represented as mean± SEM of 6 animals per
group*p<0.05. Values significantly increased (Day18) or decreased (Day 36) in
leuprolide treated animals.

#p<0.05. Values at day 36 were significantly reduced

compared with leuprolide treatment at day 18.
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Figure 5.10 : Ratio of Aβ40 levels in the CSF to those in the frontal cortex (A) and
hippocampus (B) of GDX guinea pigs administered placebo or leuprolide for 18 or
36 days. A ratio of Aβ40 levels in the CSF to those in (A) frontal cortex and (B)
hippocampus was calculated and is presented as a bar graph.(A) In the frontal cortex,
there were no treatment (F=0.169, p<0.686), duration of treatment (F=2.577, p<0.127)
and interaction effect between treatment and duration of treatment (F=3.515, p<0.078)
impacted on rates of Aβ40 clearance. Compared to placebo, leuprolide treatment led to
a trend towards increases of CSF to Aβ40 ratio following 36 days of treatment. (B) In
hippocampus, treatment (F=0.018, p<0.894), duration of treatment (F=2.2, p<0.156)
and interaction effect between treatment and duration of treatment (F=1.946, p<0.181)
did not impact on hippocampal Aβ40 levels. Similar trends was observed like in frontal
cortex. Data is represented mean± SEM, for placebo day 18, n=4, for placebo day 36
n=8, for leuprolide day 18 n=4 and leuprolide day 36 n=6/group.
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Figure 5.11 : Levels of full length APP and its C-terminal fragment in frontal
cortex and hippocampus of GDX guinea pigs administered placebo orleuprolide
for 18 or 36 days.
Gonadectomised (GDX) guinea pigs were administered placebo or LH slow release
pellet implants for 18 or 36 days and levels of APP and its C-terminal fragment (APPCTF) were assessed by immunoblotting from tissue homogenates of (A) frontal cortex
or (B) hippocampus.(A) Treatment or duration of treatment did not significantly impact
on FL-APP (F=2.619,p<0.121; F=0.981,p<0.334) or APP-CTF (F=0.133,p<0.72;
(F=1.565,p<0.225) in the frontal cortex. (B) Treatment or duration of treatment did not
significantly impact on FL-APP (F=2.509,p<0.129; F=0.416,p<0.526) or APP-CTF
(F=6.191,p<0.22; (F=0.327,p<0.574) in the hippocampus. Data is represented as mean±
SEM of 6 animals/ group.
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Figure 5.12: Levels of α-APPs in frontal cortex of GDX guinea pigs administered
placebo or leuprolide for 18 or 36 days
(A) Homogenates from the frontal cortex underwent western immmunoblotting for αAPPs using antibody WO2. Immunoblotts show 2 representative samples from each
group.
(B) Quantitative analysis of all samples followed by Two-way ANOVA analysis
revealed a main effect of treatment (F=28.158,p<0.001) and duration of treatment
(F=9.51,p<0.006). **p<0.01 Values significantly increased compared to placebo. Data
is represented as mean± SEM of 6 animals/ group.
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5.4 Discussion

The findings from Chapter 4 provided initial evidence that direct exposure of the CNS
to LH can alter cerebral Aβ metabolism. Whether this occurs under more physiological
conditions is addressed in the current chapter where peripheral LH is administered as a
slow release implant (Bowen et al., 2004; Casadesus et al., 2006). In addition,
administration of the GnRH agonist (leuprolide acetate) was also investigated as it has
been shown to reduce LH levels (Bowen et al., 2004).
In Chapters 3 and 4, GDX was shown to increase CSFAβ40 levels, and the addition of
LH was shown promote a further increase (Chapter 4, Fig 4.1), which was associated
with increases in the frontal cortex and hippocampus. In contrast to these results,
findings in the current chapter showed that peripheral addition of LH resulted in a time
dependent increase in CSF Aβ40 levels but a reduction in cerebral Aβ40 levels. This
reduction was more prominent in the frontal cortex where significant changes were
observed earlier (18 days). However, by 36 days post- LH implantation, significant
reductions were observed in both frontal cortex and hippocampus. The reduction in
cerebral Aβ40 levels associated with a corresponding increase of CSF Aβ40 suggests
that Aβ clearance is enhanced in guinea pigs administered LH. However changes were
also observed in other APP metabolites, implying effects on APP processing. Although
not significant a trend towards a reduction in full length APP and APP-CTF level was
observed. This observation may account partially for the reduction in Aβ40 levels
within the frontal cortex and hippocampus, particularly at day 36 post-implant.
However significant increases in α-APPs in post-ultracentrifugation supernatants of the
frontal cortex were also observed.
To date current findings indicate that gonadotropins promote increased neuronal Aβ
levels (Bowen et al, 2004, Barron et al., 2010). Furthermore, increased serum
gonadotropins have been shown to be negatively associated with cognitive functioning
in human (Rodrigues et al., 2008, Hyde et al., 2010) and animal studies (Casadesus et
al., 2007, Berry et al., 2008, Barron et al., 2010).

Although peripheral LH

administration did result in an increase in CSF Aβ40 levels, surprisingly cerebral Aβ40
levels were reduced. Of particular note is the contrasting results presented here
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compared to that presented in chapter 4 (Wahjoepromono et al., 2011), where the
application of LH directly to the brain resulted in an increase in frontal cortex,
hippocampal and CSF Aβ40 levels. This is consistent with direct exposure of LH to
neuronal cells in vitro, which has been shown to increase secreted and intracellular
levels of Aβ, implicating a role for LH in promoting amyloidogenic processing of APP
(Bowen et al., 2004). The results presented in this current chapter however provide an
argument against this earlier notion of LH action, as although treatment with LH
increased CSF Aβ40 levels, there is a marked reduction in cerebral Aβ levels.
The dose of LH used in the two experiments namely in Chapter 4 and this current
Chapter were the same [2.25 ug/Kg (11.25 IU/Kg) BW/day]. Taken into account the
body weight and blood volume of the guinea pigs used (500g and 35 ml, respectively),
this dose is equivalent to 160 mIU/ml, which is about 16x and 5x the doses shown to
increase the intracellular accumulation of Aβ and APP-CTFsand increase secretion of
Aβ (10 mIU/ml and 30 mIU/ml, respectively) in vitro. The most likely explanation for
the contrasting results is the site of LH application, which most likely led to a different
level of exposure between the brain and the periphery. The direct application of slow
release implants to the brain would be expected to lead to much higher levels of LH as
opposed to its administration in the periphery. It could be argued that the high exposure
to LH in the guinea pig brain described in Chapter 4 is similar to the situation where
neurons exposed to LH, in vitro, result in the accumulation of Aβ (Bowen et al., 2004).
Although studies have shown the presence of gonadotropins in CSF (Heller et al., 1968,
Knowles, 1972), one study has shown that a relatively small percentage (<1%) of
peripheral gonadotropins (hCG), can cross the blood brain barrier into the CSF and
hippocampus (Lukacs et al., 1995). Further, LH is rapidly metabolized in the plasma
with its half-life reported to be about 69 minutes (Schalch et al., 1968).
In the experiments outlined in this Chapter the relatively rapid metabolism of LH would
be compensated with a constant, daily release of LH ensuring relatively constant levels
over a long term period. The concentration of LH used in this current study was about
5x less than the dose of its more potent analogue, hCG (60IU/kg/day) which was shown
to cause a modest increase (1.5x) in soluble Aβ40 levels in mice (Barron et al., 2010).
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Given the difference in potency of LH relative to hCG and the dose used it could be
argued that minimal or no effects (as compared to direct exposure to the CSF) would
have been observed. Surprisingly the converse is true where marked (opposite) effects
in the CNS was observed when LH is administered peripherally.
The increase in CSF Aβ40, decrease in cerebral Aβ40 and increase in soluble αAPPs,
implies the LH may be acting to reduce cerebral Aβ, by actually promoting release of
this neurotoxic peptide into the CSF. In favour of this notion there is evidence in the
literature that supports increased secretion of Aβ and enhanced αAPPs generation as a
mechanism by which to reduce intracellular Aβ. Querfurth and Selkoe, (1994) showed
that treatment with a calcium ionophore (that leads to an increase in intracellular
calcium) increased cellular secretion of Aβ, APPs, and also the non-amyloidgoenic
fragment, p3. More recently, insulin has been shown to increase the secretion of α-APPs
and Aβ, and reduce intracellular Aβ levels, a response that was mediated by MAPK
signalling (Gasparini et al., 2001). Similar findings were observed with latrepirdine
(previously known as DimebonTM), an anti-histamine showing cognitive enhancing
capabilities. Treatment of neuronal cells with latrepirdine led to an increase secretion of
Aβ and α-APPs (Steele et al., 2009). The latter study also showed that latrepirdine
administered to transgenic mice promoted the release of Aβ into the interstitial fluid
(ISF) and from isolated cortical synpatoneurosomes. It was suggested that latrepirdine
may enhance synaptic activity. Synaptic activity has been shown to modulate Aβ release
into the ISF (Cirrito et al., 2008) and promote the transport of APP to synapses and
secretion of Aβ at the synapses, thereby reducing intraneuronal levels of Aβ (Tampellini
et al., 2009).
The studies above suggest, intracellular calcium levels and APP trafficking/ synaptic
activity could all modulate the release of non-amyloidogenic and amyloidogenic
fragments. It could be speculated that LH may activate these pathways thereby
promoting release of APP metabolites and reduction in intracellular Aβ, however there
is no strong evidence in the current findings presented in this chapter or in the literature
that support this notion. Interestingly though, recent evidence indicates that intracellular
Ca+2 levels rise in bovine cumulus oocyte complexes (Silvestre et al., 2012) and mouse
leydig cells (Costa et al., 2011) following exposure to increased LH. The study by Costa
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et al (2011) further showed that the LH mediated increase in Ca+2 levels was attenuated
by protein kinase (PKC and PKA) inhibitors, indicating that the LH mediated changes
in intracellular calcium homeostasis is through activation of kinases (Costa et al., 2011),
which are known to regulate APP metabolism (Caporaso et al., 1992; Buxbaum et al.,
1993; Gillespie et al., 1992; Demaerschalck et al., 1993; Gabuzda et al., 1993; Slack et
al., 1993; Hung et al., 1993). Whether LH has a similar action in regulating calcium
levels in neurons and whether this is mediated through activating protein kinases that
regulate APP processing remains to be determined.
This Chapter also investigated whether, leuprolide acetate reduced cerebral Aβ levels in
guinea pigs similar to studies that have been reported in mice, (Bowen et al., 2004,
Casadesus et al., 2006). In the Bowen et al., study, a slow release leuprolide depot (1.5
mg/kg/BW) was injected monthly to C57Bl/6J mice for 8 weeks, resulting in a 1.5 fold
and ~4 fold reduction in soluble cerebral Aβ levels. Although serum gonadotropin
levels were not measured, the action of leuprolide in reducing gonadotropin secretion
indicated that it resulted in the reduction in cerebral Aβ levels. In a more recognized
model of AD, a slow release (depot) leuprolide formulation (7.5 mg/kg), was
administered intramuscularly, twice monthly, for a period of 3 months to 21 months in
APPswe mice. In this latter study although leuprolide treatment led to a ~ 4 fold
reduction in serum LH levels, there was a significant but modest ~20% reduction in
amyloid deposition (Casadesus et al., 2006).
The results presented in this Chapter extended the previous findings by showing that
leuprolide modulated cerebral Aβ levels in a time dependent manner, which lead to
contrasting trends in CSF Aβ40 levels compared to cerebral Aβ40 levels. Here,
administering leuprolide led to an initial increase at day 18 post-treatment. Following 36
days post-treatment a significant reduction compared to placebo, was observed. This
effect was most prominent in the frontal cortex when compared to the hippocampus. In
contrast, the ratio of CSF Aβ40 to frontal cortex levels was reduced following 18 days
of treatment, and then increased by 36 days of treatment. These findings parallel the
effects of leuprolide on altering gonadotropin levels where it results in an initial
increase or “flare effects” in serum gonadotropin secretion (generally lasting 10-20
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days), followed by a precipitous reduction (Okada et al., 1996, Weckermann et al.,
2004).
The experiments outlined in this current Chapter used a lower concentration of
leuprolide than that used in the Bowen et al (2004) and Casadesus et al (2006) studies.
In addition, leuprolide was administered via a slow release implant, mimicking chronic
reductions in gonadotropins. Serum LH levels were not measured in this study due to
difficulties in detecting guinea pig LH (see Chapter 4). However, similar studies have
shown that administering leuprolide via slow release implants lead to marked reductions
in serum LH following initial spikes (Okada et al., 1996).
A very recent study also administered leuprolide to the 3xTg AD mouse model via slow
release implants, but showed contrasting effects to that observed in mice or our guinea
pig model. In this study, Rosario and colleagues (2012) administered leuprolide to sham
operated male mice and showed it did not lower cerebral amyloid deposition or improve
hippocampal dependent memory (compared to GDX animals only). Further, when GDX
mice were administered leuprolide in combination with testosterone, it negated the
benefits of administering testosterone only at reducing cerebral amyloid load and
improving memory. It is difficult to explain the contrasting results to previous rodent
studies. Highlighted by Rosario and colleagues was the differences in sex where the
Bowen and Casadesus studies used female mice. Evidence exists indicating significant
sex differences in severity of pathology in AD mouse models (Carroll et al., 2010a;
Oliveira et al., 2011).and leuprolide has been shown to have benefits at improving
hippocampal dependent memory in female rat models (Bryan et al., 2010, (Ziegler and
Thornton, 2010). Together, these studies give precedence to the possible sex-specific
benefits which could be further addressed by a direct comparison of the effects of
leuprolide on the brains of OVX female and GDX male mice.
It is noteworthy that the two transgenic mouse studies (Casadesus et al., 2006, Rosario
et al., 2012), showed a subtle or no reduction in amyloid deposition (assessed by
immunohistochemistry), whilst, similar to the current study, the Bowen et al., 2004,
showed >2 fold reduction in soluble Aβ levels (assessed by ELISA) in the brains of
wild-type mice. Transgenic mice models exhibit a marked over-expression of cerebral
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human APP and Aβ, which may mask the potency of leuprolide at modulating Aβ levels
or the deposition of amyloid. As such it can not completely rule out the possibility that
leuprolide can still modulate the metabolism of endogenous Aβ resulting in reduced
soluble Aβ levels.
Although plaque deposition is not evident in guinea pig brain, guinea pig Aβ has the
capacity to form higher order molecular structures, such as oligomers (Beck, Bruckner
et al. 2000), widely considered to be the principal contributor to neurotoxicity in AD
pathogenesis. Thus a reduction in this species would be highly relevant to AD. Whether
leuprolide may reduce guinea pig Aβ levels in the frontal cortex by modulating APP
metabolism is not clear. In this Chapter, increases in α-APPs and corresponding
reductions in Aβ40 levels observed following 36 days leuprolide treatment (Fig 5.9A
and 5.12 respectively) and no changes in CSFAβ40 levels (Fig 5.8) at this time point
suggests that leuprolide may promote non-amyloidogenic processing of APP.
Overall the findings from this Chapter indicate that administering human LH to the
guinea pig periphery can alter CSF and cerebral Aβ40 levels, but unexpectedly, reduces
cerebral and increases CSF Aβ40 levels. This provides novel data that can be extended
to further in in vitro experiments to provide insight into the mechanisms by which LH
could impact on APP processing or Aβ clearance pathways. Administering the GnRH
agonist, leuprolide to transgenic mouse models have shown no or subtle changes in
cerebral Aβ40 levels. The results presented in this Chapter have provided evidence in a
non-transgenic animal model that leuprolide cansignificantly reduce cerebral Aβ40
levels, perhaps providing a more suitable model for assessing the benefits of leuprolide
on AD related proteins.
Conclusion
Chapters 3-5 have investigated the impact of key hormones of the HPG axis,
testosterone and LH on CSF and cerebral Aβ levels in the guinea pig. Chapter 4 and 5
have provided evidence for a role of LH in modulating Aβ levels. Chapter 4 has shown
that the direct application of human LH to the guinea pig CNS, results in an
accumulation of Aβ in a similar manner that has been reported for neuronal cells in
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culture and in vivo. In contrast, the application of human LH to the guinea pig periphery
resulted in reduced cerebral Aβ levels. Although not consistent with findings obtained
in mouse models, it provides an interesting line of research that can be further explored
in the guinea pig.
The findings presented in Chapter 3 confirm the effects of testosterone depletion and
supplementation in the guinea pig. Consistent with other in vivo models, testosterone
depletion through GDX led to an increase in CNS Aβ levels, while testosterone
supplementation prevented this increase. The following chapters assess the benefits of
testosterone supplementation on cognition, blood and imaging biomarkers in a cohort of
men with testosterone levels in the lower part of the normal range.
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Chapter 6
Effect of testosterone supplementation on
plasma biomarkers in men with subjective
memory complaints (SMC)
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6.1 Introduction

Male aging is accompanied by a gradual decline in testosterone activity (andropause).
This can manifest itself in many ways, including sexual dysfunction, diminished
physical stamina, loss of muscle and bone mass, systolic hypertension, the development
of abdominal visceral fat mass, insulin resistance, high levels of cholesterol, LDL and
triglycerides, low HDL levels, and impaired quality of life with symptoms such as
depression and cognitive impairment (Kenny et al., 2001; Moffat et al.,2002; Schroeder
et al.,2004; Wang et al.,1996). The decline in testosterone levels starts in the fifth
decade of life (Gray et al., 1991) , with men 70 years of age and older having the lowest
levels. Estimates for the prevalence of men with low levels of testosterone range from 1
in 200 (Morley, J.E, 2000) ,1 in 20 (Araujo et al., 2007) to 1 in 4 (Leifke 2000),
depending on age of population, ethnicity and health factors. Such men are candidates
for carefully monitored testosterone replacement therapy.
Many studies have already been undertaken regarding testosterone replacement therapy.
However, there is a lack of data based on longitudinal, double-blind, randomized
placebo-controlled

clinical

studies

of

aging

men

which

have

investigated

comprehensively testosterone’s long-term effects on a wide range of aspects of men’s
health including the cardiovascular system, the immune system, body metabolism, and
the brain. Although men in their sixties (in general) are less prone to AD than women of
the same age (Jorm, 1987), evidence suggests that testosterone deficiency is associated
with a higher risk for AD (Hogervorstet al., 2004; Rosario et al., 2004). Importantly, a
study by Moffat et al. 2004 indicates that the

deficiency precedes the onset of

dementia.
In the previous chapter, castrated guinea pigs were used as animal models to mimic the
condition of testosterone deficiency in men. Testosterone treatment in these animals
was shown to reduce CSF and cerebral Aβ levels. In cell culture studies of primary rat
cortical neurons testosterone has also been shown to decrease Aβ levels (Gouras et al.,
2000). These findings suggest that testosterone supplementation in elderly men may
protect against AD. Clinical studies do in fact suggest that testosterone levels can
influence Aβ levels. For example, Gandy et al. 2001 recorded an elevation in plasma Aβ
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levels in men being treated with testosterone suppression drugs for prostate cancer. In
addition, Almeida et al. 2004 found that low testosterone levels are associated with
increased plasma Aβ levels in men. Testosterone supplementation in men who have AD
or mild cognitive impairment (MCI) has been shown to improve spatial memory and
cognition (Tan et al., 2003; Cherrier et al., 2005). Although there have been some
inconsistencies in study results, most studies suggest that testosterone replacement
therapy might prevent or delay AD in testosterone deficient men (Traish et al., 2011).
Almost universally, a testosterone deficient state in older men is permanent and as a
result, testosterone replacement therapy (TRT) may be for life. Therefore, any
testosterone treatment would have to be very carefully designed and well researched.
The best approach in a clinical context would be via double-blind, randomized, crossover, placebo-controlled trials. Improvements in healthcare over the last few decades
have increased life expectancy considerably. Therefore the increased risks associated
with age-related low levels of testosterone may have massive implications for both the
individuals concerned and the community faced with the prospect of an aging
population that requires more health care facilities than we currently provide.
For many decades it was thought that raising testosterone levels would increase the risk
of prostate cancer. Over the last 10 years however, there has been much debate about
this theory, the evidence for this has been disputed, and in fact testosterone is now
believed not to increase the risk, even in people already at high risk of developing
prostate cancer (Rinnab et al., 2009 ;Feneley and Carruthers 2012 in press).
Some studies have linked testosterone treatment to other important adverse health
outcomes such as increased risks of atherosclerosis and depressive illness. However,
studies showing unfavourable outcomes usually concern people deliberately trying to
achieve supraphysiological levels for the purpose of improving athletic performance, for
example (Aaronson et al., 2011). Results from such studies do not apply to patients
trying to maintain testosterone within a normal physiological range. However, extra
care needs to be taken in order to balance the possible therapeutic benefits against the
potential risks. This chapter describes a clinical study that was undertaken to investigate
the effect of testosterone treatment in a group of elderly with testosterone in the lower
part of the normal range and below. Parameters that were investigated include blood and
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brain imaging biomarkers and cognitive performance. Side-effects of the treatment were
also monitored. The blood biomarkers that were measured include testosterone and its
derivative dihydrotestosterone (DHT), SHBG, Calculated Free Testosterone, estradiol,
luteinizing hormone (LH), insulin, PSA levels, and plasma Aβ levels. Lipid profiles of
the participants were also characterised. The effect of testosterone on cognitive
performance and brain imaging biomarkers will be presented in chapters 7 and chapter 8
respectively.

6.2 Aims
The aims of this study were :


To investigate the effect of testosterone administration on plasma levels of
testosterone, its derivative dihydrotestosterone (DHT), Calculated Free
Testosterone, and its aromatization product estradiol.



To investigate the effect of testosterone treatment on luteinizing hormone (LH)
levels in blood plasma.



To investigate the effect of testosterone administration on lipid profiles in blood
plasma, which include levels of cholesterol, triglyceride, LDL, HDL, Chol/HDL
and calculated LDL/ HDL ratios.



To investigate whether testosterone treatment in men with low normal and
below reduces plasma Aβ levels.



To investigate the effects of testosterone treatment on plasma insulin levels.



To investigate the effect of testosterone treatment on Prostate Specific Antigen
(PSA) levels in blood plasma.



To determine whether there is an APOE genotype specific response to
testosterone treatment.
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6.3 Methods

Participants

Forty-four of the 50 subjective memory complainers men who met the eligibility
criteria completed the study. They were recruited and assigned to one of the two
parallel groups; placebo (n=22) or testosterone (n=22) treatment. Assignment
was random using stratification to ensure each arm of the study was balanced, in
terms of individual memory performance at baseline. The study design was such
that participants received testosterone treatment or placebo for a period of 24
weeks, followed by a washout period of 4 weeks, after which time, the
participant groups were “crossed over”, such that the placebo group received
testosterone and vice versa for a further 24 weeks. For all participants, there
were a total of 11 clinic visits to Siloam Hospital, Lippo Karawaci (Indonesia),
within the 52-week study period. The participants and the investigators were
blinded to the treatment assignment until the completion of the study.

Procedure
During the first (baseline) visit, participant blood pressure, height, weight, body
fat percentage and body mass index (BMI) were checked and blood was drawn.
Blood samples ( 45 ml) were collected using serum separating tubes (SST, that
include a gel and blood clot activator), EDTA, and heparin collection tubes.
Blood in SST collection tubes were centrifuged at 2500 rpm for 10 min to
separate the serum. This serum was removed, divided into 1 ml aliquots to
which 10l (100 g/ml) of protein inhibitor (aprotinin – Sigma) was added.
Blood samples in EDTA and heparin collection tubes were centrifuged at 1000
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rpm for 10 min at RT, to separate the plasma, leucocytes, and red blood cells.
Plasma was removed and centrifuged further at 2500 rpm for 10 min to harvest
platelets. The resulting supernatant (plasma) was aliquoted (~ 1 to 5 ml lots) and
10µl protein inhibitor (aprotinin – Sigma) was added to each ml of plasma.
These blood samples were used for baseline readings of blood counts, serum
testosterone levels, levels of LH and sex hormone binding globulin (SHBG),
DHT (dihydrotestosterone), estradiol, cholesterol, insulin, glucose, PSA, plasma
Aβ levels and lipid (as described in section 2.1.1.2.2). The participants’ APOE
genotypes were also determined.
For the testosterone treatment group (n=22), testosterone (50 mg in the form of
Andromen® FORTE cream) was applied daily to the scrotum, thus using a
transdermal route (topically), for a period of 24 weeks. For the placebo group
(n=22) the same amount of the cream base [dl- tocopherol acetate (vitamin E),
without the active ingredient, testosterone] was applied with the same frequency.
At each of the six remaining clinic visits i.e. at 4, 8, 12, 16, 20 and 24 weeks
during the first treatment period, blood collection was carried out as described
for the baseline measurement. During the 4 week washout period, the
participants were given an equivalent amount of cream base lacking testosterone
and vitamin E that was also applied to the scrotum. The placebo and testosterone
treatment arms of the study were then crossed-over for a further 24-weeks
treatment period. During this period, the participants were examined every eight
weeks (three bleeds in total i.e. at weeks 8, 16 and 24 of the cross-over period);
and blood samples were collected for analysis as described previously.

Blood biomarker measurement
Serum samples (n=535) were analyzed for total testosterone (TT) and
dihydrotestosterone (DHT) using an isotope dilution LC-MS/MS method at the
Anzac Research Institute, NSW (Handelsman et al, 2011). Other serum samples
were analyzed for LH, estradiol, PSA, SHBG and insulin in Pathwest
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Laboratory, Perth, Western Australia and plasma heparin were analyzed for lipid
profile and albumin. Serum free testosterone (CFT) was calculated from TT,
SHBG and albumin using the standard formula of Vermeulen,1999.. Plasma Aβ
was measured using an ELISA developed in Prof Martins laboratory (Mehta et
al., 2000).

Statistical analysis
Statistical analysis was performed using The Statistical Package of Social
Sciences (SPSS version 19, SPSS Inc, Chicago, IL). The Kolmogorov-Smirnov
and Levene’s test was used to examine normality of distribution of continuous
variables for each group. The analysis consisted of repeated-measures analysis
of variance to compare between treatment groups, within-subject changes over
the course of the treatment period. For parametric data, one way ANOVA
repeated measures were performed to look at changes in blood biomarkers over
time and following the different treatments, assuming no carry-over effects of
testosterone treatment. Carry over effects were tested from differences at
baseline in the first period (week 0) and at the washout period (week 24-28,
which is baseline for the second period). For non-parametric data, Friedman’s
Test and/or Wilcoxon signed-rank test was performed. When directly comparing
two groups from both arms of the study, as well as comparing two groups based
on the presence of APOEε4, two tailed independent t-tests were performed. All
analyses were two-tailed and the alpha level was set at .05.
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6.4 Results

Participant characteristics at baseline
There were no differences between the two treatment groups of the study in
terms of age, years of education, APOE allele status, and Body Mass Index
(BMI)

as shown in Table 6.1. There were also no significant differences

observed in BMI and % body fat over time for both arms (Figure 6.1a and 6.1b).

Table 6.1 Mean (SD) age, education, Body Mass Index (BMI), and % Body Fat at
baseline
Group

n

Age

Education

BMI

Treatment AB
APOE ε 4-

22
14

59.22 (7.18)
59 (5.82)

13.95 (2.84)
13.79 (3.31)

26.4 (3.64)
25.62 (2.6)

APOE ε4+

8

59.625 (9.58

14.25 (1.91)

27.77 (4.9)

Treatment B-->A

22

62.91 (8.22)

13.76 (3.39)

APOE ε 4-

18

62.72 (7.31)

13.47 (3.62)

APOE ε4+

4

63.75 (13)

15 (2)
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24.25
(3.83)
24.18
(3.92)
24.55
(3.91)

% Body Fat
24.29
(2.65)
23 (1.16)
25.58
(2.51)
22.05
(1.75)
20.9 (1.58)
23.2 (1.98)

(A)
35

BMI (kg/m2)

30
25
20
15
10

BL

A_1

A_2

A_3

A_4

A_5

A_6

WO

B_1

B_2

B_3

BMI non‐APOE ε4 (n=14) 25.62 25.78 25.91 25.90 25.74 25.60 25.49 26.16 25.47 25.52 25.64
BMI ApoE ε4 (n=8)

27.78 27.90 27.91 27.95 28.01 28.00 27.78 27.70 27.70 26.83 26.87
Treatment A‐‐>B

(B)

BMI (kg/m2)

30
25
20
15
10

BL

B_1

B_2

B_3

B_4

B_5

B_6

WO

A_1

A_2

A_3

BMI non‐APOE ε4 (n=18) 24.18 24.08 24.26 24.34 24.27 24.28 24.22 24.27 24.27 24.02 23.86
BMI APOE ε4 (n=4)

24.55 25.25 25.48 25.43 25.40 25.40 25.43 25.55 25.50 25.60 25.55
Treatment B‐‐>A

Figure 6.1(a) : Comparison of non-APOE ε4 and APOE ε4 carriers for Body Mass
Index (BMI) (n=22) at 11 visits in treatment group AB (A) and treatment group
BA (B). The bars represent the mean + standard deviation. Values in kg/m2
underneath the bars are the mean of each group. No differences were observed between
any of the groups of either arm, and APOEε4 status had no effect. BL= Baseline, A_1 to
A_6 (graph A) & B_1 to B_6 (graph B) = First Treatment period, WO=Wash-out, B_1
to B_3 (graph A) & A_1 to A_3 (graph B) = Second (Cross-over) treatment period.
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(A)
30

% body fat

25
20
15
10

BL

A_1

A_2

A_3

A_4

A_5

A_6

WO

B_1

B_2

B_3

% body fat non‐APOE ε4 (n=14) 23.00 23.21 22.97 23.27 23.52 23.64 23.21 22.70 21.66 22.71 23.48
% body fat APOE ε4 (n=8)

25.58 24.75 24.05 24.91 26.34 24.96 25.26 24.99 25.04 23.47 24.24
Treatment A‐‐>B

(B)
30

% body fat

25
20
15
10

BL

B_1

B_2

B_3

B_4

B_5

B_6

WO

A_1 A_2 A_3

% body fat non‐APOE ε4 (n=18) 20.90 21.17 21.25 21.52 21.51 21.31 21.42 20.93 21.41 20.93 20.79
% body fat APOE ε4 (n=4)

23.20 23.43 23.13 23.83 23.93 23.85 23.85 23.33 24.00 23.68 24.10
Treatment B‐‐>A

Figure 6.1(b) : Comparison of non-APOE ε4 and APOE ε4 carriers for % Body
Fat (n=22) at 11 visits in treatment AB (A) and treatment BA (B). The bars
represent the mean + standard deviation. Values in percentage underneath the bars are
the mean of each group. No differences were observed between any of the groups of the
two arms, and APOEε4 allele status did not influence results. BL= Baseline, A_1 to
A_6 (graph A) & B_1 to B_6 (graph B) = First Treatment period, WO=Wash-out, B_1
to B_3 (graph A) & A_1 to A_3 (graph B) = Second (Cross-over) treatment period.
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6.4.1 Effects of testosterone administration on plasma total testosterone levels and
its by-products, dihydrotestosterone (DHT) and estradiol.

#

#

#

#

Week 0
Week 4‐24
(Baseline) (Treatment A)

Week 25‐28
(Washout)

Week 29‐52
(Cross‐over B)

Week 0
(Baseline)

Week 4‐24
(Treatment B)

Week 25‐28
(Washout)

Week 29‐52
(Cross‐over A)

Figure 6.2 : Boxplots of total serum testosterone levels for both arms at 4 different
time points: Week 0 (Baseline), Week 4-24 (Treatment), Week 25-28 (Washout),
and Week 29-52 (Cross-over). Data were in nmol/L and are presented as median +
quartiles. Values in the first treatment are the averages of 6 measurements and values
given for the second treatment period (Cross-over) are the average of 3 measurements.
Testosterone levels were significantly increased in treatment A and cross-over A (ie
testosterone treatment times) compared to all other treatment periods in the two arms.
*p<0.05 in comparison

to baseline of each arm of the treatments, # p<0.05 in

comparison between time points (shown by brackets).
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Testosterone (nmol/L)

(A)

45
40
35
30
25
20
15
10
5
0

*

BL

A_1

A_2

*

A_3

*

A_4

A_5

A_6

WO

B_1

B_2

B_3

T non‐APOE ε4 (n=14) 16.47 29.72 25.86 22.45 23.38 19.96 22.06 17.52 16.26 16.05 15.23
T APOE ε4 (n=8)

16.46 33.24 38.31 34.10 30.71 32.78 31.46 17.03 15.00 15.89 15.44
Treatment A‐‐>B

(B)
40

Testosterone (nmol/L)

35
30
25
20
15
10
5
0

B_1

B_2

B_3

B_4

B_5

B_6

WO

A_1

A_2

A_3

T non‐APOE ε4 (n=18) 18.17

BL

17.83

18.32

18.56

18.77

17.40

17.58

18.55

28.27

28.83

31.44

T APOE ε4 (n=4)

16.43

15.93

17.08

17.22

20.88

15.61

15.13

17.80

17.78

17.66

17.58

Treatment B‐‐>A

Figure 6.3 : Comparison of serum testosterone levels in APOE ε4 and non-APOE
ε4 carriers (n=22) at 11 visits in treatment AB (A) and treatment BA (B). The
bars represent the mean + standard deviation. Values in nmol/L underneath the bars are
the mean of each group. Significant differences were observed between non-APOE ε4
and APOE ε4 group in treatment arm AB (*p<0.05). BL= Baseline, A_1 to A_6
(graph A) & B_1 to B_6 (graph B) = First Treatment period, WO=Wash-out, B_1 to
B_3 (graph A) & A_1 to A_3 (graph B) = Second (Cross-over) treatment period.
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Dihydrotestosterone (DHT), a peripheral conversion product of testosterone, was also
monitored (Figure 6.4). Free or unbound testosterone resulting from administration of
transdermal testosterone will have entered the prostate and been reduced to some degree
by 5-alpha reductase to DHT, which would then have been able to bind to androgen
receptors.

#

#

#
#

Week 0
(Baseline)

Week 4‐24 Week 25‐28
(Treatment A) (Washout)

Week 29‐52
(Cross‐over B)

Week 0
(Baseline)

Week 4‐24
(Treatment B)

Week 25‐28
(Washout)

Week 29‐52
(Cross‐over A)

Figure 6.4 : Boxplots of serum dihydrotestosterone (DHT) levels for both arms at 4
different time points : Week 0 (Baseline), Week 4-24 (Treatment), Week 25-28
(Washout), and Week 29-52 (Cross-over). Data are in nmol/L and are presented as
median + quartiles. Values shown in first treatment are the averages from 6 visits and
values in the second treatment time (Cross-over) were averaged from 3 visits. Similar to
total testosterone levels, DHT levels were significantly increased in treatment A and
cross-over A compared to all groups in both arms. *p<0.05 in comparisons to baseline
of each arm of the treatments, # p<0.05 in comparisons between groups designated by
brackets.
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Dihydrotestosterone (nmol/L)

(A)
20

*

15

*

*

*

10

5

0

BL

A_1

A_2

A_3

A_5

A_6

WO

B_1

B_2

B_3

9.81

7.13

7.51 12.27 6.98

7.56

2.01

1.90

1.76

1.83

1.83 12.41 12.97 10.43 11.89 10.58 10.55 1.58

1.32

1.69

1.58

DHT non‐APOE ε4 (n=14) 1.85
DHT APOE ε4 (n=8)

A_4

Treatment A‐‐>B

(B)

Dihydrotestosterone (nmol/L)

15

10

*
5

0

BL

B_1

B_2

B_3

B_4

B_5

B_6

WO

A_1

A_2

A_3

DHT non‐APOE ε4 (n=18)

2.15

1.73

1.83

1.83

2.03

1.76

1.68

1.72

8.77

9.15

9.12

DHT APOE ε4 (n=4)

3.60

1.91

1.84

1.63

1.48

5.15

1.87

1.70

7.39

6.90

7.60

Treatment B‐‐>A

Figure 6.5 : Comparison of serum DHT levels in APOE ε4 and non-APOE ε4
carriers (n=22) at the individual 11 visits in treatment AB (A) and treatment
BA (B). The bars represent the mean + standard deviation. Values in nmol/L
underneath the bars are the mean of each group. Significant differences were observed
between non-APOE ε4 and APOE ε4 group in both treatment arm (*p<0.05). BL=
Baseline, A_1 to A_6 (graph A) & B_1 to B_6 (graph B) = First Treatment period,
WO=Wash-out, B_1 to B_3 (graph A) & A_1 to A_3 (graph B) = Second (Cross-over)
treatment period.
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#

#
#

Week 0
(Baseline)

Week 4‐24
(Treatment A)

Week 25‐28
(Washout)

#

Week 29‐52
(Cross‐over B)

Week 0
Week 4‐24
(Baseline) (Treatment B)

Week 25‐28
(Washout)

Week 29‐52
(Cross‐over A)

Figure 6.6 : Boxplots of serum DHT/Testosterone ratios for the two treatment
arms at 4 different time points : Week 0 (Baseline), Week 4-24 (Treatment), Week
25-28 (Washout), and Week 29-52 (Cross-over). Data are presented as median
+quartiles. Values shown in the first treatment period are the averages from 6 visits and
values in the second treatment period (Cross-over) are averages from 3 visits. Similar to
results observed for testosterone and DHT levels, DHT to testosterone ratios were
significantly increased in treatment A and cross-over A compared to other treatment
periods in the two arms.

*p<0.05 in comparison to baseline of each arm of the

treatments, # p<0.05 in comparisons between other periods (shown by brackets).
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(A)

DHT/T ratio

2

1

0

BL

A_1

A_2

A_3

A_4

A_5

A_6

WO

B_1

B_2

B_3

DHT/T non‐APOE ε4 (n=14) 0.38

1.17

0.88

1.16

1.18

1.23

1.11

0.37

0.42

0.41

0.44

DHT/T APOE ε4 (n=8)

1.36

1.19

1.15

1.41

1.17

1.09

0.32

0.29

0.38

0.37

0.38

Treatment A‐‐>B

(B)

DHT / T ratio

3

2

1

0

BL

B_1

B_2

B_3

B_4

B_5

B_6

WO

A_1

A_2

A_3

DHT/T non‐APOE ε4 (n=18)

0.43

0.35

0.36

0.34

0.38

0.35

0.33

0.32

1.14

1.20

1.04

DHT/T APOE ε4 (n=4)

0.33

0.41

0.39

0.33

0.29

0.75

0.40

0.40

1.65

1.37

1.52

Treatment B‐‐>A

Figure 6.7 : Comparison of serum DHT/Testosterone ratios in APOE ε4 and nonAPOE ε4 carriers (n=22) at 11 visits in treatment AB (A) and treatment BA
(B). The bars represent the mean + standard deviation. Values underneath the bars are
the mean of each group. No significant differences were observed between the APOE
ε4- and non-APOE ε4 groups in either treatment arm (*p<0.05). BL= Baseline, A_1 to
A_6 (graph A) & B_1 to B_6 (graph B) = First Treatment period, WO=Wash-out, B_1
to B_3 (graph A) & A_1 to A_3 (graph B) = Second (Cross-over) treatment period.
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(ε2 ε3)

(ε3 ε4)

(ε3 ε3)

(ε3 ε4)

Figure 6.8 : Representative data of individual total testosterone and DHT levels in
treatment AB
(ε2 ε3)

(ε3 ε4)

(ε3 ε3)

(ε3 ε4)

Figure 6.9 : Representative data of individual total testosterone and DHT levels in
treatment BA
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#
#

Week 0
Week 4‐24
(Baseline) (Treatment A)

Week 25‐28
(Washout)

Week 29‐52
(Cross‐over B)

Week 0
(Baseline)

Week 4‐24 Week 25‐28
(Treatment B) (Washout)

Week 29‐52
(Cross‐over A)

Figure 6.10 : Boxplots of serum Estradiol levels for both treatment arms at 4
different time points : Week 0 (Baseline), Week 4-24 (Treatment), Week 25-28
(Washout), and Week 29-52 (Cross-over). Data are shown in pmol/L and are
presented as median + quartiles. Treatment A values are the averages of measurements
at 6 visits and values in the second treatment period (Cross-over) are averages from 3
visits. Significantly lower estradiol levels were measured during the placebo treatment
(Treatment B) compared to washout and testosterone treatment (Cross-over A) in
treatment arm BA. # p<0.05 in comparison to other treatment periods.

Changes in estradiol level were not found to be significant when comparing the
different treatment stages of treatment arm AB. However there were subtle changes
seen in treatment BA.

190

(A)
140

Estradiol (pmol/L)

120
100
80
60
40
20
0

BL

A_1

A_2

A_3

A_4

A_5

A_6

WO

B_1

B_2

B_3

Estradiol non‐APOE ε4 (n=14) 80.00 95.00 95.00 80.00 75.71 66.43 80.00 90.00 76.43 80.71 93.57
Estradiol APOE ε4 (n=8)

82.50 88.75 106.25 93.75 85.00 90.00 91.25 76.25 81.25 76.25 91.25
Treatment A‐‐>B

(B)
140

Estradiol (pmol/L)

120
100
80
60
40
20
0

BL

Estradiol non‐APOE ε4 (n=18) 76.67
Estradiol APOE ε4 (n=4)

95

B_1

B_2

B_3

B_4

B_5

B_6

WO

A_1

A_2

A_3

70.56

71.11

66.67

70.56

72.22

84.44

82.22

84.44

95.00

102.78

70

80

87.5

70

85

92.5

87.5

82.5

87.5

80

Treatment B‐‐>A

Figure 6.11 : Comparison of serum estradiol levels in APOE ε4 and non-APOE ε4
carriers (n=22) at the individual 11 visits of treatment AB (A) and treatment
BA (B). The bars represent the mean + standard deviation. Values in pmol/L
underneath the bars are the mean of each group. No differences were observed between
the non-APOE ε4 and APOE ε4 groups of the two treatment arms. BL= Baseline, A_1
to A_6 (graph A) & B_1 to B_6 (graph B) = First Treatment period, WO=Wash-out,
B_1 to B_3 (graph A) & A_1 to A_3 (graph B) = Second (Cross-over) treatment period.
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Week 0
(Baseline)

Week 4‐24
(Treatment A)

Week 25‐28
(Washout)

Week 29‐52
(Cross‐over B)

Week 0
Week 4‐24
(Baseline) (Treatment B)

Week 25‐28
(Washout)

Week 29‐52
(Cross‐over A)

Figure 6.12 : Boxplot of serum Estradiol/Testosterone ratios for both treatment
arms at the 4 different treatment stages: Week 0 (Baseline), Week 4-24
(Treatment), Week 25-28 (Washout), and Week 29-52 (Cross-over). Data are
presented as median + quartiles. No significant differences were observed between any
of the treatment stages of either of the arms. However, there was a trend towards
decreased estradiol/testosterone ratios following testosterone treatment.
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Testosterone / Estradiol

(A)
1400

*

1200
1000
800
600
400
200
0

BL

A_1

A_2

A_3

A_4

A_5

A_6

WO

B_1

B_2

B_3

T/E non‐APOE ε4 (n=14) 215.78 782.27 300.65 329.36 337.17 317.80 282.76 201.22 236.43 205.51 168.36
T/E APOE ε4 (n=8)

215.00 468.04 392.97 400.52 387.37 392.94 398.63 225.44 222.29 230.48 172.41
Treatment A‐‐>B

(B)

Testosterone/Estradiol

600

*
400

200

0

BL

B_1

B_2

B_3

B_4

B_5

B_6

WO

A_1

A_2

A_3

T/E non‐APOE ε4 (n=18) 261.582 282.963 301.042 311.197 307.968 280.703 247.520 245.997 405.222 347.977 320.916
T/E APOE ε4 (n=4)

189.164 242.290 207.087 203.544 267.234 287.244 167.983 178.225 219.425 223.904 215.455
Treatment B‐‐>A

Figure 6.13 : Comparison of the testosterone/estradiol ratios in non-APOE ε4 and
APOE ε4 carriers (n=22) at the 11 individual visits of treatment AB (A) and
treatment BA (B). Values are presented as mean + standard deviation. Significant
differences were observed between the non-APOE ε4 and APOE ε4 groups in both arm
treatment within 4 weeks of testosterone treatment(*p<0.05). BL= Baseline, A_1 to
A_6 (graph A) & B_1 to B_6 (graph B) = First Treatment period, WO=Wash-out, B_1
to B_3 (graph A) & A_1 to A_3 (graph B) = Second (Cross-over) treatment period.
However it needs to be noted that there were only 4 APOE ε4 patients in the BA
treatment group
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6.4.2 Effects of testosterone administration on Luteinizing Hormone (LH) levels in
the plasma

#
#

#

#

Week 0
(Baseline)

Week 4‐24
(Treatment A)

Week 25‐28
(Washout)

Week 29‐52 Week 0
(Cross‐over B) (Baseline)

Week 4‐24 Week 25‐28
(Treatment B) (Washout)

Week 29‐52
(Cross‐over A)

Figure 6.14 : Boxplots of serum Luteinizing Hormone (LH) levels for both
treatment arms measured at the 4 different treatment stages: Week 0 (Baseline),
Week 4-24 (Treatment), Week 25-28 (Washout), and Week 29-52 (Cross-over).
Data are in U/L and are presented as median +quartiles. Values in the Treatment stages
are average serum levels from 6 visits and values in the second (Cross-over) treatment
period are the averages from 3 visits. LH levels were significantly decreased in
treatment A and cross-over A (ie testosterone treatment times) compared to all other
treatment periods in both arms. *p<0.05 in comparison to baseline, # p<0.05 in
comparisons between other treatment periods.
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(A)
7
6

LH (U/L)

5

*

4
3
2
1
0

A_1

A_2

A_3

A_4

A_5

A_6

WO

B_1

B_2

B_3

LH non‐APOE ε4 (n=14) 4.21

BL

2.04

1.72

1.91

2.09

2.04

2.85

4.28

4.93

4.93

5.07

LH APOE ε4 (n=8)

1.70

1.58

1.66

2.05

1.40

1.44

4.13

4.63

3.88

4.63

4.25

Treatment A‐‐>B

(B)

Figure 6.15 : Comparison of serum LH levels in non-APOE ε4 and APOE
ε4carriers (n=22) at the 11 individual visits of treatment AB (A) and treatment
BA (B). The bars represent the mean + standard deviation. Values in U/L underneath
the bars are the mean of each group. Significant differences were observed between the
non-APOE ε4 and APOE ε4 groups of both treatment arms at the end of testosterone
treatment (*p<0.05). BL= Baseline, A_1 to A_6 (graph A) & B_1 to B_6 (graph B) =
First Treatment period, WO=Wash-out, B_1 to B_3 (graph A) & A_1 to A_3 (graph B)
= Second (Cross-over) treatment period.
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6.4.2 Effects of testosterone administration on plasma lipid profiles of the
participants.

Week 0
(Baseline)

Week 4‐24
(Treatment A)

Week 25‐28
(Washout)

Week 29‐52
(Cross‐over B)

Week 0
(Baseline)

Week 4‐24
Week 25‐28
(Treatment B) (Washout)

Week 29‐52
(Cross‐over A)

Figure 6.16 : Boxplots of Total serum Cholesterol levels for both treatment arms at
the 4 different treatment stages: Week 0 (Baseline), Week 4-24 (Treatment), Week
25-28 (Washout), and Week 29-52 (Cross-over). Data are in mmol/L

and are

presented as median +quartiles. Values in the Treatment stages are average levels from
6 visits and values in the second (Cross-over) treatment period are the averages from 3
visits. There was a significant decrease in total cholesterol levels during testosterone
treatment in treatment arm AB. *p<0.05 in comparison to baseline in treatment arm
AB.
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Figure 6.17: Comparison of total cholesterol levels in non-APOE ε4 and APOE
ε4carriers: average results from each of the 11 visits for treatment arms AB (A)
and BA (B). The bars represent the mean + standard deviation. Values in mmol/L
underneath the bars are the mean of each group. No significant differences were
observed between the non-APOE ε4 and APOE ε4 groups of the two treatment arms.
BL= Baseline, A_1 to A_6 (graph A) & B_1 to B_6 (graph B) = First Treatment period,
WO=Wash-out, B_1 to B_3 (graph A) & A_1 to A_3 (graph B) = Second (Cross-over)
treatment period, (n=22).
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Figure 6.18: Boxplots of serum Triglyceride (TG) levels for the two treatment arms
at the 4 different treatment stages: Week 0 (Baseline), Week 4-24 (First
Treatment), Week 25-28 (Washout), and Week 29-52 (Cross-over). Data are in
mmol/L and are presented as median +quartiles. The values in the first treatment stages
are the average levels from 6 measurements over the treatment period and values in the
second treatment (Cross-over) period are the average of 3 measurements. There were no
significant differences observed in either of the treatment groups.
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Figure 6.19 : Comparison of serum triglyceride (TG) levels in non-APOE ε4 and
APOE ε4 carriers: average results from the 11 individual visits in treatment arms
AB (A) and treatment BA (B). The bars represent the mean + standard deviation.
Values in mmol/L underneath the bars are the mean of each group. No significant
differences were observed between the non-APOE ε4 and APOE ε4 groups in either
arm. BL= Baseline, A_1 to A_6 (graph A) & B_1 to B_6 (graph B) = First Treatment
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period, WO=Wash-out, B_1 to B_3 (graph A) & A_1 to A_3 (graph B) = Second
(Cross-over) treatment period. (n=22).

Week 0
(Baseline)

Week 4‐24
(Treatment A)

Week 25‐28
(Washout)

Week 29‐52
(Cross‐over B)

Week 0
(Baseline)

Week 4‐24
(Treatment B)

Week 25‐28
(Washout)

Week 29‐52
(Cross‐over A)

Figure 6.20 : Boxplots of serum Low Density Lipoprotein (LDL) levels for the two
treatment arms showing averages from the 4 different treatment periods: Week 0
(Baseline), Week 4-24 (Treatment), Week 25-28 (Washout), and Week 29-52
(Cross-over). Data are in mmol/L and are presented as median + quartiles. Values
shown in the first treatment period are the average results from blood samples from 6
visits, and values in the second (Cross-over) treatment period were averaged from 3
visits. There were no differences observed between any of the 4 stages of either arm.
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Figure 6.21 : Comparison of LDL levels in non-APOE ε4 and APOE ε4 carriers at
each of the 11 visits of treatment arms AB (A) and BA (B). The bars represent
the mean + standard deviation. Values in mmol/L underneath the bars are the mean of
each group. No significant differences were observed between non-APOE ε4 and APOE
ε4 groups of either arm. BL= Baseline, A_1 to A_6 (graph A) & B_1 to B_6 (graph B)
= First Treatment period, WO=Wash-out, B_1 to B_3 (graph A) & A_1 to A_3 (graph
B) = Second (Cross-over) treatment period. (n=22).
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Overall, no significant changes in LDL level were observed between the stages of either
of the treatment arms. However, in treatment arm AB, we found a slight decrease in
LDL levels in the non-APOE ε4 group following testosterone treatment. After
testosterone treatment, LDL levels returned back to that seen at baseline level.
Interestingly, in treatment BA, we found a slight increase of LDL following
testosterone treatment in the APOE ε4 group. (Figures 6.20 and 6.21).
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Week 25‐28
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(Cross‐over A)

Figure 6.22 : Boxplots of High Density Lipoprotein (HDL) levels for both
treatment arms during the 4 different treatment periods: Week 0 (Baseline), Week
4-24 (Treatment), Week 25-28 (Washout), and Week 29-52 (Cross-over). Data are
in mmol/L and presented as median + quartiles. The values in the first treatment stages
are the averages of blood sample measurements from 6 visits and values in the second
(Cross-over) treatment are the averages from 3 visits. Compared to baseline levels, there
were significant decreases in HDL levels at all other stages in treatment arm AB.
*p<0.05 in comparison to baseline, however there were no significant differences in the
BA arm.
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Figure 6.23 : Comparison of HDL levels in APOE ε4 and non-APOE ε4 carriers at
the 11 individual visits in treatment AB (A) and treatment BA (B). The bars
represent the mean + standard deviation. Values in mmol/L underneath the bars are the
mean of each group. There were no significant differences observed between the nonAPOE ε4 and APOE ε4 groups of either arm. BL= Baseline, A_1 to A_6 (graph A) &
B_1 to B_6 (graph B) = First Treatment period, WO=Wash-out, B_1 to B_3 (graph A)
& A_1 to A_3 (graph B) = Second (Cross-over) treatment period. (n=22).
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Figure 6.24 : Boxplots of Cholesterol/HDL ratios for each of the 4 stages of
treatment AB and treatment BA: Week 0 (Baseline), Week 4-24 (Treatment),
Week 25-28 (Washout), and Week 29-52 (Cross-over). Data are presented as median
+quartiles. The values in the first treatment stages are the averages of blood sample
measurements from 6 visits and values in the second treatment (Cross-over) stages are
the average results from 3 visits. There were no differences observed in either treatment
arm.
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Figure 6.25 : Comparison of plasma cholesterol/HDL ratios in non-APOE ε4 and
APOE ε4 carriers at each of the individual 11 visits of treatments AB (A) and
BA (B). The bars represent the mean + standard deviation. Values underneath the
bars are the mean of each group. No significant differences were observed between the
non-APOE ε4 and APOE ε4 groups of either treatment arm. BL= Baseline, A_1 to A_6
(graph A) & B_1 to B_6 (graph B) = First Treatment period, WO=Wash-out, B_1 to
B_3 (graph A) & A_1 to A_3 (graph B) = Second (Cross-over) treatment period.
(n=22).
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Figure 6.26: Boxplots of LDL/HDL ratios at each treatment stage in treatment
AB and treatment BA: Week 0 (Baseline), Week 4-24 (Treatment), Week 2528 (Washout), and Week 29-52 (Cross-over). Data are presented as median +
quartiles. The values in the first treatment stages are the averages of blood sample
measurements from 6 visits and values in the Cross-over (second treatment) stages are
the averages from 3 visits. There were no differences observed between the stages of
either treatment group.
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Figure 6.27: Comparison of LDL/HDL ratios in non-APOE ε4 and APOE ε4 at
each of the individual 11 visits in treatment AB (A) and treatment BA (B). The
bars represent the mean + standard deviation. Values underneath the bars are the mean
of each group. No significant differences were observed between the non-APOE ε4 and
APOE ε4 groups of either treatment arm. BL= Baseline, A_1 to A_6 (graph A) & B_1
to B_6 (graph B) = First Treatment period, WO=Wash-out, B_1 to B_3 (graph A) &
A_1 to A_3 (graph B) = Second (Cross-over) treatment period. (n=22).
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6.4.3. Effects of testosterone on plasma Aβ levels
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Aβ40 level between different groups
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Week 29‐52
(Cross‐over A)

Figure 6.28 : Boxplots of average plasma Aβ40 levels at each of the 4 stages of
treatment

AB and treatment BA. : Week 0 (Baseline), Week 4-24

(Treatment), Week 25-28 (Washout), and Week 29-52 (Cross-over). Data are in
pg/mL and presented as median + quartiles. The values in the first treatment stages are
the averages of blood sample measurements from 6 visits and values in the Cross-over
(second treatment) stages are the averages from 3 visits. There were no differences
observed between any of the stages of either treatment arm.
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Figure 6.29 : Comparison of plasma Aβ40 levels in the non-APOE ε4 and APOE
ε4carriers at each of the 11 individual visits of treatment AB (A) and treatment
BA (B). The bars represent the mean + standard deviation. Values in pg/mL
underneath the bars are the mean of each group. No significant differences were
observed between non-APOE ε4 and APOE ε4 participants. BL= Baseline, A_1 to A_6
(graph A) & B_1 to B_6 (graph B) = First Treatment period, WO=Wash-out, B_1 to
B_3 (graph A) & A_1 to A_3 (graph B) = Second (Cross-over) treatment period.
(n=22).
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Figure 6.30 : Boxplots of average plasma Aβ42 levels for each of the 4 stages of
treatment AB and treatment BA: Week 0 (Baseline), Week 4-24 (Treatment),
Week 25-28 (Washout), and Week 29-52 (Cross-over). Data are in pg/mL and
presented as median + quartiles. The values in the first treatment stages are the averages
of blood sample measurements from 6 visits and values in the Cross-over (second
treatment) stages are the average results from 3 visits. There were no differences
observed between any of the stages of either treatment arm.
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Figure 6.31 : Comparison of plasma Aβ42 levels in non-APOE ε4 and APOE ε4
carriers at each of the 11 visits of treatment AB (A) and treatment BA (B). The
bars represent the mean + standard deviation. Values in pg/mL underneath the bars are
the mean of each group. Significant differences were observed between the APOE ε4
and non-APOE ε4 subjects at baseline of both arm and the end of the treatment in
treatment arm AB only (*p<0.05). BL= Baseline, A_1 to A_6 (graph A) & B_1 to
B_6 (graph B) = First Treatment period, WO=Wash-out, B_1 to B_3 (graph A) & A_1
to
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(n=22)

Plasma Aβ levels, including Aβ40 as well as Aβ42 were rarely found to be significantly
different between any of the treatment stages. However, from the Figure 6.31 above,
there seemed to be a trend towards decreasing Aβ42 levels following testosterone
treatment in the non-APOEε4 subjects of both treatment groups. In treatment AB, A1
to A6 show lower testosterone levels compared to baseline, however this doesn’t return
to baseline levels until end of placebo (cross-over) treatment. In Treatment BA,
testosterone treatment is in the A1 to A3 time points, and a trend towards decreasing
Aβ42 levels can be seen in the non-APOE ε4 subjects during the testosterone treatment
period.

6.4.4. Effects of testosterone on plasma insulin levels
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Figure 6.32 : Boxplots of insulin levels at each of the 4 stages of treatment AB
and treatment BA: Week 0 (Baseline), Week 4-24 (Treatment), Week 25-28
(Washout), and Week 29-52 (Cross-over). Data are in mU/L and are presented as
median +quartiles. The values in the first treatment stages are the averages of blood
sample measurements from 6 visits and values in the Cross-over (second treatment)
stages are the average results from 3 visits. Insulin levels were significantly increased in
Treatment B compared to Cross-over A in treatment arm BA. # p<0.05 but clinical
relevance is questionable as no changes were seen when compared to baseline in the
same treatment arm B to A.
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Figure 6.33 : Comparison of plasma insulin levels in non-APOE ε4 and APOE ε4
carriers at each of the individual 11 visits in treatment AB (A) and treatment
BA (B). The bars represent the mean + standard deviation. Values in mU/L
underneath the bars are the mean of each group. Significant differences were observed
between the non-APOE ε4 and APOE ε4 groups of treatment arm AB (*p<0.05),
participants with APOE ε4 alleles had higher insulin levels. BL= Baseline, A_1 to A_6
(graph A) & B_1 to B_6 (graph B) = First Treatment period, WO=Wash-out, B_1 to
B_3 (graph A) & A_1 to A_3 (graph B) = Second (Cross-over) treatment period. (n=22)
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6.4.5 Effect of testosterone on Prostate Specific Antigen (PSA) levels in the plasma,
assessed to investigate testosterone treatment safety

#
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Week 0
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Week 4‐24
(Treatment A)

Week 25‐28
(Washout)

#

Week 29‐52 Week 0
Week 4‐24
(Cross‐over B) (Baseline) (Treatment B)

Week 25‐28
(Washout)

Week 29‐52
(Cross‐over A)

Figure 6.34 : Boxplots of PSA levels at each of the 4 stages of treatment AB and
treatment BA: Week 0 (Baseline), Week 4-24 (Treatment), Week 25-28
(Washout), and Week 29-52 (Cross-over). Data are in μg/L and presented as median +
quartiles. The values in the first Treatment stages are the averages of blood sample
measurements from 6 visits and values in the Cross-over (second treatment) stages are
the average results from 3 visits. Significant differences were observed in Treatment A
and Treatment B compared to baseline (*p<0.05). There were also significant
differences observed between the testosterone and placebo groups of both arms: the
testosterone treatment groups had higher PSA levels when compared to placebo
(#p<0.05).
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Figure 6.35 : Comparison of Prostate Specific Antigen (PSA) levels in non-APOE
ε4 and APOE ε4carriers at each of the 11 visits in treatment AB (A) and
treatment BA (B). The bars represent the mean + standard deviation. Values in μg/L
underneath the bars are the mean of each group. Although not significant, participants
with APOE ε4 alleles had higher PSA levels compared to the non-APOE ε4
participants. BL= Baseline, A_1 to A_6 (graph A) & B_1 to B_6 (graph B) = First
Treatment period, WO=Wash-out, B_1 to B_3 (graph A) & A_1 to A_3 (graph B) =
Second (Cross-over) treatment period. (n=22).
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6.4.6 Effects of testosterone on Red Blood Cells and Hemoglobin levels in the
plasma

Week 0
(Baseline)

Week 4‐24
(Treatment A)

Week 25‐28
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Week 29‐52
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Week 4‐24
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Figure 6.36 : Boxplots of Red Blood Cell counts (RBC) at each of the 4 stages of
treatment AB and treatment BA: Week 0 (Baseline), Week 4-24 (Treatment),
Week 25-28 (Washout), and Week 29-52 (Cross-over). Values are in 106 cells/µL and
are presented as mean + quartiles. There were significant increases in RBC levels
following testosterone treatment compared to baseline levels in both treatment arms
(*p<0.05), as well as compared to other groups (#p<0.05).
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Figure 6.37 : Comparison of Red Blood Cell (RBC) levels in non-APOE ε4 and
APOE ε4 carriers at each of the individual 11 visits of treatment AB (A) and
treatment BA (B). The bars represent the mean + standard deviation. Values in 106
cells/µL underneath the bars are the mean of each group. No significant differences
were observed between the non-APOE ε4 and APOE ε4 groups of the treatment arms.
BL= Baseline, A_1 to A_6 & B_1 to B_6 = Treatment period, WO=Wash-out, B_1 to
B_3 & A_1 to A_3 = Cross-over period. (n=22).
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Figure 6.38 : Boxplots of serum Hemoglobin (Hb)

Week 4‐24
Week 25‐28
(Treatment B) (Washout)

Week 29‐52
(Cross‐over A)

levels at the 4 stages of

treatment AB (A) and treatment BA (B). Week 0 (Baseline), Week 4-24
(Treatment), Week 25-28 (Washout), and Week 29-52 (Cross-over).Values are in
g/dL and are presented as mean +quartiles. There were significant increases in Hb levels
following testosterone treatment compared to baseline in both arms of the study
(*p<0.05) as well as compared to other groups (#p<0.05).
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Figure 6.39: Comparison of hemoglobin (Hb) levels in non-APOE ε4 and APOE ε4
carriers at the individual 11 visits in treatment AB (A) and treatment BA (B).
The bars represent the mean + standard deviation. Values in g/dL underneath the bars
are the mean of each group. There were no significant differences observed between the
non-APOE ε4 and APOE ε4 groups of either arm. BL= Baseline, A_1 to A_6 (graph A)
& B_1 to B_6 (graph B) = First Treatment period, WO=Wash-out, B_1 to B_3 (graph
A) & A_1 to A_3 (graph B) = Second (Cross-over) treatment period. (n=22).
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Figure 6.40 : Boxplots of serum Sex Hormone Binding Globulin (SHBG) levels at
the 4 different stages of treatment AB (A) and treatment BA (B). Week 0
(Baseline), Week 4-24 (Treatment), Week 25-28 (Washout), and Week 29-52
(Cross-over).Values are in nmol/L and are presented as mean +quartiles. No significant
differences were observed between any of the stages of either treatment arm.
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Figure 6.41: Comparison of hemoglobin (Hb) levels in non-APOE ε4 and APOE ε4
carriers at the individual 11 visits in treatment AB (A) and treatment BA (B).
The bars represent the mean + standard deviation. Values in nmol/L underneath the bars
are the mean of each group. There were no significant differences observed between the
non-APOE ε4 and APOE ε4 subjects of either treatment arm. BL= Baseline, A_1 to
A_6 (graph A) & B_1 to B_6 (graph B) = First Treatment period, WO=Wash-out, B_1
to B_3 (graph A) & A_1 to A_3 (graph B) = Second (Cross-over) treatment period.
(n=22).
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Figure 6.42: Boxplots of serum Albumin levels at the 4 stages of treatment AB
(A) and treatment BA (B). Week 0 (Baseline), Week 4-24 (Treatment), Week 2528 (Washout), and Week 29-52 (Cross-over). Values are in g/L and are presented as
mean +quartiles. Compared to baseline levels, albumin levels were significantly lower
during the placebo treatment, in both treatment arms. (*p<0.05).
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Figure 6.43 : Comparison of albumin levels in non-APOE ε4 and APOE ε4 carriers
at the 11 individual visits in treatment AB (A) and treatment BA (B). The bars
represent the mean + standard deviation. Values in g/L underneath the bars are the mean
of each group. No significant differences were observed between the non-APOE ε4 and
APOE ε4 groups of either treatment arm. BL= Baseline, A_1 to A_6 (graph A) & B_1
to B_6 (graph B) = First Treatment period, WO=Wash-out, B_1 to B_3 (graph A) &
A_1 to A_3 (graph B) = Second (Cross-over) treatment period. (n=22).
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Figure 6.44 : Comparison of Calculated Free Testosterone levels in APOE ε4 and
non-APOE ε4 carriers (n=22) at 11 visits in treatment AB (A) and treatment
BA (B). The bars represent the mean + standard deviation. Values in ng/dL
underneath the bars are the mean of each group. Significant differences were observed
between non-APOE ε4 and APOE ε4 group in treatment arm AB (*p<0.05). BL=
Baseline, A_1 to A_6 (graph A) & B_1 to B_6 (graph B) = First Treatment period,
WO=Wash-out, B_1 to B_3 (graph A) & A_1 to A_3 (graph B) = Second (Cross-over)
treatment period.

226

6.5 Discussion
Our knowledge and understanding of testosterone replacement therapy in aging males
has greatly improved over the last 15-20 years, however data on many of its effects
remain inconclusive. There is a growing need for clinical studies that can help us
improve our understanding of the long-term effects of testosterone treatment.
The study design in this trial involved the treatment of subjective memory complainers
for a period of nearly 6 months. This length of time was necessary to differentiate true
benefits of therapy from placebo effects. Moreover, in this double blind, randomized,
and placebo-controlled trial, all participants underwent both testosterone treatments and
placebo treatments within the trial’s one year duration, thus all participants served as
their own “controls”. Part of the strength of this study is due to this design, as it reduced
the problems of patient to patient variability when comparing the placebo to the
testosterone effect. Another strength of the study came from the fact that both potential
orders of treatment were tested – testosterone followed by placebo, as well as the
reverse. From the point of view of the participants, their role was the same for a whole
year – for all stages a cream was to be applied daily.
In the initial screening of elderly men who presented with signs and symptoms of
testosterone deficiency, we measured total testosterone levels. The conventional view is
that total testosterone is the test of choice, it also has the advantage of being one of the
most widely available and the gold standard of the testosterone assays. Total
testosterone levels were also used to monitor the efficacy of testosterone treatment.
Total plasma testosterone represents testosterone that is tightly bound to sex hormone
binding protein (SHBG, 44%) as well as that weakly associated with albumin (54%),
with the remaining 2% free (and able to pass the blood brain barrier) (Bates et al., 2005)
With aging, the rate of decrease in total testosterone level is on average, approximately
110 ng/dL (~3.8 nmol/L) per decade (Morley et al., 1997). The most commonly used
test is early morning serum total testosterone level. If it is less than 300 ng/dL (~ 10.4
nmol/L) then the patient should be considered testosterone deficient (Basaria and Dobs,
2001). However, the threshold of testosterone levels varies for various symptoms and
among individuals. Most androgen deficiency symptoms will occur in men who have
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testosterone levels that correspond to or are below the lower limit of the normal range
for young men, which is 10.4 nmol/L (Wu et al., 2010; Orwoll et al., 2010; Mulligan et
al., 2006; Araujo et al., 2007; Kelleher et al., 2004). The mean of the total testosterone
levels from the 44 participants in our study was slightly above the borderline for
testosterone deficient men, since the determination of the borderline was based on the
normal testosterone levels found in Indonesian people in Siloam Hospitals, using
VIDAS Testosterone Immunoassay kit (Bio-Merieux). After the samples being
analyzed with gas chromatography-mass spectrometry (GC-MS), the level of total
testosterone levels at baseline was above 300 ng/dL. Therefore, the limitation in this
study is the screening measurement methods of total testosterone. The therapy was
aimed to raise serum testosterone levels to that seen in the mid-normal range, which for
these Indonesian people was 600-1000 ng/dL, based on the laboratory reference range
using immunoassays. In addition, calculated free testosterone was also measured in this
experiment, and showed similar results to those observed with total testosterone levels
following testosterone treatment (Fig 6.44).

6.5.1 Effects of testosterone administration on plasma total testosterone levels and
its metabolites, DHT and estradiol
The day to day variation in testosterone levels may be considerable, therefore repeated
testosterone measurements at 4 week intervals in weeks 4-24 (first treatment period) and
at 8 week intervals in weeks 28-52 (second treatment period) were undertaken. From the
total testosterone level results (Figs 6.2 & 6.3) it is easy to see that treatment A is
testosterone whilst treatment B is placebo. Testosterone levels were significantly higher
following testosterone treatment in both treatment groups. Within four weeks posttestosterone treatment, referred to as the washout period, testosterone levels were back
to that seen at baseline which indicated no carry-over effects. Individual levels of
testosterone varied in response to testosterone treatment (Fig 6.8 & 6.9; Appendices
Table 1 & 2). This may have been due to the androgen receptor polymorphisms (CAG
repeats) conferring differential individual sensitivity to testosterone or due to the
possibility that inadvertently different amounts of testosterone may have been applied
for some individuals. Previous studies have shown that the length of the CAG repeats in
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exon 1 of the androgen receptor determines the transactivation activity of the receptor,
in which shorter CAG repeats are associated with higher androgenicity and longer CAG
repeats with lower androgenicity in healthy (Zitzmann et al., 2001; Zitzmann et al.,
2003a) as well as in testosterone deficient men (Zitzmann et al., 2003b).
Furthermore,the number of androgen receptor CAG repeats is negatively correlated
with AR sensitivity and positively correlated with body fat, insulin levels, and leptin in
healthy men (Stanworth et al., 2008).
The mechanisms of action of testosterone on target organs are relatively complex since
effects may be mediated directly via testosterone or indirectly via its metabolic
products, dihydrotestosterone (DHT) and estradiol. Furthermore, testosterone only has a
short half-life of approximately 12 minutes in the blood (Carruthers, 2004). In the
curent study, the testosterone cream resulted in elevated serum DHT levels with no
carry-over effect, most likely as a result of the high concentrations of 5- reductase in
the scrotum. The DHT produced would have been available to bind to androgen
receptors (Fig 6.4 & 6.5). These results are in agreement with those of Cunningham et
al., 1989, where it was found that DHT is elevated following testosterone treatment
using a transdermal cream. The results in Figs 6.6 and 6.7 show that elevating
testosterone levels resulted in a relatively greater increase in DHT, as observed by the
increased ratios in these figures. These results indicated that the testosterone has been
converted mostly to DHT, which is consistent with application of the cream- based
hormone to the scrotum.
The transport of testosterone and its metabolites into various tissues of the body is
dependent on their binding to the transport proteins, their rate of dissociation, their
membrane permeability and their capillary transit time through an organ
(Pardridge,W.M, 1981). Testosterone is known to affect body composition in men, for
example testosterone reduces abdominal fat and increases muscle mass. The quantity of
fat, both subcutaneous as well as visceral, correlates with levels of both testosterone and
DHT (Nielsen et al. 2007). DHT and testosterone levels also affect proliferation of fat
cells - they block the transformation of pluripotent cells into adipocytes (Singh et al.
2003). It has also been demonstrated that unlike testosterone, DHT has a positive effect
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on bone density (Ilangovan et al. 2009). These are all studies that support the notion that
low testosterone and DHT are detrimental to health.
Determining whether testosterone or DHT levels are low or not, is in itself difficult –
normally ratios of DHT/testosterone do not vary much past puberty, yet can be different
depending on race. For example, although testosterone levels were found to be very
similar in a large US study, higher DHT levels and lower DHT/testosterone ratios were
found in black people when compared to white or Hispanic people. Geographical
differences have also been found, with people from similar racial backgrounds having
quite different DHT levels depending on country of residence (Duskova and
Pospisilova, 2011). It is likely that diet and other health issues may play an important
contributory role to these differences.
The conversion of testosterone to estradiol via the enzyme cytochrome P450 aromatase
in men, unlike women, helps to maintain or modulate levels of serum estradiol as men
age (Burger, 2000; Gray, 1991). Thus, in the presence of aromatase, testosterone can
exert its effects on cell metabolism by influencing estrogen receptors as well as
androgen receptors (Tietz, 1986). Our results show moderate changes in estradiol levels
do occur following testosterone treatment (Fig 6.10 & 6.11).
However, some studies have observed an increase in estradiol levels with age, resulting
from increased adiposity or increased body fat which would be responsible for an
increase in levels of serum sex-hormone-binding globulin (SHBG) and enhanced
peripheral aromatization of androgens (Basaria et al., 2001). Estradiol should be in the
mid- to lower-normal range, which is 10-82 pg/mL in fertile Asian men (Yamamoto et
al., 1995). If estradiol levels are at least one-third above the normal reference range, this
excessive level of estradiol should be reduced. The results from this study showed that
estradiol levels were still in the normal reference range in baseline and all of the
treatment groups (Fig 6.10 & 6.11).
The normal production ratio of testosterone to estradiol is approximately 100:1 and the
normal circulating ratio of testosterone to estradiol is approximately 300:1
(www.emedicine.medscape.com). Increased production or action of estradiol compared
to testosterone will result in gynecomastia: benign enlargement of the male breast; an
unusual side effect associated with testosterone replacement therapy. Rhoden and
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Morgentaler, 2004 have shown that 6 months of testosterone treatment can induce
gynecomastia in men with history of gynecomastia. Therefore, in these studies the ratio
of testosterone to estradiol was also calculated to monitor the risk of gynecomastia.
Findings from this current study revealed an almost 2-fold increased ratio of circulating
testosterone to estradiol in the first 4 weeks following testosterone treatment in both
arms, which subsequently decreased until the end of the treatment (Fig 6.12). These
results indicate that increased testosterone levels were more prominent than the
increased estradiol levelswhich indicates that risk of gynecomastia was minimal
following this testosterone treatment.
From Figures 6.14 and 6.15, it can be seen that testosterone, DHT, and estradiol had
inhibitory effects on LH levels in plasma. Once the participants stopped using the
testosterone cream, the LH levels rose back to levels seen in the baseline readings which
indicated no carry-over or long-term effects. Thus the normal feedback loops and
enzymatic conversions of testosterone were occuring during the treatment times. In
men, both testosterone and DHT exert their effects on LH mainly at the hypothalamic
level, by decreasing the frequency of LH pulses, whilst estradiol reduces the amplitude
of LH at the pituitary level (Carruthers, 2004). Among testosterone deficient men, LH
has been shown to be suppressed (reduced) down to levels in the eugonadal range
following injectable and implantable testosterone (Fennel et al., 2010; Conway et al.,
1988).
Apolipoprotein E (ApoE), a major carrier of cholesterol in the central nervous system is
produced from the APOE gene, which exists mainly as three different alleles in humans
– APOE ε2, ε3 and ε4. The possession of one or more APOE e4 alleles is the strongest
known risk factor for sporadic or late onset AD. Participant APOE allele status was also
determined in this study to try to evaluate any effect apoE protein isoform differences
may have on testosterone treatment. Hogervorst et al., 2002 found that persons with at
least one APOE ε4 allele had significantly lower testosterone levels than those without
an ε4 allele. However, from their results it remained unclear how the ApoE protein may
interact with testosterone. In the current study, total testosterone levels were not found
to differ between APOE ε4 and non-APOE ε4 carriers at their baseline levels. However,
there were significantly greater increases in total testosterone levels in the APOE ε4
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carriers compared to the non-APOE ε4 carriers, at some of the testing periods during the
testosterone treatment (Figure 6.3). However, this result was observed in one arm only
(treatment AB), and the trend in the BA treatment group appeared to go in the
opposite direction. These unexpected results may be a discrepancy due to the very small
number of APOE ε4 participants in the two arms, particularly in the treatment BA
group which had only 4 ApoE ε4 carriers, and two of these participants did not respond
to testosterone treatment (see Appendices Table 2 and Figure 2). In other studies,
Panizzon et al. 2010 demonstrated an interaction between testosterone and the
possession of APOE 4 alleles with regards to hippocampal volume in middle-aged men
with low testosterone levels. APOE 4 men with low testosterone levels had the
smallest hippocampal volumes. The reason for this is not clear. APOE allelic
differences may interact with androgen receptor polymorphisms and/or genes associated
with testosterone production. Many more studies are required to elucidate such
relationships.
Further studies with larger numbers of participants would be needed to get a clearer
picture of any differences in total testosterone levels caused by APOE allele differences.
We also pooled the participants from both treatment arms of the study to increase the
statistical power (number of participants), but found no significant differences between
APOE ε4 and non-APOE ε4 carriers for all of the blood parameters, despite this
increase in statistical power.

6.5.2 Effects of testosterone administration on lipid profiles in the plasma
The hormonal regulation of lipid metabolism in men is complex and has not been
researched in depth. Sex steroids appear to be key regulatory factors, exerting influence
on lipid metabolism in both men and women. However, there is little information in the
literature concerning the effects of exogenous testosterone on serum lipids and
lipoproteins, especially after prolonged administration. The effects of testosterone on
different lipoproteins and lipid levels is of particular interest due to the similarity
between cardiovascular disease risk factors and factors thought to influence the risk of
AD. The testosterone dosage is also of importance in this issue, as achieving
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supraphysiological testosterone levels has been reported to have unfavourable effects on
the cardiovascular system (Aaronson et al., 2011) – for example as mentioned below,
supraphysiological testosterone has been shown to lower HDL levels. In the
experiments reported here, the testosterone dose restored levels of testosterone to an
average of 27 nM (see Figures 6.2 and 6.3), and as mentioned at the start of this chapter,
the mid-normal range for these Indonesian people is 600-1000 ng/dL, which translates
to 21-35 nM. There were differences in responses to testosterone treatment depending
on APOE allele status, yet it was found that two of the APOE ε4 participants in
Treatment BA did not respond to the treatment, as mentioned above. Characterising
further the effects of testosterone on lipid profiles may shed some light into the possible
roles of this hormone in the pathogenesis of AD. Many studies now show there are
strong links between lipid profiles (cardiovascular risk factors), APOE allele status and
androgen response, and these require further study.
Within the blood, ApoE delivers and transports lipids, especially triglycerides and
cholesterol, by mechanisms that involve the binding, uptake and catabolism of
lipoproteins. Compared to the APOE ε2 and ε3 alleles, ε4 is associated with poorer
transport and clearance of serum cholesterol (Mahley, 1988; Davignon et al., 1988 and
Eichner et al., 1993). Researchers have shown that APOE ε4 carriers have higher than
average serum cholesterol levels, and interestingly, several animal studies have shown
elevated serum cholesterol level are associated with rises in brain Aβ levels (Kuo et al.,
1998; Pappolla et al., 2003). One might assume that there is an effect of APOE allele
status causing higher serum cholesterol levels, which would then lead to increased brain
cholesterol levels. However, it is important to note that brain cholesterol levels are
maintained independently - serum cholesterol levels do not influence brain cholesterol
levels directly because cholesterol does not cross the blood brain barrier (Hooijmans et
al., 2007). Therefore any increases in brain Aβ levels may not be due to changes in
brain cholesterol per se, but rather to effects of increased circulating cholesterol or other
influences of ApoE ε4.
In these experiments, no differences were found in total cholesterol, triglyceride, LDL,
and HDL results between APOE ε4 carriers and non-APOE ε4 carriers (Figures 6.17,
6.19, 6.21 & 6.23). All of the cholesterol, triglyceride, LDL, HDL, cholesterol to HDL,
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and LDL to HDL levels observed in both arms of the study were within normal
desirable ranges for Indonesian people in Siloam Hospitals, based on the American
Heart Association and National Cholesterol Education Program with total cholesterol
ranges being 4.6 - 5.2 mmol/L, triglyceride 0.5 - 1.7 mmol/L, LDL < 3.4 mmol/L and
HDL > 1.04 mmol/L. When it comes to measurement of LDL and triglyceride values, a
lower level is better because these lipids drive the development and progression of
atherosclerosis. In contrast, when it comes to HDL, with few exceptions, a higher level
is better because HDL is beneficial and protects patients from the development and
progression of atherosclerotic disease (Toth, 2005).

There have been many studies concerning the effects of testosterone on lipid
metabolism with conflicting and inconsistent results. Similar to the current study,
several studies have found no significant effects on LDL levels (Figure 6.20 & 6.21) but
testosterone has been found to result in a mild decrease in HDL levels (Thompson et al.,
1989; Freidl et al., 1990; Bhasin et al., 1997). However, several studies have
consistently demonstrated an inverse correlation between testosterone and LDL (Saad et
al., 2007; Saad et al., 2008; Howell et al., 2001; Ly et al., 2001). The findings in the
current study although only showing a trend towards decreasing LDL levels following
testosterone treatment are in agreement with these latter studies.
From the results in Figure 6.22 it can be seen that HDL levels were significantly
decreased following testosterone treatment, and that these lower levels were maintained
until the end of the study. If the participants were classified based on their total
cholesterol baseline threshold levels, only those who started off with higher than normal
or desirable levels of total cholesterol (moderate) showed significant changes in HDL
levels following testosterone treatment, whilst for those participants who initially had
low and desirable total cholesterol levels at baseline, it may be that the treatment may
not be able to lower levels further, because the body’s metabolism will compensate and
produce cholesterol to maintain cholesterol levels above a certain minimum level, so
these people are not likely to show any change (Appendices).
There have been many studies of effects of testosterone on various aspects of lipid
profiles and metabolism, with inconsistent results. In line with the current study’s
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results, a study by Arver et al. (1997) found that transdermal testosterone replacement
in testosterone deficient men resulted in a decrease in HDL cholesterol and an increase
in the total cholesterol/HDL ratios. Tyagi et al, 1999 also showed that testosterone
administration in supraphysiological doses reduced plasma HDL-cholesterol levels, and
a study by Handa et al., 1997 showed an inverse relationship between testosterone
levels and HDL levels. In other studies, testosterone treatment was found to increase
cholesterol, LDL and triglyceride levels (Traish et al., 2009). Furthermore, Malkin et
al., 2004 demonstrated that testosterone treatment in hypogonadal men resulted in
significant increases in IL-10, a reduction in IL-1 and TNF-α as well as a reduction in
total cholesterol and LDL levels, with no significant effect on HDL levels. On the other
hand, some studies have shown beneficial effects of testosterone on serum lipids. For
example, many epidemiological studies have shown a positive correlation between
serum testosterone levels and HDL in healthy men (Khaw, et al., 1991; Freedman et al.,
1991). Tenover J.S, (1999) found that testosterone replacement therapy led to an 11%
decrease in LDL. In yet other studies, Morley et al., 1993 reported a 9% decrease in
total cholesterol levels and no changes in HDL, and a study by Wang et al., 2000
indicated no adverse effects on lipid profile following the administration of testosterone
gel.
The clinical significance of a small decrease in HDL levels is still unknown. Serum
high-density lipoproteins (HDL) are lower in men than in premenopausal women (Heiss
et al.,1980). The enzyme which is primarily responsible for clearance of HDL, hepatic
endothelial triglyceride lipase, has been found to have greater activity in men and has
been shown to be stimulated by androgens and suppressed by estrogens (Glueck, et al.,
1976) . Recently, it has been found that a decrease in CAG repeat polymorphisms of the
androgen receptor lowers HDL but concurrently lowers the risk of cardiovascular
disease (Hersberger et al., 2005). The reason for the discrepancy above may be that the
effects of exogenous testosterone on lipids differ from those of endogenous
testosterone, doses and formulations of testosterone used, patient age or testosterone
deficiency state or that effects may depend on the route of administration (Thompson et
al.,1989). Nevertheless, the effects of testosterone on lipid profiles as well as
cardiovascular disease remain uncertain.
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Cross-sectional studies indicate an inverse relationship between coronary heart disease
(CHD) incidence and/or severity and endogenous testosterone levels, irrespective of age
(Wu et al., 2003), and testosterone treatment increases coronary blood flow and
improved signs on myocardial ischemia in men with CHD (Webb et al., 1999; English
et al., 2000). Therefore, total cholesterol/HDL ratios as well as the LDL/HDL ratios
were monitored to predict the chances of developing cardiovascular disease. Managing
the total cholesterol/HDL ratio below 5:1 is the goal and the ideal one is 3.5 : 1. Results
presented in this chapter show no significant changes in total cholesterol/HDL ratios,
and the ratios were still below 5 (Fig. 6.24). Also, no significant changes in LDL/HDL
ratios (Fig. 6.26) following testosterone treatment were observed which indicates there
is no increased risk of cardiovascular disease.
Testosterone has been found to affect estrogen levels that are required to induce
apolipoprotein CII and apolipoprotein AI by a mechanism that involves high-affinity
androgen receptors (Tam, 1986). In this same study, testosterone was found not to affect
the rates of apolipoprotein secretion. At this stage, it appears that few studies have
investigated whether testosterone or DHT can influence apolipoprotein production.
Other studies have shown that testosterone is lipophilic, suggesting testosterone would
be able to intercalate into bilayer cell membranes, potentially altering the fluidity and
function of membranes (Whiting, 2000). Considering the low circulating levels of
testosterone, this would depend on where and how much the hormone could be
concentrated, and factors that would influence where the testosterone would
concentrate.
When investigating lipids specifically, animal and human studies have suggested that
androgen deficiency is associated with increased triglyceride, total cholesterol, and LDL
levels.

As mentioned above, similar investigations of HDL levels have been

inconclusive, with some people reporting a decrease in HDL levels (Thompson et al.,
1989; Bagatell et al., 1984) as found in this study, some showing no change
(Zgliczynski et al., 1996; Uyanik et al., 1997), and most of the studies showing
increased HDL associated with normalizing testosterone (Saad et al., 2007; Zitzmann
and Nieschlag, 2007) . A significant decrease in HDL is a change that would be
considered to increase cardiovascular risk. Interestingly, more recent studies of
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androgen therapy have shown an increase in HDL levels, which may be associated with
improved reverse cholesterol transport (Traish et al., 2009a).

6.5.3 Effects of testosterone on Abeta (A) levels in plasma
Abeta (A) peptides, the main constituent of amyloid plaques found in brain in AD, are
produced in most tissues and can be detected in the cerebrospinal fluid (CSF) and
bloodstream. CSF levels of Apeptides, particularly the more amyloidogenic A42 are
being considered for inclusion in a panel of biomarkers for AD. Plasma levels of
Apeptides are currently thought to be much less reliable, yet as plasma is much more
accessible than CSF (which requires lumbar puncture), characterising changes in plasma
A levels is still worthwhile. It may be that A levels in the bloodstream are influenced
by testosterone and our earlier work looking at endogenous testosterone levels support
this notion (Bowen et al., 2005).
Aβ in the blood originates from tissues, or blood components such as platelets (Chen et
al., 1995). A is also produced in the brain (CNS), and can be transported across the
blood-brain barrier into the periphery (Zlokovic, 2004) and be detected in plasma. Once
in the bloodstream, Aβ is rapidly taken up by the liver and degraded.
Several studies have demonstrated the diagnostic utility of plasma levels of Aβ40 and
Aβ42. However, the results of these studies are not consistent. (Prvulovic & Hampel,
2011). Our results (Figs. 6.28, 6.29, 6.30 & 6.31) showed no significant changes in
plasma Aβ40 or Aβ42 levels following testosterone treatment, although there was a
strong trend towards decreasing Aβ42 levels. This results maybe because most of the
Aβ in the plasma is bound to albumin and lipoproteins, with very little free Aβ (Biere et
al., 1996) and thus measured Aβ levels may be affected by confounding factors
(Prvulovic & Hampel, 2011). Interestingly, participants in both treatment arms with
APOE ε4 alleles also showed a trend towards reduction of Aβ40 following testosterone
treatment as opposed to non-APOE ε4 participants (Fig 6.29) which indicates the
involvement of APOE in Aβ clearance.
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Plasma Aβ levels will have been influenced by many factors: age, cerebrovascular
disease, liver catabolism, and advanced AD-related pathology are all factors known to
affect plasma Aβ metabolism (Lopez et al., 2008). In addition, lipoproteins in plasma
might influence immunological detection of plasma Aβ (Kawarabayashi and Shoji,
2008). From an assay point of view, this problem is exacerbated by the levels of plasma
Aβ peptide which are about 10-fold lower than in the CSF and by the diversity of
ELISA antibodies used (Prvulovic & Hampel, 2011).
Studies by Almeida et al. 2004 demonstrated that low levels of testosterone are
associated with increased plasma Aβ levels in men. In relation to Alzheimer’s disease,
recent follow-up studies have shown that declining plasma Aβ42, but not Aβ40 levels
may be related to AD progression (Mayeux et al., 2003). Before Aβ deposition in the
brain begins, it is hypothesized that high plasma Aβ levels will be observed, and with
the initiation of Aβ deposition in the brain, it is postulated that Aβ in the plasma then
declines (Locascio et al., 2008).

6.5.4 Effects of testosterone on insulin levels in plasma
The components of the condition known as metabolic syndrome include insulin
resistance, glucose abnormality, high blood pressure, obesity or increased waist
circumference, and hyperlipidemia. All of the components above are also known risk
factors for cardiovascular disease. It has been found that there is an increased risk of
testosterone deficiency in men with metabolic syndrome or its individual components,
especially insulin resistance, considered by some to be at the core of metabolic
syndrome (Guay, 2009). It should not be surprising that testosterone may influence the
metabolic syndrome or cardiovascular risk, since testosterone influences lipid
metabolism, and can affect a wide range of tissues. For example, vascular cells contain
steroid hormone receptors and testosterone can exert effects on vascular walls either
directly or indirectly via aromatization (Shabsigh et al., 2005) In addition, androgen
deprivation therapy, similar to testosterone deficiency, has been found to increase
cardiovascular risk factors and to have adverse effects on cardiovascular function
(Traish et al., 2009; Shabsigh et al., 2005).
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Based on these findings, there is a strong need to assess the value of testosterone
therapy regarding benefits to cardiovascular health. In an early study, testosterone
therapy was not associated with the risk of cardiovascular disease in elderly men (Hajjar
et al., 1997). Most recent studies have found that many indicators of cardiovascular
health, such as high blood pressure, glycemic control, insulin resistance and high LDL
levels are altered favourably on treatment with testosterone (for example, Jones et al.,
2011).
However some studies have reported transient improvements or no change in one or
more variables. For example, data on the effect of testosterone replacement therapy on
insulin sensitivity have yielded conflicting results. Some studies have reported favorable
effects in men with obesity (Marin et al., 1992) or type 2 diabetes (Kapoor et al., 2006)
and in healthy older men (Emmelot-Vonk et al., 2008). Contradictively, other studies
have shown no changes in insulin sensitivity on healthy young and older men. Other
cross-sectional studies have shown a negative correlation between total testosterone and
insulin levels in the plasma (Seidell et al., 1990; Pasquali et al., 1991; Simon et al.,
1992). The current study showed some effects of testosterone on insulin sensitivity,
although no strong correlation was observed (Figs. 6.32 & 6.33). Perhaps if this study
was repeated with a much larger cohort, statistically different results would be obtained.
More recently, epidemiological studies have suggested that low levels of total
testosterone and SHBG can be considered to be predictive of metabolic syndrome and
to increase the risk of diabetes Type II (Saad, 2009). Low testosterone levels appear to
precede elevated fasting insulin, glucose, and hemoglobin A1c (HbA1C) values and
have been associated with increased deposition of visceral fat, which serves as an
endocrine organ, producing inflammatory cytokines and thus promoting endothelial
dysfunction and vascular disease (Traish et al., 2009c). In fact recent comprehensive
reviews have found that testosterone treatment may be able to slow the progression
from metabolic syndrome to diabetes Type II or cardiovascular disease, via beneficial
effects on insulin regulation, lipid profile and blood pressure (Saad et al., 2011;
Makhsida et al., 2005). The positive effects that androgen replacement therapy may
have in combating obesity in testosterone deficient men remains largely unknown to
medical professionals, partly because of the (incorrectly) perceived increased risk of
prostate cancer. The reports of myocardial infarction, hypertension, arrhythmia, cardiac
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failure, pulmonary embolism and stroke in men following androgen abuse have also not
helped to promote the restoring of normal levels of testosterone (Weidemann and
Hanke, 2002).
Recent studies suggest that long-term treatment with low doses are safe (Miner et al.,
2008). Due to studies of individuals keen to achieve supraphysiological testosterone
levels, it has nevertheless been suggested that there may be an ideal testosterone
“physiological window”: within this window testosterone has favourable effects, but
above or below the safe window these androgens can have a negative effect on the body
(Blouin et al., 2008; Basaria et al., 2010). These reported negative effects of
supraphysiological levels of testosterone are likely deterring physicians from
considering testosterone therapy for the treatment of androgen deficiency.
Future studies are required to determine how hormone changes and hormone therapy
can help reduce the health problems associated with the increasing number of people
suffering from metabolic syndrome, and determine if such treatment can also reduce the
risk or development of AD.

6.5.5 Effects of testosterone on Red Blood Cell (RBC) counts and Hemoglobin
levels
Androgens have long been known to stimulate red blood stem cell numbers (Shahidi,
1973). Several androgen replacement therapy treatments have reported significant
increases in hemoglobin and hematocrit levels in a dose-dependent manner (Hajjar, et
al., 1997; Sih et al., 1997; Bachman et al., 2010; Covellio et al., 2008), with greater
increases in red blood cells in older men than in young men (Covellio et al., 2008).
The results in the current study are in agreement with these previous studies, as they
show that the administration of testosterone enhances red blood cell levels in the plasma
(Figure 6.36 and Figure 6.37). It has been found that testosterone treated-men are nearly
four times as likely to have hematocrits of >50% as compared to placebo-treated men
(Calof et al., 2005) . Therefore, it is important to note that testosterone treatment should
not be administered to men with baseline red blood cells or hematocrit of 50% or
greater without appropriate evaluation and treatment of erythrocytosis (Bhasin et al.,
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2010) since testosterone treatment can worsen pre-existing erythrocytosis. Although it
had been postulated that testosterone stimulates eryropoiesis by modulating
erythropoietin and stem cell proliferation, recent data suggests that testosterone
increases red cell mass by inhibiting hepcidin (Bachman et al., 2010).
Testosterone deficiency has also been associated with lower hemoglobin levels, as
shown by the lower normal range for haemoglobin in women. In line with studies by
McCullagh et al., 1942 and Hamilton et al., 1964 which showed that testosterone
replacement restores the red blood cell counts, this study has also found a significant
increase in hemoglobin levels following testosterone treatment (Figs 6.38 & 6.39),
similar to that seen in the results of the red blood cell levels. The normal range of
hemoglobin in men is 14-18 ng/dL (Billet, 1990), and although significant increases in
hemoglobin were observed following testosterone treatment, the levels seen in our
results were still in the safe range in all of the treatment groups in both arms.

6.5.6 Effects of testosterone on Prostate Specific Antigen (PSA) levels in plasma
In the past there have been major concerns regarding testosterone therapy promoting the
growth of metastatic prostate cancer. However, it has now been established that there is
no evidence of increased risk of prostate cancer (Jackson, 2012; Feneley and Carruthers
2012 pub on-line JSM). The general view now is that testosterone does not promote
prostate cancer but can exacerbate existing cancer (Fowler et al., 1981; Bhasin et al.,
2003) and should not be administered in men with already high PSA levels (Bhasin et
al., 2010). In fact in one study an increased risk of prostate cancer has been associated
with low plasma level of testosterone (Raynaud, 2006). Therefore, testosterone therapy
should be accompanied by a standardized monitoring plan which includes periodic
ascertainment of prostate specific antigen (PSA) levels and digital prostate examination.
Most studies have shown no significant increases in PSA or prostate volume following
testosterone administration to testosterone deficient men (Behre,H.M, 1994).
The results in this Chapter (Figs 6.34 & 6.35) show a significant increase in PSA levels
following testosterone treatment, although levels still remained within the safe and
normal range, which is 0-4 μg/L (American Cancer Society). According to the
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American Cancer Society, a PSA level between 4 and 10 μg/L indicates a 25% risk of
having prostate cancer. A PSA higher than 10, increases the risk of having prostate
cancer to 50% and above. Since PSA levels tend to increase with age, the use of agespecific PSA reference ranges has been suggested to improve the accuracy of PSA tests
(National Cancer Institute). In accordance with our study, Khera et al., 2011 have
shown a small increase in PSA levels following 12 months of testosterone treatment. A
number of open-label trials have also reported that testosterone treatment results in very
low rates of developing prostate cancer (Agarwal et al., 2005; Kaufman et al., 2004).
Although PSA levels were higher in the testosterone treated group compared to placebo,
these results was not found to be significant (Calof et al., 2005). Interestingly, subjects
with APOE ε4 alleles had higher levels of PSA than non-APOE ε4 subjects (Fig. 6.35).
All of the participants in both arms had normal PSA levels at baseline (Appendices).

6.5.7 Effects of testosterone on Body Mass Index (BMI) and body fat percentage
According to the World Health Organization (WHO), the normal reference range for
BMI is 16-19 kg/m2 for the Indonesian population. A BMI of over 22 kg/m2 is
considered to be overweight and a person with a score over 27 kg/m2 is considered
obese. Therefore, according to their BMI levels, most participants in both arms of this
study were considered to be overweight (see Appendices Table 7 & 8). Although no
significant changes in BMI levels were observed in any of the treatment groups, most of
the participants showed an increase in BMI following testosterone treatment at
individual levels in both arms (see Appendices). However, it is important to note that
BMI includes both the body fat mass as well as body muscle and there was no
differentiation between the two.
The WHO has concluded that the Asian population generally has a higher percentage of
body fat than Caucasian people of the same age, sex, and BMI. However, there is no
reference range of body fat percentage in Asian populations to date. Gallagher et al.
2000 established that people aged 41-60 with an age-adjusted body fat percentage of
over 27% should be considered to be obese. Based on this reference, only 5 participants
in this study should be considered to be obese at baseline (see Appendices Table 9 &
10). Although there were no significant differences in body fat percentage observed
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following testosterone treatment, most of the participants showed a trend towards
increasing body fat at individual levels in both treatment arms. Taken together, an
increased BMI and body fat percentage in these men following testosterone treatment
suggests most of the participants produced more fat cells compared to muscle mass.
This result may be due to the fact that most of the participants were already overweight
at baseline.

Conclusions
In conclusion from this Chapter, testosterone replacement therapy for 6 months in
testosterone deficient men caused a significant increase in testosterone and DHT levels
(but not estradiol) as expected, a significant decrease in LH, a decrease in HDL, a trend
towards increasing plasma insulin, and a significant increase in the number of red blood
cells and hemoglobin. No changes in estradiol, total cholesterol, triglycerides, or LDL
levels were found. The slight increase in PSA levels is unlikely to be sufficient to
influence risk of prostate changes. Aβ40 and Aβ42 levels in the plasma were not
significantly affected by testosterone treatment, although, there seemed to be an
encouraging trend towards decreasing levels of Aβ42 following testosterone treatment.
With the increasing number of people suffering from metabolic syndrome, future
studies are required to determine how hormone changes and hormone therapy can help
reduce the health problems associated with metabolic syndrome, and determine if such
treatment can also reduce the risk or development of AD.
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Chapter 7
Effect of testosterone supplementation on
cognitive performance, depression and quality of
life in men with subjective memory complaints
(SMC)
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7.1 Introduction
Aging is associated with a general decline in many cognitive functions, with the rate of
decline varying between individuals. Serum testosterone levels also decline with aging
in men after 30 years of age (Harman et al., 2001), decreasing at an annual average rate
of 0.2-1% for total testosterone and 2-3% for free testosterone (Feldman et al., 2002). It
has been shown in many laboratory-based studies that sex steroid hormones such as
estrogens and testosterone, have neurotrophic and neuroprotective properties, and
many clinical reports suggest these hormones could provide neuroprotection during
aging (Lee et al., 2001; McEwen et al., 1997; Torrand-Allerand et al., 1992). Similarly,
age-related declines in testosterone levels have recently been associated with declines in
cognitive function, such that low testosterone is now believed to be a risk factor for
cognitive decline. Elderly men generally have higher sex hormone levels than elderly
women (Hogervorst et al., 2001; Hogervorst et al., 2004). Therefore, theoretically,
aging men should preserve certain aspects of cognitive function to a better extent than
aging women. Studies of elderly subjects which have investigated the relationship
between cognitive function and endogenous as well as supplemented (hormone
replacement therapy) steroid hormone levels have provided some support for this
theory, however these relationships also seem to be modified by other gender-related
factors (Hogervorst et al., 2007)
There has been extensive research into the association between the age-associated
decline in testosterone levels in men and their performance in various cognitive
measures. Serum levels of testosterone have been found to correlate with cognitive
performance in a number of neuropsychological tests in elderly men. Cross-sectional
studies have shown positive associations, such that higher levels of bio-available
testosterone, but not of bio-available estradiol, are associated with better cognitive
function in older men (Yaffe et al., 2002). Moreover, there were curvilinear associations
between total testosterone and verbal memory (Muller et al., 2005) as well as between
free testosterone and attention or working memory (Barret-Connor et al., 1999;
Matousek et al., 2010), and global cognition (Yeap et al.,2008). These curvilinear
associations suggests an optimal testosterone level for particular cognitive tasks.
Meanwhile, these curvilinear associations may contribute to negative associations
(Hogervorst et al., 2004; Martin et al., 2007) as well as to non-significant associations
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(Wolf et al., 2002; Carlson et al., 2000). These associations further suggest that there is
an optimal level for testosterone, above or below which there is no further improvement
in cognition and more likely there will be negative effects. However, there are many
longitudinal studies which have reported no significant associations between
testosterone and cognition (Moffat et al., 2002 ; Hogervorst et al., 2010). All these
studies have produced a variety of results, and this is most likely due to significant
differences in age ranges, types of cognitive tests used, cohort and sampling
methodologies, inclusion and exclusion criteria, different assays for measuring
testosterone, and the absence of follow-up testosterone measurements.
Testosterone has demonstrated neuroprotective effects in laboratory-based studies. Such
results from cell culture and animal studies indicate that testosterone could also provide
neuroprotection in the brain, especially in those regions that are susceptible to AD
pathogenesis. Such regions include the hippocampus and cortical regions which have a
high density of androgen receptors (Simerly et al., 1990). In the brain, testosterone can
mediate its neuroprotective effects directly through binding to androgen receptors, or
following conversion to estradiol (Pike et al., 2009). There is growing evidence to
support these neuroprotective effects of testosterone. However, the effects of
testosterone on the brain in terms of cognitive function are not fully understood and the
available data are not conclusive.
Beneficial effects of testosterone supplementation have been reported previously
(Alexander, et al., 1998; Janowsky, et al., 1994; Klaiber, et al., 1971). However,
testosterone supplementation in testosterone deficient men have not always
demonstrated any significant effects on cognition (Ly et al, 2001; Cherrier et al., 2003;
Kenny et al., 2002; Kenny et al., 2004; Vaughan et al., 2007; Sih et al., 1997).
On the other hand, testosterone depletion does tend to increase depression. A study by
Almeida et al. (2003) showed that chemical castration resulting in testosterone
depletion caused an increase in depression and anxiety. This suggests that age-related
depression may be due to the age-related declines in testosterone levels. There are
studies which suggest that depression and the development of AD may be linked: for
example, two studies (Dal Forno et al., 2005; Fuhrer et al., 2003) have demonstrated
that a relationship between depression and a risk for AD mainly exists in men.
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Therefore, current depression levels and any history of depression need to be considered
carefully when assessing elderly men and their risk of AD.
The role of estradiol, luteinizing hormone (LH), and genetic factors when considering
AD risk in men is also not fully understood. During normal aging, testosterone levels
gradually decline, but estradiol levels do not change significantly (Rosario et al., 2009 ;
Twist et al., 2000). Several observational studies have shown negative associations
between high estradiol levels and cognition. There is a possible role for gonadotropin
levels that may further modify the role of testosterone in relation to cognition and brain
function. The LH levels may have a negative association with cognition (Hyde et al.,
2010). The potential role of genetic factors is also of interest. In particular, the optimal
level of testosterone may be influenced by APOE genotype. In male non-APOE ε4
carriers, testosterone levels have been found to correlate with performance on cognitive
tests that investigate working memory, attention and executive functioning, whereas in
men carrying APOE ε4 alleles, higher testosterone concentrations have been associated
with a lower performance in such cognitive tests (Burkhardt et al., 2006).
This chapter shows results of the assessment of the effect of transdermal testosterone
supplementation on cognitive performance, verbal memory, depression, as well as
quality of life in testosterone-deficient elderly men. This study assessed the efficacy of
testosterone in improving cognitive function during a six month treatment trial while
statistically controlling for the effects of age and education.

7.2 Aims
The aims of this study were :


To investigate the effects of testosterone administration on global cognitive
functioning;



To investigate the effects of testosterone administration on verbal memory;



To investigate the effects of testosterone administration on depression;



To investigate the effects of testosterone administration on health-related quality
of life which constitutes both physical and mental health;
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To investigate whether there are different responses to testosterone treatment in
relation to cognition, depression, and quality of life in the presence of APOE ε4
allele.

7.3 Methods
Participants
Participants were healthy older men with low levels of testosterone, aged 50 to 75 years
old (mean age 61 years +8 years) who had some concerns about their memory
functioning and were recruited from the community through flyers. The study protocol
was approved by the Edith Cowan University (Western Australia), and the Faculty of
Medicine, University of Indonesia Independent Ethical Commitee, and approved
informed consent procedures were followed. Details of the study design are described in
section 6.3.Participants underwent a screening assessments at the baseline visit to
determine eligibility criteria as described in section 2.1.1.1. The following eligibility
criteria were used: 1) Males 50 years of age or older; 2) A Mini Mental State
Examination (MMSE) score of 24 or above; .3) A normal range of prostate-specific
antigen (PSA); 4) Blood pressure within normal limits, 110/75 – 130-85 5) No history
of diabetes mellitus; 6) Normal liver and kidney enzyme function; and 7) No history of
major head injury, based on the medical track record. Apart from blood tests to measure
plasma testosterone levels, participants also underwent a cognitive screening test
(MMSE) at baseline. Participants with MMSE scores below the recommended cut-off
score (<24) were excluded from the study.
Neuropsychological test measures
In clinical practice, neuropsychological tests have always been fundamental in the
clinical diagnosis of AD and other dementias. The recent development of potential drug
treatments and preventative therapies has raised the issue that earlier diagnosis, as well
as a more solid framework of neuropsychological assessment of AD are required. The
majority of current tests have an acceptable sensitivity and specificity for screening of
mild to moderate stage of AD. For example, the MMSE shows a sensitivity of 87% and
specificity of 92% with the cut-off score 24 (Grut et al., 1993) and the Rey Auditory
Verbal Learning Test (RAVLT) can distinguish between AD patients and those without
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dementia, or between AD and other forms of dementia with a diagnostic accuracy of 8386% (Gilhus et al., 2011).
In these studies, the cognitive test battery consisted of the MMSE and the RAVLT. The
MMSE is a brief cognitive measure which has been translated into many languages to
assess memory, attention, language, orientation, aphasia and apraxia and it is widely
used in clinical trials and research (Dufoil et al., 2000).
The RAVLT evaluates a wide diversity of functions: short-term auditory-verbal
memory, rate of learning, learning strategies, retroactive, and proactive interference,
presence of confusion in memory processes, retention of information, and differences
between learning and retrieval. The test was administered to each participant according
to standard procedure (Lezak, 1983). The RAVLT consists of a list of 15 unrelated
words that need to be remembered. After presentation of Trial 1 – Trial 5, followed by
free recall of the words immediately and consecutively, participants were presented with
an interference list of 15 words. After free recall of interference list, participants were
asked to recall words from the original list without additional presentation of the words
(Trial 6). The last recall trial was followed by a 20-minute interval (Trial 7). Finally,
participants were presented with word lists for recognition consisting of of 15 words
from list A, 15 words from list B, and 20 words as distracters. Participants were to
indicate words they recognized. The recognition measures used in this study include:
List A recognition score (true positives), the number of words correctly identified from
List A; List B recognition score, the number of words correctly identified from List B;
distractors correctly identified score (true negatives); and the number of words
mistakenly identified from either List A or List B. The application of RAVLT list of
words in this study used parallel forms of the RAVLT (matched for equal difficulty) to
ensure that retesting could be conducted over time without the memory data being
potentially confounded by practice or learning effects. RAVLT Test type A, B, C, and
then D were administered starting from the baseline until the end of the study.
Depression levels were measured by the Geriatric Depression Scale (GDS). The GDS
has demonstrated an acceptable specificity and sensitivity, and is widely used for
depression screening in the elderly (Yesavage et al., 1983 ; Segulin, 2007). The GDS
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scores range from 0-30 with a score of >11 as the cut-off score for depression. A higher
score is indicative of a higher depression level.
Health-related quality of life was measured using the Short-Form Health Survey (SF36). The SF-36 comprises 36 items measuring 8 different dimensions including physical
functioning, physical status, mental health, emotional status, social functioning, vitality,
pain, and general health perceptions. From the results, two aggregate scores can be
generated which indicate physical health and mental health. The scores on each scale
range from 0 (the worst health state) to 100 (best health state) (Ware et al., 1992).
The MMSE and SF36 tests were conducted at baseline and repeated at week 24 (end of
treatment period), week 28 (washout period), and week 52 (end of cross-over period).
The RAVLT and GDS tests were conducted at baseline and were repeated every 2
months following the first treatment period, the washout period, and following the
second treatment period (cross-over period). All neuropsychological tests were
translated into Indonesian and have been validated in Indonesian hospitals. Physicians,
participants, and investigators were blind to the treatment conditions.

APOE genotyping
At the end of cognitive and clinical assessment sessions, whole blood samples were
collected and were separated into various components using standard centrifugation
techniques. White blood cells were used for APOE genotyping, which was determined
using PCR as already described in section 2.1.1.2.3.
Statistical analysis
Statistical analysis was performed using The Statistical Package for Social Sciences
(SPSS version 19, SPSS Inc, Chicago, IL). The Kolmogorov-Smirnov and Levene’s
tests were used to examine normality of distribution of continuous variables for each
group. The data from the MMSE, RAVLT, GDS, and SF36 tests were found to be
normally distributed. Therefore, one-way repeated measures ANOVA were performed.
Carry-over effects were tested from differences at baseline in the first period (week 0)
and at the washout period (week 24-28, which was baseline for the second period).
Statistical analyses were performed to look at changes in general cognitive function,
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memory, depression level and quality of life over time and in various groups. When
directly comparing two groups from both arms of the study, as well as comparing two
groups based on the presence of APOE-ε4 alleles, two tailed independent t-tests were
used. Correlations of cognitive performances were assessed by Pearson productmoment correlation coefficient (r) for parametric data, whilst Spearman (rho) was used
for non-parametric data. All analyses were two-tailed and the alpha level was set at
p<.05

7.4 Results
Table 7.1 Mean (SD) age and education
Non-APOE ε4

APOE ε4

p value

Age

59 (5.82)

59.625 (9.58)

0.87

Education

13.79 (3.31)

14.25 (1.91)

0.68

Age

62.72 (7.31)

63.75 (13)

0.88

Education

13.47 (3.62)

15 (2)

0.25

Treatment A-->B

Treatment B-->A

Based on the statistics above, neither age nor education was significantly different when
comparing any of the groups. The p value indicates that there were also no significant
differences in age or education between non-APOE ε4 and APOE ε4 carriers.
Therefore, age and education would not be expected to influence the following
statistical analyses in this study.
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Figure 7.1 (a) : The MMSE score for treatment AB (A) and treatment BA (B)
at 4 different time points : BL= Baseline (Week 0), A_6 & B_6 = End of First
Treatment period (Week 24), WO=Wash-out (Week 28), B_3 & A_3 = End of
Second Treatment or Cross-over period (Week 52). Bar represent mean and standard
deviation (+), with values underneath the bars for the mean of each groups. MMSE
score was significantly improved after testosterone treatment in both arms and after
washout and placebo treatment in treatment AB. *p< 0.05 in comparison to baseline
of each arm of the treatments. No significant differences were observed between nonAPOE ε4 and APOE ε4 group.
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Figure 7.1 (b): The MMSE score for treatment AB (A) and treatment BA (B)
at 4 different time points : BL= Baseline (Week 0), A_= Mean of Testosterone
treatment,

WO=Wash-out (Week 28), B = Mean of Placebo treatment. Bar

represent mean and standard deviation (+), with values underneath the bars for the mean
of each groups. MMSE score was significantly improved following testosterone
treatment compared to placebo in treatment BA only, regardless of APOE (Graph B).
#p< 0.05 in comparison between groups. No significant differences were observed
between non-APOE ε4 and APOE ε4 group.
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Figure 7.2: MMSE score comparison between treatment arm AB and treatment
BA. Bars represent the means +standard deviation, with actual mean values shown
underneath the bars of each group No significant differences were observed between
any of the groups. N=22 for each arm.
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Figure 7.3 : Immediate Recall (Total Learning from Trial 1 to Trial 5) score for
treatment AB (A) and treatment BA (B) at 8 different time points. BL=
Baseline, A_2 to A_6 (Graph A) & B_2 to B_6 (Graph B) = First Treatment period ,
WO=Wash-out, B_1 to B_3 (graph A) & A_1 to A_3 (Graph B) = Second Treatment or
Cross-over period. Bars represent mean and standard deviation (+), with values
underneath the bars for the mean of each group. Immediate recall score (as measured by
RAVLT) was significantly increased over time at visit 9 (week 36) in both arms,
regardless of APOE (Graph A and B) *p< 0.05 in comparison to baseline for each arm
of the treatments. No significant differences were observed between non-APOE ε4 and
APOE ε4 groups. However, participants with APOE ε4 tend to recall the words better
than non-APOE ε4 participants.
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Figure 7.4 : Short-term delayed recall for treatment AB (A) and treatment BA
(B) at 8 different time points. BL= Baseline, A_2 to A_6 (Graph A) & B_2 to B_6
(Graph B) = First Treatment period , WO=Wash-out, B_1 to B_3 (graph A) & A_1 to
A_3 (Graph B) = Second Treatment or Cross-over period. Bars represent mean and
standard deviation (+), with values underneath the bars for mean of each group. Shortterm delayed recall score (as measured by Trial 6 RAVLT) was significantly increased
at the end of testosterone treatment compared to baseline (*p< 0.05) at treatment BA
only, regardless of APOE (Graph B). No significant differences were observed between
non-APOE

ε4

and

APOE

ε4

group.
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Figure 7.5: Long-term delayed recall for treatment AB (A) and treatment BA
(B) at 8 different time points. BL= Baseline, A_2 to A_6 (Graph A) & B_2 to B_6
(Graph B) = First Treatment period , WO=Wash-out, B_1 to B_3 (graph A) & A_1 to
A_3 (Graph B) = Second Treatment or Cross-over period. Bars represent mean
+standard deviation, with values underneath the bars for mean of each group. There
were no significant differences in long-term delayed recall score (as measured by Trial
7 RAVLT) between any of the groups of either arm. No significant differences were
observed between non-APOE ε4 and APOE ε4 groups.
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Figure 7.6: Learning Over Trials (LOT) score for treatments AB (A) and BA
(B) at 8 different time points. BL= Baseline, A_2 to A_6 (A) & B_2 to B_6 (B) = First
Treatment period , WO=Wash-out, B_1 to B_3 (A) & A_1 to A_3 (B) = Second
Treatment or Cross-over period. LOT = Total Learning – (5 x Trial 1) (Tierney et al.,
1994). Bars represent mean +standard deviation, with mean values shown below the
bars. LOT score

(as measured by RAVLT) was significantly increased following

testosterone treatment compared to the end of placebo treatment in treatment AB (A).
#p< 0.05 in comparison between groups. No significant differences were observed
between non-APOE ε4 and APOE ε4 groups. However, APOE ε4 participants tended to
have a higher learning effect than non-APOE ε4 participants.
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(A)

(B)

Figure 7.7 List A Recognition score for treatments AB (A) and BA (B) at 8
different time points. BL= Baseline, A_2 to A_6 (A) & B_2 to B_6 (B) = First
Treatment period , WO=Wash-out, B_1 to B_3 (A) & A_1 to A_3 (B) = Second
(Cross-over) Treatment. Bars represent mean +standard deviation, with mean values
underneath the bars for each group. There were no significant differences observed in
List A recognition (as measured by RAVLT) between any of the groups of either arm
(A and B). No significant differences were observed between non-APOE ε4 and APOE
ε4 groups. However, APOE ε4 participants tended to recognize words from list A better
than non-APOE ε4 participants after testosterone treatment.
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Figure 7.8 : List B Recognition score for treatment AB (A) and treatment BA
(B) at 8 different time points. BL= Baseline, A_2 to A_6 (Graph A) & B_2 to B_6
(Graph B) = First Treatment period , WO=Wash-out, B_1 to B_3 (graph A) & A_1 to
A_3 (Graph B) = Second Treatment or Cross-over period. Bars represent mean and
standard deviation (+), with values underneath the bars for mean of each group. There
were significant differences of List B recognition (as measured by RAVLT) observed in
all of the groups of both arms, regardless of APOE (Graph A and B). No significant
differences were observed between non-APOE ε4 and APOE ε4 group (Sodergard,
1987).
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Figure 7.9 : Distracters Correctly Identified (True negatives) score for treatment
AB (A) and treatment BA (B) at 8 different time points. BL= Baseline, A_2 to
A_6 (Graph A) & B_2 to B_6 (Graph B) = First Treatment period , WO=Wash-out,
B_1 to B_3 (graph A) & A_1 to A_3 (Graph B) = Second Treatment or Cross-over
period. Bars represent mean and standard deviation (+), with values underneath the bars
for mean of each group. There were significant decrease of true negatives score (as
measured by RAVLT) observed in all of the groups in treatment AB (Graph A) and
following testosterone treatment in treatment BA, regardless of APOE (Graph B).
*p< 0.05 in comparison to baseline. Participants in both arms have better recognition
memory over time, maybe due to the practice effect. No significant differences were
observed between non-APOE ε4 and APOE ε4 group.
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Figure 7.10: Verbal Learning score for treatments AB (A) and BA (B) at 8
different time points. BL= Baseline, A_2 to A_6 (A) & B_2 to B_6 (B) = First
Treatment period , WO=Wash-out, B_1 to B_3 (A) & A_1 to A_3 (B) = Second
(Cross-over) Treatment. Bars represent mean +standard deviation, with mean values
underneath the bars of each group. There were no significant differences in Verbal
Learning (as measured by RAVLT) observed between any of the groups of either arm.
There were significant differences between non-APOE ε4 and APOE ε4 groups, such
that APOE ε4 participants had higher verbal learning scores. Verbal learning = Trial 5 –
Trial 1 score (Sodergard, 1987).

277
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Figure 7.11: Verbal Forgetting (VF) score for treatments AB (A) and BA (B)
at 8 different time points. BL= Baseline, A_2 to A_6 (A) & B_2 to B_6 (B) = First
Treatment period , WO=Wash-out, B_1 to B_3 (A) & A_1 to A_3 (B) = Second
(Cross-over)Treatment. Verbal forgetting (loss of information) = Trial 6 – Trial 5
score45 (recall after interference). Bars represent mean +standard deviation, with mean
values underneath the bars of each group. There were no significant differences
observed between any of the groups of either arm. However, a trend towards a decrease
in verbal forgetting was observed following testosterone treatment. No significant
differences were observed between non-APOE ε4 and APOE ε4 groups.
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Figure 7.12 (a) : Depression score for treatment AB (A) and treatment BA (B)
at 8 different time points. BL= Baseline, A_2 to A_6 (Graph A) & B_2 to B_6 (Graph
B) = First Treatment period , WO=Wash-out, B_1 to B_3 (graph A) & A_1 to A_3
(Graph B) = Second Treatment or Cross-over period. Bars represent mean mean and
standard deviation (+), with values underneath the bars for mean of each group.
Depression score (as measured by GDS) was significantly decreased following
testosterone treatment, washout, and following placebo treatment in both arms,
regardless of APOE (Graph A & B). p< 0.05 in comparison to baseline of each arm of
the treatments. # p< 0.05 in comparison between groups. Significant difference was
observed between non-APOE ε4 and APOE ε4 group at baseline in treatment BA
only (** p<0.05)
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Figure 7.12 (b) : Depression score for treatment AB (A) and treatment BA (B)
at 4 different time points. BL= Baseline, B = Mean of Testosterone treatment ,
WO=Wash-out, B = Mean of Placebo teatment. Bars represent mean and standard
deviation (+), with values underneath the bars for mean of each group. Depression score
(as measured by GDS) was improved by testosterone treatment and carry-over effect
was observed in treatment AB, regardless of APOE (Graph A)*p< 0.05 in
comparison to baseline of each arm of the treatments. #p< 0.05 in comparison between
groups. Significant difference was observed between non-APOE ε4 and APOE ε4 group
at baseline in treatment BA only.
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Figure 7.14 : Physical health (PH) score for treatment AB (A) and treatment
BA (B) at 4 different time points. BL= Baseline (Week 0), A_6 & B_6 = End of
First Treatment period (Week 24), WO=Wash-out (Week 28), B_3 & A_3 = End of
Second Treatment or Cross-over period (Week 52). Bars represent mean and standard
deviation (+), with values underneath the bars for mean of each group. There were no
significant differences of PH score (as measured by SF-36) observed in treatment AB
(Graph A). However, PH score were significantly increased starting after placebo
treatment, washout, and after testosterone in treatment BA, regardless of APOE
(Graph B). *p<0.05 in comparison to baseline of each arm of the treatments. No
significant differences were observed between non-APOE ε4 and APOE ε4 group.
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Figure 7.15 : Mental health (MH) score for treatment AB (A) and treatment
BA (B) at 4 different time points. BL= Baseline (Week 0), A_6 & B_6 = End of
First Treatment period (Week 24), WO=Wash-out (Week 28), B_3 & A_3 = End of
Second Treatment or Cross-over period (Week 52). Bars represent mean and standard
deviation (+), with values underneath the bars for mean of each group. MH score
significantly increased at washout and after placebo in treatment AB (Graph A).
Whilst in treatment BA, significant increased of PH score were observed starting
after placebo treatment, washout, and after testosterone, regardless of APOE. *p<0.05
in comparison to baseline of each arm of the treatments. #p<0.05 in comparison
between groups. No significant difference was observed between non-APOE ε-4 and
APOE ε4 group.
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Figure 7.16 Physical Health score (A) and Mental Health score (B) comparison
between treatment arms AB and BA. Values are presented as mean +standard
deviation. No significant differences were observed between any of the groups of either
arm . N=22 for each arm.
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7.5 Discussion
Upon examining the relationship between circulating levels of testosterone and
cognition in older men, it is important to note that only small amounts of total plasma
testosterone (+2%) may pass the blood-brain barrier and enter the brain (Sodergard,
1987). Given that lower levels of testosterone are associated with cognitive impairment,
testosterone administration might have a beneficial effect. Although studies examining
the association between testosterone levels and cognition have frequently used measures
of free testosterone, in this study total testosterone was measured as this has previously
been shown to be a sensitive and valid measure for hormone treatment studies. Indeed,
our study has shown significant improvements on MMSE scores after testosterone
treatment in both arms of the study compared to baseline (Figures 7.1 A and B).
Interestingly, in treatment AB significant effects were also observed in the washout
and placebo treatments. These results suggest that carry-over effects from the
testosterone treatment lasted at least 28 weeks post-testosterone treatment. These
apparent beneficial effects of testosterone on general cognition are in line with results
obtained in a previous study by Slabbekoorn et al. (1999) which indicated that changes
in cognition from hormone manipulation do not return to baseline levels but remain or
continue to change in the same direction after cessation of hormone treatment.
Therefore, carry-over effects of testosterone treatment delay further memory
impairment.
In addition, another study by Cherrier et al. (2001) found that testosterone
supplementation in elderly men improved visuospatial abilities as well as verbal
memory even in the short-term period of 6-weeks. It remains unclear whether the
improvements in cognition are due to increased testosterone levels, or estradiol levels,
or both. Beneficial effects of testosterone treatment have also been observed by Muller
et al. (2005) who demonstrated a positive relationship between overall cognitive
functioning and free testosterone levels in older men.
Verbal memory has been measured in a variety of standardized episodic memory
measures. RAVLT was chosen in this study because of its ease of administration and its
sensitivity to impairment in different memory components (Dal Forno et al., 2005).
Furthermore, the RAVLT is a very efficient instrument for assessing episodic verbal
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memory, which allows the evaluation of acquisition and recall of information
(Mitrushina et al., 2005). Because of possible rapid effects of testosterone, RAVLT
were administered once every 2 months to monitor changes in verbal memory. As
mentioned before, global cognitive changes as measured by MMSE were improved
following testosterone treatment in this study. However, verbal memory and recall was
not significantly improved following testosterone supplementation as measured by
RAVLT (Tables 7.1 – 7.4, and Figures 7.3 – 7.7 and 7.11). This is in line with findings
from the Hogervorst et al. (2004) study which showed that some neuropsychological
tests could be more sensitive to hormone levels than others. Our RAVLT data (Fig 7.10
and Learning curve in Appendices) show that the increasing number of words recalled
were more likely due to the improvement of memory over time because of practice or
learning effects, rather than testosterone treatment itself. In addition, there may be a
psychological effect of using the cream which we could not control for. That is, the
participants strived to do their best in each tests (placebo effects) to receive the
treatment. Therefore, it is quite difficult to differentiate between testosterone and
placebo effects in terms of increasing verbal memory and words recall over time in this
study. These results are in accordance with a study by Emmelet-Vonk et al. (2008),
which studied men aged 60-80 years old with testosterone levels < 13.7 nmol/L. Their
cognitive levels were measured by the same word lists of RAVLT in each treatment
group. Other studies by Wolf and Kirschbaum (2002) and Yonker et al. (2006) further
indicate non-significant associations between testosterone and episodic memory.
Most studies of testosterone treatment in testosterone deficient men have found no
effects on cognition. It has been hypothesized that this could be due to decreased
sensitivity of androgen receptors after prolonged exposure to low testosterone
conditions (Hogervorst et al., 2005). Alternatively, Cherrier et al. (2007) observed
memory performance in 57 healthy elderly men after replacing testosterone with 50,
100, or 300 mg weekly injections. They found that only men with moderate testosterone
increases demonstrated verbal and spatial memory improvement whilst men with low or
high increases did not. The total testosterone levels shown in this study (Chapter 6) have
shown high increases following testosterone treatment. Therefore, improvements in
verbal memory following this testosterone treatment were subtle. This may indicate an
ideal range of testosterone with respect to verbal memory improvement.
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Another study by Wolf et al. (2002) also suggests that testosterone has no effect on
verbal memory and is negatively associated with verbal fluency in men. Although this
study did not explain the negative associations, the results are in line with those of
another study which investigated the effects of long-term testosterone replacement on
several neuropsychological tests (Sih et al., 1997), and also found negative associations
Initially, this study used four different types of RAVLT at the visits to minimize
learning effects which could overshadow any treatment effects. However, the use of
different types of RAVLT in this study may have reduced the sensitivity in detecting
any subtle testosterone treatment effects on verbal memory.
Depression affects a large number of elderly individuals and has been associated with
cognitive decline (Yaffe et al., 1999) and increased risk of mild cognitive impairment
(MCI) (Geda et al., 2006). Depression is also a common feature of testosterone
deficiency and it usually responds well to testosterone treatment (Gooren, 2007). With
testosterone levels in the hypogonadal range, depression was a common occurrence
(Zitzmann et al., 2006). Assessments may have been complicated by this fact as
performance in cognitive tests can be influenced by depression (Yeap et al., 2008). The
results of these experiments show that participants with APOE ε4 alleles tend to have
higher depression scores when compared to non-APOE ε4 carriers (Fig 7.12 A&B).
Interestingly, the depression score of participants with APOE ε4 (n=4) in treatment
BA was significantly different than the non-APOE ε4 at baseline, even they have
been categorized to be depressed based on GDS cut-off score (Fig 7.12 B). Overall, as it
was expected, depression was shown to be significantly reduced following testosterone
treatment in both treatment arms (Fig 7.12 A&B), although in treatment BA the effect
was only seen in APOE ε4 carriers, and may not have been due to treatment as GDS
scores dropped initially in the placebo treatment time, which preceded testosterone
treatment. The results for the APOE ε4 carriers more likely reflects the low number of
participants (n=4). The baseline already-low GDS scores (mean = 5) in treatment BA
for the non- APOE ε4 carriers (unlike the higher baseline GDS scores in the AB
treatment group, means of 7 and 8) makes it rather difficult to determine a drop in
depression using this scoring system.

Interestingly, in arm treatment AB, the

testosterone effect was carried over to the washout and placebo treatment, with further
reductions in depression levels (Fig 7.12 A). The significant reduction in GDS score
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with placebo treatment observed for the APOE ε4 carriers in treatment BA (Fig 7.12
B). may be due to the baseline condition of most participants. The APOE ε4 carriers
had high depression levels at baseline, giving the treatment greater opportunity to
improve GDS scores following treatment. As mentioned earlier though, the significant
reduction of depression followed placebo treatment, which together with the large error
bars on the graphs, more likely reflects the low number of participants. The results of
treatment AB however are in agreement with Seidman et al.,2001 who reported that
total testosterone levels are negatively associated with depression in middle-aged men.
The association between depression and AD is still unclear. Associations are
complicated by the possibility that depression may be a prodromal symptom of AD,
which may appear before the recognition of AD. As a result, there are still insufficient
data to determine whether depression represents an early symptoms or an independent
risk factor of AD (Jorm, 2001).
There are limited data on the effects of testosterone on the quality of life in testosterone
deficient men. However the information that exists suggests that testosterone can
improve the quality of life significantly (restoring to the same level as men with normal
testosterone levels) and the more severe the symptoms before treatment, the greater the
benefits of testosterone replacement (Moncada, 2006). Although the effect of
testosterone deficiency on quality of life has not been well established, it is clear that
testosterone deficiency in the elderly has a negative effect on physical, mental and
social functioning (Novak et al., 2002).
In this study, quality of life comprising physical health and mental health were not
significantly improved by testosterone treatment. Although, in treatment BA, both
physical and mental health scores were significantly increased after being treated with
testosterone compared to baseline. However, it is important to note that there were
“carry-over effect” observed in which physical health (PH) and mental health (MH) at
washout were still significantly different from baseline (Figure 7.14 B and Figure 7.15
B). In accordance with our results, Reddy et al., 2000 and Kenny et al., 2002 also failed
to show testosterone therapy-induced improvements in quality of life

testosterone

therapy. These two studies used the SF-36 test too. Using a different measure, namely
the Quality of Life-Alzheimer Disease (QOL-AD), Lu et al. 2000 also observed no
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significant difference following the assessment of quality of life in healthy elderly men
treated with testosterone for 24 weeks.
However, in a study by Snyder et al., 1999 which used the SF-36 test for assessment,
transdermal testosterone treatment in men over 65 years of age improved the patients’
perception of physical functioning (but no other domains of the SF-36) compared with
placebo. This study observed the effect of testosterone treatment for 36 months, whilst
the treatment in the current study lasted only 6 months. The testosterone replacement
therapy by Kenny et al., 2002 for 12 months also did not show improvement of quality
of life. The effect of testosterone on quality of life in this study was not significant
enough to be detected – this may be because the quality of life was determined to be
quite adequate in these participants at baseline.
It is possible that the SF-36 assessment is too general and not particularly suitable for
assessing quality of life in a testosterone deficient population (Jorm, 2001). There are
other more specific scales to measure quality of life in testosterone deficient men, such
as The Aging Male’s Symptoms (AMS) (Daig et al., 2003) and the Age-Related
Hormone Deficiency-Dependent Quality of Life questionnaire (A-RHDQoL) (McMilan
et al., 2003). The questionnaires detailed in these studies may be more specific in
addressing issues related to hormone deficiencies, and may assess better the effects of
testosterone replacement therapy in men with low testosterone and show that quality of
life can improve following testosterone treatment.
A study from my supervisor’s laboratory (Sohrabi, et al., 2009) has shown that mental
health and quality of life in memory complainers were independent of APOE genotype.
Results in the current study were consistent with these previous findings as they did not
show significant differences between APOE ε4 and non-APOE ε4 carriers in relation to
quality of life, in the AB treatment arm, although there appears to be a trend towards
better physical health in both APOE ε4 and non-APOE ε4 carriers at all stages
following testosterone treatment (Fig.7.14). A similar trend is visible in the BA
group, however this is possibly due to the (only 4) APOE ε4 carriers having a low
baseline score, which is followed by the apparently high physical health scores at
washout stage, which is obviously not due to the subsequent testosterone treatment in
this group. These results show that either the number of APOE ε4 carriers and/or the
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size of the whole BA cohort is too small for good statistical analysis, the SF36 test
from which the physical health scores were obtained is not appropriate for assessment
of testosterone treatment, or both. From the perspective of mental health scores, in the
AB group there appears to be a trend towards better mental health in both APOE ε4
and non-APOE ε4 carriers over the stages following testosterone treatment. In the BA
group, no change can be seen in the non-APOE ε4 carriers (Fig. 7.15), however due to
the low baseline score of the APOE ε4 carriers, it appears that the placebo treatment has
raised mental health levels, which then stay high for the rest of the trial.

This

discrepancy, again, may be due to the very small sample sizes for APOE ε4 carriers
compared to non-APOE ε4 rather than any effect of possession of APOE ε4 alleles.
Controlled clinical trials of testosterone supplementation in healthy elderly men with
partial androgen deficiency have yielded inconsistent results in relation to quality of
life. Some studies have found an increased sense of well-being (Tenover, 1992 ; Park et
al., 2003) while others have observed no significant effects (Reddy et al., 2000).
Assessment of quality of life offers a window of opportunity into the effects of
testosterone intervention on the patients and caregivers' perceived well-being and may
assist clinicians in determining the potential functional benefits and risks of therapy.
This study had some limitations. This study was underpowered, with relatively small
sample sizes (n=44) to find associations between testosterone treatment and cognition,
despite its cross-over design. There may be age dependent optimal testosterone levels
which vary for different brain functions which we did not investigate in this study.
Furthermore, the chosen instrument of RAVLT may lack sensitivity to detect small or
subtle changes in cognitively intact participants within 6 months of testosterone
treatment. Therefore, longer duration of studies may have yielded greater effects of
testosterone on cognition and verbal memory (Yonker et al., 2006 ; Gordon et al.,
1986). It is also important to note that comparisons with other studies are difficult since
there were large variations in testosterone levels across studies despite having similar
age ranges. Furthermore, many studies have used different cognitive tests to assess
similar brain functions, and sometimes have used insensitive tests. Another potential
explanation for differences in results is that many studies have measured total
testosterone (Hassler et al., 1992 ; Gordon, 1986 ; Tan, 2005) rather than free
testosterone (Hooven et al., 2004 ; Moffat, 1996 ; Gouchie, 1991 ; Christiansen, 1987).
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However, this study has attempted to measure general cognition (with verbal memory,
in particular), depression level, and quality of life at various time points of treatment
while capturing peak testosterone levels.
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Chapter 8
Effects of testosterone treatment
on brain metabolite levels
and on rates of medial temporal atrophy
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8.1 Introduction
Alzheimer’s Disease (AD) cognitive symptoms arise only after extensive synaptic loss
and neuronal death has already occurred. As a result, diagnosis is usually made many
years after the start of the disease process. A screening process that could provide early,
accurate diagnosis of AD would enable earlier intervention, and thus allow current and
future treatments to be more effective. Potential biomarkers for AD screening are being
sought from many fields including genetic analysis, blood proteomics, cerebrospinal
fluid proteomics and brain imaging. With respect to imaging techniques, both structural
and functional neuroimaging methods are being tested.
AD is characterized by early loss of memory, with the hippocampus and entorhinal
cortex being the first sites of pathological changes. Brain structural changes include
generalized cerebral atrophy, ventricular enlargement and mild to moderate white
matter changes or leukoaraiosis. Focal temporal atrophy can be detected using
computerised tomography, and a suggested diagnostic marker for AD involves the use
of angled temporal lobe views to detect medial temporal lobe atrophy associated with
the disease (O’Brien, 2007). Unfortunately this has been found to have limited utility
both in early disease and in the differentiation of AD from other causes of dementia.
Magnetic resonance imaging (MRI) has been widely investigated in AD and consistent
with the temporal development of plaque and NFT pathology, very early structural
changes have been demonstrated in the hippocampus and entorhinal cortex. However,
the particular structure that would be most useful for early diagnosis remains unclear
(Scheltens et al., 2002, Du et al., 2001). Atrophy of the hippocampus and entorhinal
cortex can be assessed using simple validated scales, and such atrophy occurs in 8090% of AD cases and in around 5-10% of control subjects (Du et al., 2001). Other early
changes in AD include atrophy of the posterior cingulate (Scahill et al., 2002), not a
prominent site of pathology but changes may be related to loss of afferent input from
associated fibres.
Serial MRI has been useful in increasing our understanding of disease progression in
AD and other dementias. Atrophy rates of around 2% per year occur in AD compared to
0.25-0.5% in control subjects (O’Brien, 2007), and using serial MRI, it has been
possible to identify structural changes in familial AD cases 2-3 years before they could
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be detected by cross-sectional volumetric measurement (Ridha et al., 2006). Serial MRI
has sometimes been used as an outcome measure in clinical trials, being a robust
biological measure that shows little variability. Power calculations have shown that
clinical studies of disease progression can be undertaken with significantly fewer
subjects when using serial MRI as opposed to a clinical outcome measure (Fox et al.,
2000). Using this method, it has been possible to measure a decreased rate of
hippocampal atrophy in those receiving cholinesterase inhibitors (Hashimoto et al.,
2005), Serial MRI in another study measured increased brain atrophy in a group of
patients given the active amyloid vaccine. This was suggested to be due to increased
clearance of amyloid plaques from the brain (Fox et al., 2005).
Atrophy of the medial temporal lobe (MTA), including the hippocampus and entorhinal
cortex, is a sensitive marker for AD, and studies have shown that decreased volume of
the medial temporal lobe is also marker for dementia in patients with mild cognitive
impairment (MCI) (Esther et al., 2004). However, MTA is present in other dementias as
well, for example in frontotemporal lobe degeneration (FTLD), vascular dementia
(VaD) and dementia with Lewy bodies (DLB). It may also be seen in normal aging.
Volumetric assessment of MTA is difficult because of the time-consuming analysis
required, and because automated hippocampal volume measurement techniques are not
widely available. In contrast, the assessment of MTA using a standardized visual rating
scale is a quick and easy measurement, with comparable predictive accuracy. Such
visual assessment of MTA from brain MRI using a standardized rating scale is powerful
and can function as an independent predictor of conversion to dementia in relatively
young MCI patients (Scher et al., 2007). In fact, the MTA scale has been shown to be a
better predictor of memory impairment when compared to neuropsychological tests
(Scheltens et al., 2002). AD hippocampal volumes have been measured to be 11.5%
smaller than in control cases, with similar size differences for the median left (12%) and
median right (11.6%). Hippocampal shape analysis has shown that differences are more
evident in the hippocampal body than in the head, and more consistent differences have
been found in the left hippocampus than the right (Scher et al., 2007, Kantarci et al.,
2004).
Functional MRI is another form of scanning that can measure brain activity indirectly,
by measuring blood flow in the brain. Deoxygenated hemoglobin attenuates the MR
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signal, thus a vascular response leads to a signal increase that is related to neural
activity. It has several potential advantages, particularly for clinical trials, as it is a noninvasive technique that does not require the injection of contrast agent or radiation
exposure and thus can be repeated many times during a longitudinal study. fMRI has
relatively high spatial and reasonable temporal resolution, and can be acquired in the
same session as structural MRI (Sperling, 2011).
In an AD brain, volume loss has been intrepreted to reflect neuron loss, possibly
together with non-neural changes, such as loss of glial components. Such changes are
now thought to be detectable using yet another relatively new technology - proton
magnetic resonance spectroscopy (1H MRS), which has the potential to provide noninvasive assessments of metabolic and functional correlates of dementia in research and
clinical settings (Lin et al., 2005). An MRS spectrum shows frequency or chemical shift
(compared to a reference chemical) on the horizontal axis, which allows the
identification of the metabolites being investigated, and the vertical axis shows the
signal strength in arbitrary units. MRS allows for non-invasive and repeated
quantitation of several different brain metabolites, most commonly N-acetyl aspartate
(NAA), choline (Cho), myo-Inositol (mI), and creatinine (Cr) containing compounds.
Each of these metabolites is thought to be sensitive to a different aspect of in vivo
pathologic processes at the molecular or cellular level (Kantarci et al., 2007). Increases
in choline and myo-Inositol (markers of membrane turnover) have been demonstrated in
several studies of AD brains, implying significant cellular membrane (and glial)
pathology. Large decreases in brain NAA (a marker of neuro-axonal integrity) are
commonly seen in grey and white matter in AD (as well as in other forms of dementia),
indicating the presence of significant axonal damage. Levels of NAA also appear to
correlate with disease severity. Recent studies suggest MRS has the potential to
distinguish AD patients from healthy control at pre-clinical stages of the disease in
which AD-modifying therapies are likely to be most beneficial (Fallini et al., 2005). For
example, in a study of cognitively normal older adults, higher ratios of mI/Cr and
Cho/Cr were associated with higher Aβ loads, as measured by PiB retention. Higher
Cho/Cr was found to be associated with worse performance on domain-specific
cognitive tests independent of Aβ load, suggesting that Cho/Cr elevation may also be
dependent on other preclinical dementia pathologies characterized by Cho/Cr ratio
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elevation such as Lewy body or ischemic vascular disease in addition to Aβ load
(Kantarci et al., 2011).
Another recent study carried out MRS on MCI patients to see if it was possible to
predict conversion to dementia within the 2-year period after baseline assessment. The
brain regions examined were the posteromedial bilateral parietal lobe and left medial
occipital lobe. After the 2 year follow-up, 27 (38%) patients converted to AD. The mean
NAA/Cr ratio in the poster medial bilateral parietal cortex was 1.38 in converters versus
1.49 in non-converters (p<0.0001). In this study, neither the APOE ε4 genotype nor
leucoaraiosis was predictive of conversion to dementia (Modrego et al., 2011). Several
other studies have looked at various concentrations or ratios of the 4 metabolites
(NAA/Cr, Cho/Cr, mI/Cr and NAA/mI ratios), such as one study which found that the
NAA/Cr ratio in the posterior cingulate gyri showed considerable potential for
distinguishing amnestic MCI from normal elderly controls (Wang et al., 2012), and
another study which compared AD and subcortical ischemic vascular dementia (SIVD),
which are known to have overlapping pathologies and risk factors, and found that the
pattern of mI concentration changes differed between the two disorders; mI was
increased in AD but not increased in SIVD (Shiino et al., 2012). All these results
suggest MRS may provide a valuable biomarker for predicting the development of AD
as well as to differentiate between AD, vascular dementia and MCI.
Another recent study showed that the discrimination between early AD and elderly
healthy control subjects can be improved by adding MRS measures to MRI measures: it
was found that combining MRI and MRS measures resulted in a sensitivity of 97% and
a specificity of 94% compared to using MRI or MRS measures alone (sensitivity: 87%,
76%, specificity: 86%, 83% respectively) (Westman et al., 2011). In AD patients, 1H
MRS

measurements

of

NAA/Cr

and

mI/Cr

ratios

correlated

with

the

neuropsychological measures of cognitive function. This correlation was found to be
region-specific, depending on the cognitive domain being studied. For example, 1H
MRS metabolite changes in patients with AD correlate with verbal memory loss in the
left medial temporal lobe, and correlate with language impairment and visuoconstructional abilities in the left parietotemporal cortex (Kantarci et al., 2007).
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Since a variety of metabolite differences have been recorded, possibly due to the regionspecific nature of these differences, more studies need to be conducted to characterise
these MRS differences further, and to discover which metabolite differences and which
brain regions are the most appropriate for differentiating people with early stages of AD
from healthy elderly controls.
With regard to the monitoring of treatment effects, there are very few studies that have
directly examined testosterone’s effects on brain activity (Moffat et al., 2004). Applying
this new MRS technology to measure brain metabolite changes in a testosterone
treatment trial may indicate how testosterone is affecting brain function, thus providing
valuable information. Overall, this chapter will investigate the effects of testosterone on
brain metabolite changes and atrophy rates, as well as the association between MTA
scale measurements and neuropsychological performance.

8.2 Aims
The aims of my study were:


To determine whether testosterone treatment can influence brain
metabolite levels in testosterone deficient men;



To determine whether testosterone treatment alters rates of medial
temporal lobe atrophy;



To determine whether testosterone treatment in men influences
hippocampal atrophy, as assessed by the MTA scale;



To determine whether there is any correlation between MTA scale
measurements

and

neuropsychological

performance

following

testosterone treatment in testosterone deficient men.
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8.3 Methods
Participants
All participants were randomized in both arms of the treatment, the details of which
have previously been described in section 6.3. Testosterone deficient men were seen at
baseline and underwent structural brain MRI and MRS, following completion of the
neuropsychological assessment. Participants attended follow-up MRI and proton MRS
imaging at the following intervals from baseline: at 24 weeks which was the endpoint of
the first treatment (either treatment A or B), and at 52 weeks which was the end of the
second treatment (either treatment B or A) respectively.

1H MR Spectroscopy- Chemical Shift Imaging (CSI)
1

H MR Spectroscopy (MRS) spectra were acquired on a 1.5 T Philips Gyroscan ACS-

NT system using a quadrature Head coil. MRI of the brain was done before the
commencement of MRS for assessment of brain condition at that time. The first step of
the MRI was a SCOUT / SURVEY. Twenty axial or transversal scout images were
obtained by T2/FLAIR ( Fluid Attenuated Inverse Recovery) using a thickness of 5 mm
and 0.5 mm gaps. From these sequences, evaluation of the whole brain for lacunar
infarcts or lesions was possible. Twenty sagittal scout images were then acquired by
T1/FFE (Fast Field Echo) using a 5 mm thickness and 0.5 mm gap. This sequence
represents the long axis of the hippocampus for coronal slice determination by MRS.
The next acquisitions were 20 coronal scout images with T2/TSE ( Turbo Spin Echo ) at
a thickness of 5 mm and gaps of 0.5 mm. Slices were made perpendicular to the long
axis of the hippocampus body. For serial acquisition, the same voxel size was used for
each patient in coronal slides and repositioned as accurately as possible by the same
study radiographer who was blinded to clinical / cognitive information.
2D Spectroscopic Imaging (SI) methods (TR = 1500 ms, TE = 272, matrix = 512 x 512)
were used for spectra generation. An Echo Time (TE) of 272 ms and water suppression
techniques were used to reduce the contribution from underlying broad resonances. The
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plane of the 2D SI grid can be angulated with the echo defined volume, the direction
can be freely chosen to be transverse, sagital or coronal so 2D SI could be use to capture
an irregular shape structure in whole voxel. Five spectroscopic points were generated
on the right and left hippocampi, right and left medial temporal lobe, and one in the
white matter of the thalamus, this last one providing a “normal” spectrum which served
as a control (no pathologies observed). Acquired spectra were reviewed visually by an
experienced neuro-radiologist for quality as well as artifacts that would interfere with
metabolite quantization. The metabolite ratios NAA/Cr and Cho/Cr were generated
from the software of the Gyroscan ACS-NT system, using the physiologically stable
metabolite Creatine (Cr) as the internal reference metabolite. Due to the selection of
long echo time in this study, myo-Inositol was not available. A total of 1980 spectra
were acquired. Total scan time for MRI and MRS acquisition was 50-60 minutes for
each patient.

Medial Temporal Atrophy (MTA) rating
A standardized Scheltens scale was used to assess atrophy of the right and left medial
temporal lobes including the hippocampus from hard film copies of coronal slice T1weighted images, with slice thicknesses being 8 mm. Atrophy is graded on a 5-point
scale (0=absent, 1=minimal, 2=mild, 3=moderate and 4=severe) based on the height of
the hippocampus, the width of the choroid fissure, and the width of the horn. (Figure
8.1). These MTA ratings were performed at three time points, which were at baseline
(before any treatment), the end of testosterone treatment, and the end of placebo
treatment.
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Figure 8.1: Medial Temporal Atrophy (MTA) visual assessment scale. MTA scaling
performed on T1-MR coronal slices. The right and left sides are rated separately and
also combined. Score range of atrophy: 0=absent, 1=minimal, 2=mild, 3=moderate and
4=severe.
For the purpose of statistical analysis, two experienced radiologists (blinded to
treatments and age) were employed to provide two sets of results to assess atrophy in
the right and left medial temporal lobes. In addition, the right and left MTA scales were
combined to generate an average MTA score.
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Statistical analysis
The Statistical Package of Social Sciences (SPSS version 19, SPSS Inc, Chicago, USA)
was used for data analysis. The Shapiro-Wilk test was used to examine normality of
distribution of continuous variables for each group. All of the data were found to be not
normally distributed (non-parametric data), therefore Friedman’s Test and/or Wilcoxon
signed-rank test was used to look at differences between groups. The inter-class
correlation coefficient was used to assess the inter-rater reliability of the qualitative
MTA scale using Kappa Measure Agreement. Regression analysis was done in order to
determine whether the efficacy of testosterone treatment in men can be determined by
the rate of hippocampal atrophy. Partial correlations between MTA scores and measures
of neuropsychological assessment (Mini Mental State Examination, Geriatric
Depression Scale,, and Rey Auditory Verbal Learning Test) were examined using
Spearman Rho correlation, controlling for the effect of age and education.

Measures
The details about the neuropsychological, and clinical measures used in this study can
be found in Chapter 7, page 267. Briefly, to measure the general cognitive functions and
the potential cognitive decline severity Mini Mental State Examination (MMSE) and
Geriatric Depression Scale (GDS) were used. The verbal memory was assessed using
the Rey Verbal Learning Test (RAVLT).
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8.4 Results
8.4.1 Effects of testosterone on brain metabolites as measured by 1H MR
Spectroscopy
To determine the effects of testosterone on brain metabolite levels, the N-AcetylAspartate, Choline (Cho) and Creatinine (Cr) levels were assessed using 1H MRS and
the NAA/Cr and Cho/Cr ratios were calculated. For an individual metabolite, the parts
per million (ppm) refer to the unit of measure used to identify a metabolite’s peak
location or resonance on the x-axis. The ppm is calculated by dividing the difference in
frequency (in Hertz) of two peaks (with one peak being the reference) by the operating
frequency of the MR scanner (in Hertz). The signal intensity (amplitude on the y-axis)
and line width provide the "area" which can be used to quantify the amount of the
observed metabolites (Figure 8.2). Every metabolite has a normal concentration that
generates a pattern of peaks which is uniform from person to person unless there is an
underlying pathology. Therefore, diagnosis with MRS can be made by comparing
between normal and abnormal peak patterns. According to numerical peak-height ratios
with the assumption that Cr=1, a ratio of NAA/Cr of 1.25 + 0.07 would suggest a
dementia diagnosis. A value of NAA/Cr >1.11 may be classified as probable AD
(Shonk et al., 1995).
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Figure 8.2: Example of a

1

H MRS-2DCSI set of scans with 5 different

spectroscopic points obtained using a Gyroscan Intera 1.5T (Philips). 1: right
hippocampus. 2: left hippocampus. 3: right medial temporal (MT) lobe 4: left MT
lobe 5: thalamus (normal) area
The mean and standard deviation for longitudinal metabolite changes between
testosterone and placebo treatment as revealed by NAA/Cr and Cho/Cr ratios are shown
in Figures 8.3 and 8.4. There were no significant changes in the two ratios in either the
left or right hippocampi, or the medial temporal lobes over the three time points
(between baseline, treatment A, and treatment B) based on Friedman’s test and
Wilcoxon signed-rank test.

309

(A)
NAA/Cr&le) &hippocampus&
Treatment&A66>B&

NAA/Cr&

NAA/Cr&

NAA/Cr&right&hippocampus&&
Treatment&A55>B&

310

NAA/Cr&le) &Medial&Temporal&Lobe&
Treatment&A66>B&
NAA/Cr&

NAA/Cr&

NAA/Cr&right&Medial&Temporal&Lobe&&
Treatment&A77>B&

(B)
NAA/Cr&right&hippocampus&
Treatment&B66>A&

NAA/Cr&

NAA/Cr&

NAA/Cr&le) &hippocampus&
Treatment&B77>A&

NAA/Cr&le) &Medial&Temporal&Lobe&
Treatment&B77>A&
NAA/Cr&

NAA/Cr&

NAA/Cr&right&Medial&Temporal&Lobe&
Treatment&B88>A&

Figure 8.3 : NAA/Cr ratios measured at four different spectroscopic points in
treatment AB (A), and treatment BA (B). There were no significant changes
over time in any of the groups. (n=22).
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C h o /C r&

C h o /C r&
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Cho/Cr&le) &hippocampus&
Treatment&B55>A&
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Cho/Cr&right&hippocampus&
Treatment&B44>A&
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Treatment&B66>A&
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Figure 8.4 : NAA/Cr ratios measured at four different spectroscopic points in
treatment AB (A) and treatment BA (B). There were no significant changes over
time in any of the groups. (n=22).
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8.4.2 Effects of testosterone on medial temporal atrophy (MTA)
The variability between the ratings put forward by the three different raters were
investigated. There was little agreement with Kappa Measure of Agreement between
raters 1 and 2 (0.01, 0.02), versus rater 3 (0.015). Therefore, the MTA scores were
generated from two out of three radiologists whose scores were in close agreement.
MTA scale results were generated for the right and left temporal lobes separately, as
well as combined, to generate one score which ranged from 0-4, with a greater score
indicating more atrophy (as demonstrated in Fig. 8.1). The MTA scaling was done at
three time points (as used in section above) in both arms of the experiment, with
measurements taken at baseline, the end of testosterone treatment, and the end of
placebo treatment.
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Figure 8.5: Boxplots of right MTA and left MTA scaling results (n=22) of subject
brains from both arms of the study: treatment AB (1st row) and treatment BA
(2nd row).
Significant reductions in atrophy were observed on the left MTA scale of treatment
BA, compared to baseline. There were no other significant differences observed. Data
are presented in the scale range from 0-4 as described in Fig. 8.1, as medians +
quartiles.
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Combined MTA scale Treatment AB

Combined MTA scale Treatment BA

*
*

Figure 8.6 : Boxplots of combined right and left MTA scaling results (n=22) of
subjects from both arms of the study: treatment AB (left ) and treatment BA
(right). Significant reductions in atrophy following testosterone and placebo treatments
were observed only in arm treatment BA compared to baseline; *p<0.05, in
comparison to baseline.

Due to the small number of participants in the two arms of the study, the added
statistical power that might be obtained following pooling of the MTA results of all
participants from both arms of the study was also investigated.
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*

*

*

Combined MTA scale

*

*

Figure 8.7: Boxplot of the combined MTA measurements (n=44) of both arms of
the study: right MTA and left MTA (both on top row), and combined right and left
MTA (2nd row). Data are presented using the scale range of 0-4 (as described in Fig.
8.1), showing the medians + quartiles. Significant differences were observed in the left
MTA measurements, as well as the combined right and left MTA results following both
treatments (testosterone and placebo) compared to baseline. In the right MTA scaling
results, a significant reduction in MTA scaling was observed following testosterone
treatment only. However, pooling the results from the two treatment arms no longer
takes into account the order of the testosterone and placebo treatments; *p<0.05 in
comparison to baseline.
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Figure 8.8: Boxplot of Right and Left Medial Temporal Atrophy (MTA) results for
treatment AB (1st row) and treatment BA (2nd row), as assessed by rater 1.
Data are presented in the scale range from 0-3 showing the median + quartiles.

The results of the Friedman Test for treatment AB as well as treatment BA
indicated that there were no significant differences across the three time points
(baseline, testosterone treatment, and placebo treatment) for the right MTA results: Х2
(2, n=22) = 1.5, p>0.005, left MTA results : Х2 (2, n=22) = 4, p>0.867005, and
combined MTA results : Х2 (2, n=22) = 3.44, p>0.005. However, there is a general trend
suggesting that decreases in MTA scale results (i.e. reductions in MTA) could be
achieved through testosterone treatment. This trend can be found in both arms of the
experiment [treatment (A->B) and treatment (B->A)].
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8.4.3 Baseline Medial Temporal Atrophy (MTA) scale as a predictor of
testosterone treatment effect on subsequent rate of atrophy
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Figure 8.9: Scatter plots of linear regression analyses showing the levels of
correlation between baseline MTA scale and testosterone treated-MTA scale
results. The results have been grouped according to APOE ε4 status for both
treatment AB (A) and treatment BA (B).
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Figure 8.10 : Scatter plots of linear regression analyses showing the levels of
correlation between baseline MTA scale and testosterone treated-MTA scale
results, after pooling treatment AB (A) and treatment BA results. Participants
are still grouped according to APOE ε4 status.
From Figure 8.9 and Figure 8.10 above, it appears that the non-APOE ε4 participants
had a reduced amount of MTA in response to testosterone treatment compared to APOE
ε4 participants.
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8.4.4 Correlation between medial temporal atrophy and neuropsychological
changes.
The cognitive function assessments of the subjects in this clinical trial were carried out
at the same three stages as the MRI/MRS assessments. Thus cognitive function was
assessed before any treatment had begun (baseline), then 24 weeks later after the first
treatment of either testosterone (AB group) or placebo (BA group), then 52 weeks
later after the second placebo (AB group) or testosterone (BA group) treatment.
The neuropsychological tests carried out were the Mini Mental State exam (MMSE),
Geriatric Depression Scale (GDS), and the Rey Auditory Verbal Learning Test
(RAVLT). The results are listed below in Tables 8.1 to 8.9.
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Table 8.1 Correlations of Right MTA scale with MMSE and GDS for Treatment AB arm (n=22)

Spearman's rho MMSE_BL_AB

Correlation Coefficient

GDS_13_AB

End of Testo

End of

AB

AB

Placebo AB

.816

.978

.888

-.301

-.293

-.320

.173

.186

.147

-.196

-.102

-.211

.382

.653

.345

-.166

-.148

-.168

.461

.510

.454

-.139

-.160

-.117

Sig. (2-tailed)

.538

.477

.603

Correlation Coefficient

.293

.250

.294

Sig. (2-tailed)

.185

.262

.185

22

22

22

Correlation Coefficient

Correlation Coefficient

Correlation Coefficient
Sig. (2-tailed)

GDS_6_AB

Baseline

-.032

Sig. (2-tailed)
GDS_BL_AB

RIGHT MTA

.006

Sig. (2-tailed)
MMSE_9_AB

RIGHT MTA

-.053

Sig. (2-tailed)
MMSE_6_AB

RIGHT MTA

Correlation Coefficient

N (for all of above)
**. Correlation is significant at the 0.01 level (2-tailed).
*. Correlation is significant at the 0.05 level (2-tailed).
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Table 8.2 Correlations of Left MTA scale with MMSE and GDS Treatment AB (n=22)

Spearman's rho MMSE_BL_AB

Correlation Coefficient

GDS_13_AB

End of

AB

AB

Placebo AB

.711

.817

-.392

-.385

-.265

.071

.077

.234

-.150

-.089

.008

.504

.694

.973

-.267

-.341

-.199

.230

.121

.374

-.264

-.386

-.286

Sig. (2-tailed)

.235

.076

.198

Correlation Coefficient

.280

.129

.288

Sig. (2-tailed)

.207

.568

.193

22

22

22

Correlation Coefficient

Correlation Coefficient

Correlation Coefficient

Correlation Coefficient

N (for all of above)
**. Correlation is significant at the 0.01 level (2-tailed).
*. Correlation is significant at the 0.05 level (2-tailed).
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End of Testo

.749

Sig. (2-tailed)
GDS_6_AB

Baseline

.052

Sig. (2-tailed)
GDS_BL_AB

LEFT MTA

-.084

Sig. (2-tailed)
MMSE_9_AB

LEFT MTA

-.072

Sig. (2-tailed)
MMSE_6_AB

LEFT MTA

Table 8.3 Correlations of Combined MTA Scale with MMSE and GDS Treatment AB (n=22)
RIGHT&LEFT RIGHT&LEFT RIGHT&LEFT

Spearman's rho MMSE_BL_AB

Correlation Coefficient

GDS_13_AB

Testo AB

Placebo AB

.737

.844

.821

-.359

-.329

-.243

.101

.135

.276

-.198

-.134

-.100

.376

.552

.657

-.267

-.214

-.122

.230

.339

.589

-.234

-.226

-.142

Sig. (2-tailed)

.295

.313

.530

Correlation Coefficient

.282

.192

.373

Sig. (2-tailed)

.204

.392

.087

22

22

22

Correlation Coefficient

Correlation Coefficient

Correlation Coefficient
Sig. (2-tailed)

GDS_6_AB

AB

.051

Sig. (2-tailed)
GDS_BL_AB

MTA End of

-.044

Sig. (2-tailed)
MMSE_9_AB

MTA End of

-.076

Sig. (2-tailed)
MMSE_6_AB

MTA Baseline

Correlation Coefficient

N (for all of above)
**. Correlation is significant at the 0.01 level (2-tailed).
*. Correlation is significant at the 0.05 level (2-tailed).
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Table 8.4 Correlations Right MTA scale with MMSE and GDS Treatment BA (n=22)

Spearman's rho MMSE_BL_BA

MMSE_6_BA

MMSE_13_BA

GDS_6_BA

GDS_13_BA

RIGHT MTA

BAseline

End of

End of Testo

BA

Placebo BA

BA

.065

.098

.016

Sig. (2-tailed)

.773

.665

.945

Correlation Coefficient

.054

.055

.048

Sig. (2-tailed)

.810

.810

.833

-.157

-.043

-.048

.486

.850

.831

Correlation Coefficient

Correlation Coefficient

.-319

*

.466

*

.508

Sig. (2-tailed)

.148

.029

.016

Correlation Coefficient

.155

.-348

.328

Sig. (2-tailed)

.491

.112

.136

Correlation Coefficient

.403

Sig. (2-tailed)

.063

.038

.028

22

22

22

N (for all of above)
**. Correlation is significant at the 0.01 level (2-tailed).
*. Correlation is significant at the 0.05 level (2-tailed).
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RIGHT MTA

Correlation Coefficient

Sig. (2-tailed)
GDS_BL_BA

RIGHT MTA

*

.444

*

.469

Table 8.5 Correlations of Left MTA scale with MMSE and GDS Treatment BA (n-22)

Spearman's rho MMSE_BL_BA

MMSE_6_BA

MMSE_13_BA

Correlation Coefficient

GDS_6_BA

GDS_13_BA

LEFT MTA

LEFT MTA

Baseline

End of

End of Testo

BA

Placebo BA

BA

-.015

.004

-.070

Sig. (2-tailed)

.949

.985

.756

Correlation Coefficient

.192

.112

-.016

Sig. (2-tailed)

.391

.621

.943

-.048

.037

.049

.830

.870

.830

.-294

.303

.305

Sig. (2-tailed)

.184

.170

.167

Correlation Coefficient

.212

.078

.037

Sig. (2-tailed)

.344

.731

.869

Correlation Coefficient
Sig. (2-tailed)

GDS_BL_BA

LEFT MTA

Correlation Coefficient

Correlation Coefficient
Sig. (2-tailed)
N (for all of above

*

.499

*

*

.455

.443

.018

.033

.039

22

22

22

**. Correlation is significant at the 0.01 level (2-tailed).
*. Correlation is significant at the 0.05 level (2-tailed).
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Table 8.6 Correlations of Combined MTA scale with MMSE and GDS Treatment BA (n=22)
RIGHT&LEFT RIGHT&LEFT RIGHT&LEFT

Spearman's rho MMSE_BL_BA

MMSE_6_BA

MMSE_13_BA

GDS_BL_BA

GDS_6_BA

GDS_13_BA

MTA End of

MTA End of

BA

Placebo BA

Testo BA

Correlation Coefficient

.026

-.198

.075

Sig. (2-tailed)

.907

.378

.740

Correlation Coefficient

.201

-.392

.120

Sig. (2-tailed)

.369

.072

.595

-.166

-.204

-.058

Sig. (2-tailed)

.459

.364

.797

Correlation Coefficient

.334

.346

.293

Sig. (2-tailed)

.129

.115

.185

Correlation Coefficient

.253

.224

.122

Sig. (2-tailed)

.255

.316

.590

Correlation Coefficient

Correlation Coefficient
Sig. (2-tailed)
N (for all of above)

**. Correlation is significant at the 0.01 level (2-tailed).
*. Correlation is significant at the 0.05 level (2-tailed).
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MTA Baseline

*

.449

*

.464

.386

.036

.030

.076

22

22

22

Table 8.7 Correlations of Right MTA scales with MMSE and GDS (n=44)

Spearman's rho MMSE_BL

Correlation Coefficient

GDS_BL

GDS_Testo

GDS_Placebo

RIGHT MTA

Baseline

Testo

Placebo

-.010

.015

.896

.948

.923

-.226

-.171

-.172

.140

.267

.265

-.146

-.075

-.126

Sig. (2-tailed)

.345

.627

.416

Correlation Coefficient

.056

.161

.-147

Sig. (2-tailed)

.717

.296

.342

Correlation Coefficient

.145

Sig. (2-tailed)

.349

Correlation Coefficient

.260

Sig. (2-tailed)

.089

.040

.249

44

44

44

Correlation Coefficient
Sig. (2-tailed)

MMSE_Placebo

RIGHT MTA

-.020

Sig. (2-tailed)
MMSE_Testo

RIGHT MTA

Correlation Coefficient

N (for all of above)

*

.356

.164

.018

.288

*

.311

.178

**. Correlation is significant at the 0.01 level (2-tailed).
*. Correlation is significant at the 0.05 level (2-tailed).
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Table 8.8 Correlations of Left MTA scale with MMSE and GDS (n=44)

Spearman's rho MMSE_BL

Correlation Coefficient

GDS_BL

GDS_Testo

GDS_Placebo

Baseline

Testo

Placebo
.016

.699

.584

.919

-.215

-.147

-.096

.161

.342

.534

-.035

-.072

.009

Sig. (2-tailed)

.824

.644

.952

Correlation Coefficient

.011

.004

.073

Sig. (2-tailed)

.943

.979

.640

Correlation Coefficient

.134

.073

.115

Sig. (2-tailed)

.385

.638

.456

.069

.206

.045

.658

.179

44

44

44

Correlation Coefficient

Correlation Coefficient

Correlation Coefficient
Sig. (2-tailed)
N (for all of above)

**. Correlation is significant at the 0.01 level (2-tailed).
*. Correlation is significant at the 0.05 level (2-tailed).
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LEFT MTA

-.085

Sig. (2-tailed)
MMSE_Placebo

LEFT MTA

-.060

Sig. (2-tailed)
MMSE_Testo

LEFT MTA

*

.303

Table 8.9 Correlations of Combined MTA scale with MMSE and GDS (n=44)

Spearman's rho MMSE_BL

Correlation Coefficient

GDS_BL

GDS_Testo

GDS_Placebo

RIGHT&LEFT

MTA Baseline

MTA Testo

MTA Placebo

.004

-.019

.811

.977

.901

-.258

-.184

-.191

.091

.232

.214

-.038

-.028

-.162

Sig. (2-tailed)

.808

.856

.293

Correlation Coefficient

.035

.053

.083

Sig. (2-tailed)

.824

.731

.592

Correlation Coefficient

.130

.113

.136

Sig. (2-tailed)

.401

.464

.378

Correlation Coefficient

.292

.141

.214

Sig. (2-tailed)

.054

.361

.164

44

44

44

Correlation Coefficient
Sig. (2-tailed)

MMSE_Placebo

RIGHT&LEFT

-.037

Sig. (2-tailed)
MMSE_Testo

RIGHT&LEFT

Correlation Coefficient

N (for all of above)
**. Correlation is significant at the 0.01 level (2-tailed).
*. Correlation is significant at the 0.05 level (2-tailed).
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From all the results above, it can be seen that in the treatment group BA, there were
positive correlations between subject’s GDS and right and left MTA scale results,
following testosterone treatment (Tables 8.4 and 8.5). In the treatment group AB, this
association was not seen. If the results from the patients in both arms are pooled
according to treatment type (i.e., either testosterone treatment, or placebo treatment,
regardless of treatment order), we found positive correlations between GDS results and
right MTA scale results (but not left MTA scale results) following testosterone
treatment. The number of subjects in this trial is small, but the positive correlations
suggest that serial measurements of atrophy in the medial temporal lobe/hippocampus
region will help to indicate whether testosterone reduces the rate of brain atrophy.
Changes in brain atrophy appear to be reflected by changes in depression levels, as
determined by the GDS. However, there were no significant correlations found between
the MTA scale and either the MMSE or the RAVLT. While the finding reported in this
chapter hold promise for the role of testosterone in protecting against atrophy of brain
regions most susceptible to AD related neurodegeneration a larger study with a more
robust neuropsychological battery will need to be undertaken for the clinical
significance of this potential therapeutic approach to be determined.

332

8.5 Discussion
In this chapter, we have summarised results of a serial MRI study and a multiple voxel
serial MRS study that were carried out on the low-testosterone subjects in this clinical
study, in order to evaluate the effect of testosterone treatment on brain region atrophy
and brain metabolite levels, compared to the original baseline levels. To our knowledge,
this longitudinal study is the first that has involved the systematic acquisition of
multiple serial spectra from patients in a testosterone clinical study. Brain metabolite
levels (N-acetyl aspartate (NAA), choline (Cho) and creatinine (Cr)) were measured and
the NAA/Cr and Cho/Cr ratios were calculated, to assess whether testosterone treatment
could influence these parameters.
At baseline, lower NAA/Cr ratios in the left and right hippocampi and medial temporal
lobe were observed, when compared with the thalamus white matter which provided
“normal” spectra (control spectra - no pathologies observed). However, no significant
alterations in Cho/Cr ratios were observed. These findings are consistent with a
previous longitudinal study undertaken over a 13 month period14 which showed a
greater decline in the NAA/Cr ratio in AD patients compared to controls (-1.8%/year in
AD, 0.5%/year in controls) though non-significant rates of change were observed for
Cho/Cr ratios in these same cases (1.2% in AD, 2.6% in controls). The reduction in
NAA levels likely reflects neuronal loss or dysfunction. The 44 low-testosterone
participants in this study did not have AD, but it needs to be remembered that they were
subjective memory complainers, with MMSE scores ranging from 24-30, and a group
average of 2. The 14 participants with MMSE scores <26 could probably be rated as
approaching mild cognitive impairment. Decreased NAA levels have also previously
been associated with increasing age in healthy participants.
Serially-acquired MRS, used as an outcome measure in this testosterone clinical trial, is
dependent on a number of factors, including the variability and reproducibility of the
technique. An ideal biomarker of neuroimaging should make it possible to, (1) detect
early neurodegenerative pathology, (2) reflect pathological stage across the entire
severity spectrum, (3) predict when an individual with early pathology may become
demented, and (4) monitor the effect of a therapeutic intervention. Another property
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relevant to an AD biomarker is to be able to differentiate between AD and other forms
of dementia.
Studies of different common dementias have shown that NAA/Cr ratios are decreased in
dementias that are characterized by neuron loss such as AD, frontotemporal lobe
dementia (FTLD), and vascular dementia. It also seems that MI/Cr ratios are elevated in
dementias that are pathologically characterized by gliosis such as AD and FTLD,
whereas Cho/Cr ratios are elevated in dementias characterized by significant cholinergic
deficit such as AD and dementia with Lewy bodies (Kantarci et al., 2004).
Positron emission tomography imaging using PiB to bind to amyloid is currently more
sensitive and recent studies suggest this is an excellent method to detect pre-clinical
neurodegeneration. AD brain atrophy as detected by MRI both precedes and parallels
cognitive decline. Significant plaque deposition also occurs prior to clinical decline.
However cognitive decline is not directly due to amyloid deposition, rather the
neurodegeneration that also occurs as part of the pathology of AD. Thus, PiB PET
imaging and MRI could have complimentary roles in the pre-clinical diagnosis of AD
(Jack et al., 2009).
To date the potential 1H MRS biomarkers have provided little or no advantages over
other neuroimaging biomarkers. Thus, MRS biomarkers appear to be sensitive, however
complimentary diagnostic tools are needed to help with diagnosis, as well as differential
dementia diagnosis. Instead, recent studies in AD suggest that NAA may be more useful
as a prognostic marker for monitoring neurodegeneration, stabilization, or
improvement, and for evaluating therapeutic responses to novel drugs (Chen et al.,
2000).
Few longitudinal studies have used brain magnetic resonance spectroscopy as a
predictor of conversion to dementia. One recent longitudinal study gave encouraging
evidence that MRS (looking at the posteromedial bilateral parietal lobe and left medial
occipital lobe) in MCI may identify patients at risk of early conversion to dementia
(Modrego et al., 2011) . This study used MRS data at baseline and then followed-up 2
years later to examine rates of conversion from MCI to AD. Their results showed that
the mean NAA/Cr ratio in the posteromedial bilateral parietal cortex was 1.38 in
converters versus 1.49 in non-converters (p<0.0001). From the results in this chapter,
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the effects of successful testosterone treatment on brain metabolite levels are not yet
clear. If, however, future studies demonstrate that NAA depletion or Cho elevation are
reversed to a significant extent as a result of testosterone treatment, the measurement of
these AD “biomarkers” using current MRS methodology may prove extremely useful in
assessing treatment efficacy.
Unfortunately, MRS results of NAA/Cr ratio as well as Cho/Cr ratio did not show any
significant changes following treatments in these current experiments. This may be due
to the technical limitation of the low gradient 1.5 T MRI which was inadequate to
exhibit the spectrum changes of brain metabolites. In order to acquire and detect brain
metabolite changes accurately in future experiments, an MRI 1.5 T with a high gradient,
or more preferably an MRI 3T may be necessary.
A study by DeCarli et al. (2007) has shown that qualitative ratings of MTA may have
added impact in a clinical trial in a prospective and blinded manner for subjects with
memory complaints, who may or may not be included in the MCI category. The MTA
scale used in this study was simple, had good reliability, and could be easily
implemented into standard clinical practice, albeit there were no alterations of MTA
scale over time. Moreover, Schelten’s MTA scale has been compared to a computerized
hippocampal volume measurement method and gave similar prediction accuracy
(Westman et al., 2011).
Animal studies have shown that testosterone treatment is indeed neuroprotective
following motor neuron loss, and testosterone has been shown to attenuate somal and
dendritic atrophy (Little et al., 2009; Fargo et al., 2007). However, there is still a lack of
clinical studies which have investigated the effect of testosterone treatment on rates of
brain atrophy. Based on published literature, this is the first study which has utilised the
MTA scale to assess the effects of testosterone treatment on preserving brain structure.
The MTA scale measurement showed no significant changes for either the right MTA,
left MTA, or combined MTA of treatment AB (Figs 8.5 and 8.6). With follow-up
measurements at 6 month intervals or less as in this study, it is unlikely that small
changes in brain anatomy would be detectable, even in the early stage of AD (Mizuno et
al., 2000). However, significant reductions in atrophy were observed in the left MTA
and combined MTA of treatment BA (Figures 8.5 and 8.6). as well as if we pooled
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the participants of both arms (Figure 8.7). These results are unlikely to be due to the
effect of testosterone treatment since the initial reduction in MTA was observed
following placebo treatment (which in the BA arm of the study was prior to
testosterone treatment). The MTA changes that were observed over 6 months in this
experiment are in accordance with results of a study by Murphy et al. 2010, who
showed that increased MTA after six months was associated with subsequent memory
decline in healthy elderly people. However, it is still unclear which region of the medial
temporal lobe degenerates first in the earliest stage of AD.
The effect of APOE genotype was also investigated in this study since studies by Raz et
al. 2005 and Du et al. 2005 have shown that both APOE genotype and age alter
hippocampal atrophy and its rate of volume loss. Moreover, possession of APOE ε4
alleles has been shown to be associated with less frontal and more medial temporal lobe
atrophy in AD (Geroldi et al., 1999). In another study, Lehtovirta et al., 1995
demonstrated that compared to healthy participants, ε4 homozygous people had more
pronounced right hippocampal atrophy than ε4 heterozygous and non-APOE ε4 carriers.
Such a gene dose effect of APOE ε4 has not been firmly established in non-demented
elderly people. In this study, there were no differences observed in MTA scale results
between APOE ε4 and non-APOE ε4 carriers. However, this is most likely due to the
small number of participants in this study, resulting in a lack of statistical power to
demonstrate significant differences between the APOE ε4 and non-APOE ε4 carriers.
Nevertheless, these results were in agreement with a study by Lemaitre et al., 2005
which found no effect of APOE ε4 on hippocampal atrophy in healthy elderly
individuals. However, to date, associations between APOE genotype and medial
temporal lobe atrophy rates (including the hippocampus) remain inconclusive.
The baseline MTA scale results were essential in determining the efficacy of
testosterone treatment. The baseline MTA results could be interpreted as the sum of all
structural changes occurring prior to the six months testosterone treatment. As shown in
Fig 8.9 A&B, participants who started with high atrophy levels at their baseline
measurement (MTA scale >2) showed a reduction in MTA scale following 6 months
testosterone treatment in both arms, even after pooling all of the participants (Fig 8.10).
This effect was observed in non-APOE ε4 carriers only but not in APOE ε4 carriers.
These results may indicate that the carriers of the APOE ε4 allele may not be responsive
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to testosterone treatment in terms of modifying medial temporal atrophy. In addition,
longitudinal data by Cohen et al., 2001 have shown that APOE ε4 heterozygotes have
greater annual rate of hippocampal volume loss compared to non-APOE ε4 carriers.
Therefore, another possible explanation for the results in this study in relation to APOE
genotype is that testosterone may reduce the atrophy rate in APOE ε4 carriers, but to a
lesser extent than that observed in non-APOE ε4 carriers.
For participants younger than 75 years, an MTA score of > 2 is considered to be
abnormal, whilst for participants greater than 75 years, a score of > 3 is abnormal
(Shonk et al., 1995). The data distribution in this chapter showed that the cohort
included men with normal as well as abnormal classifications in the age category of less
than 75 years.
A psychological assessment of memory function and evaluations of structural changes
in the medial temporal lobe are important for early diagnosis of AD. Therefore, the
relationship between MTA and cognitive performance has been widely studied. In this
experiment, no correlation between MTA and cognitive performance was found, as
assessed by MMSE and RAVLT (see Tables 8.1-8). Concordantly, Crivello et al. 2010
did not find any interactions between APOE genotype or age and cognitive decline in
the healthy elderly. A study by Mizuno et al. 2000 found no correlation between
hippocampal volume and verbal memory. However, a recent study by Duchesne et al.
2009 did demonstrate a relationship between baseline MRI and MMSE after a 1 year
follow-up using voxel-based morphometry (VBM).
In relation to depression, structural brain changes have been correlated with level of
depression and cognitive performances. Lower depression scores (ie less depression)
have been found to correlate with greater levels of medial temporal atrophy amongst
those with cognitive impairment, suggesting that decreasing insight into cognitive status
may lead to lower depression scores (Greig et al., 2008). The results in the experiments
here have shown a strong negative correlation (p< 0.05) between right and left MTA
levels and depression levels as measured by the Geriatric Depression Scale (GDS);
(although in treatment BA only, Tables 8.4 & 8.5). The results indicate that the lower
the depression level, the lower the medial temporal atrophy was found to be following
testosterone treatment. However, these results were only observed in treatment BA. It
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is possible this could be due to the fact that the BA group only had 4 APOE ε4
carriers (who as mentioned above have a greater likelihood of not responding as much
to testosterone treatment), whereas the AB group had 8 out of the 22 participants
being APOE ε4 carriers.
The pattern of medial temporal atrophy observed in this study was shown to be
improved to some extent by testosterone treatment. Future studies carried out on a
larger cohort, possibly using longer treatment times and different doses, will determine
the significance of the current results, and evaluate the full potential of testosterone
treatment in the prevention or reduction of cognitive decline.
The results presented in this chapter have highlighted the importance of MRI as a
powerful biomarker and MRS as a potentially useful biomarker for evaluating
testosterone treatment. Both imaging biomarkers (MRI and MRS) would be more robust
if combined with additional biomarkers (such as blood biomarkers or PiB-PET
imaging). However, with MRS techniques being researched in earnest in recent years,
longitudinal studies may soon provide earlier and more accurate MRS-based diagnostic
tools. Future applications in the clinical setting may add such in vivo direct imaging
techniques to allow more accurate assessment of hippocampus volume as well as brain
metabolite changes, thus providing more useful diagnostic and treatment information.
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Chapter 9
General Discussion
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Extensive research has been undertaken, particularly in the last 20 years, to improve our
knowledge of androgen replacement therapy in the aging male, although conclusions
from this research, on many aspects, remain controversial. A marked reduction in
testosterone levels has a number of physiological and psychological effects. Recenly,
reduced testosterone has been linked to an increased risk of developing AD. This
testosterone effect on AD risk is thought to arise from testosterone’s numerous
influences on the brain and on A

metabolism. Firstly, testosterone is produced in the

testis, and a small amount reaches the brain and binds to the androgen receptor (AR) in
target cells, and this has been shown to provide some neuroprotection (in some studies
but not all) (Pike et al., 2006). Testosterone may also be aromatized into estradiol
(shown in many cell culture studies) (Haren et al., 2002) and estradiol has been shown
to influence Aβ levels (Gandy et al., 2001). Importantly,

testosterone levels are

inversely correlated with plasma Aβ levels (Gillet et al., 2003). Thus, many clinical
trials and animal studies are currently being undertaken to assess the potential of
testosterone as a neuroprotective agent.
In addition to testosterone, other hormones of the hypothalamic-pituitary-gonadal
(HPG) axis such as luteinizing hormone (LH) have also gained attention as evidence has
shown they may also influence the pathogenesis of AD. A marked reduction in
testosterone levels causes disruption to the HPG axis. The subsequent loss of negative
feedback by these hormones on the hypothalamus and pituitary leads to increased
release of LH levels. Compared to age-matched controls, serum levels of LH have been
shown to be higher in subjects with AD (Bowen et al., 2000; Short et al., 2001).
Furthermore, increased serum LH levels have been associated with poorer cognitive
performance in post-menopausal women (Rodrigues et al., 2008) and serum LH levels
have been found to correlate with plasma Aβ40 levels in cognitively normal elderly men
(Verdile et al., 2008). Coupled with findings that gonadotropin releasing hormone
(GnRH) agonists decrease Aβ levels in mouse brain (Bowen et al., 2004; Casadesus et
al., 2006), these findings indicate that increased gonadotropin levels, particularly LH
may be physiologically relevant in AD as they potentially modulate neurodegeneration
in the aging brain. It is unlikely that any one of the hormones from the HPG axis plays
a single and predominant role, but rather it may be a combination of hormones acting in
concert.
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While any specific underlying causes of AD are still yet to be determined, many risk
factors have been identified. Three such risk factors, which are most likely interdependent, were investigated in this thesis: lack of testosterone, elevated LH levels due
to the loss of negative feedback on the HPG axis, and increased Aβ levels. Many studies
have examined the relationship between these three risk factors and the development of
AD biomarkers. However, good randomized, double blind, placebo-controlled clinical
studies in aging men are still lacking. The research presented in this thesis examined the
cellular, structural and neuropsychological changes in response to exogenous
testosterone supplementation using two models of testosterone depletion. The first
involved in vivo validation of testosterone, LH and LH lowering agents in an animal
model (castrated Guinea Pig). The second involved a trial of testosterone in testosterone
deficient men with subjective memory complaints.

9.1 Effects of peripheral testosterone supplementation in castrated guinea pigs,
which were used as an animal model for low testosterone levels and impaired HPG
axis
A lack of the sex hormone testosterone results in increased pathology characteristics of
AD, including decreased expression of APP in the brain (particularly the hippocampus),
increased production of APP-CTF fragments and increased cerebral Aβ levels
(Drummond et al., 2009). The results presented in Chapter 3 show the effect of
exogenous testosterone administration on testosterone levels, Aβ, and APP and its
metabolites in castrated guinea pigs. As expected, castration of the guinea pigs (GDX)
caused a significant reduction in plasma testosterone levels, and the administration of
high levels of testosterone increased the plasma testosterone levels which progressively
returned to the non-GDX level. CSF Aβ40 levels in the guinea pigs increased after
castration and levels correlated with low testosterone levels. The administration of
testosterone, at either a low dose or high dose significantly reduced the CSF Aβ40
levels to non-GDX levels after 36 days. Nevertheless, the Aβ40 levels in plasma
increased significantly following testosterone administration in both the low dose and
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high dose testosterone supplementation. Thus, the testosterone appears to decrease
Aβ40 levels in the CNS, yet increase Aβ40 levels in the plasma. This phenomenon is
considered to be the result of rapid clearance from the brain, nevertheless further, more
extensive studies are needed to confirm this observation. The results suggest strongly
that the measurement of blood plasma Aβ levels only is not necessarily appropriate or
sufficient for the monitoring of testosterone therapy for AD prevention.
Interestingly, Aβ levels were found to be high in GDX hippocampi after 18 days of lowlevel testosterone supplementation, yet Aβ levels did normalize after 36 days. In
contrast, high-level testosterone supplementation resulted in a decrease in Aβ levels
after 18 days, with the same lower levels measured again at 36 days of supplementation,
suggesting Aβ levels had stabilised earlier on the higher dose. These findings suggest
that high testosterone levels can regulate Aβ levels in the blood and brain, especially in
the hippocampus, and that the testosterone levels can influence the time taken for
normal Aβ levels to be reached. Testosterone supplementation in the GDX was also
found to increase levels of α-APPs in the frontal cortex. This result suggests that
testosterone supplementation can influence the metabolism of α-APPs, an APP cleavage
product known to have a neuroprotective role, Increasing production of α-APPs has also
been associated with a decrease in production of Aβ. The results from Chapter 3 provide
further evidence of a role for reduced testosterone levels in AD pathogenesis.

9.2 Effects of CNS as well as peripheral administration of LH in castrated guinea
pigs
There is growing evidence that increases in gonadotropin levels associated with aging
may also contribute to AD pathogenesis. The results in Chapter 4 support this notion, as
results demonstrated that direct exposure of the brain to LH can cause a significant
increase in Aβ production, as measured in the frontal cortex and in the hippocampus,
resulting in an increase in CSF and cerebral Aβ levels. Furthermore, APP metabolites
were found to be altered in the hippocampus 28 days after LH administration. Hence,
the hippocampus appears to be a major target for LH. Unfortunately,

LH levels

couldn’t be directly measured in the guinea pigs. This study has revealed that LH
administration can increase Aβ production in the brain, yet in this case there were no
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increases in Aβ levels in the blood. Studies of LHR (-/-) APPsw mice have shown that
removing the LH receptor results in lower Aβ plaque deposition, less astrogliosis and
less tau phosphorylation (Lin et al., 2010).
It is not clear how LHR ablation reduces A

levels. The mRNA levels of enzymes

involved in the amyloidogenic and non-amyloidogenic APP cleavage pathways were
measured in the LHR (-/-) mice, as well as mRNA levels of A

degrading enzymes

such as insulin degrading enzyme and neutral endopeptidase, These mRNA levels were
found to be unchanged, suggesting post-translational mechanisms are involved in the
changes in A

levels. LH works not only through the LHR, but also through other

pathways that may influence the amyloidogenic process, thus the LH signalling
pathways in neurons are still not well understood. Other possibilities that need further
investigation include the role of astrocytes and microglia in removing A

from the

brain. Astrogliosis is believed by many to be a reaction to Aβ deposition, yet
astrogliosis is also known to inhibit microglial phagocytosis, an effect also likely to
reduce Aβ removal. Therefore, the mechanisms by which LH modulates Aβ metabolism
remain to be determined.

9.3 Effects of a peripheral LH lowering agent in castrated guinea pigs
Chapter 4 provided further evidence that LH levels can influence AD pathogenesis, as
direct application of human LH to the guinea pig CNS resulted in an accumulation of
Aβ in a similar manner to that reported for neuronal cells in culture and in vivo. In
Chapter 5 we did further investigations of LH, using LH implanted in the periphery. In
contrast with results in Chapter 4, the application of human LH to the guinea pig
periphery resulted in reduced cerebral Aβ levels. Although not consistent with findings
obtained in mouse models, it provides an interesting line of research that can be further
explored in the guinea pig.
Leuprolide, a potent GnRH agonist, was also used in this study to investigate further the
role of LH in guinea pigs. In vivo studies of leuprolide, as a suppressor of LH (to lower
endogenous LH (Ravivarapu, 2000), found that administration to female mice causes a
decrease in cerebral Aβ levels (Bowen et al., 2004; Casadesus et al., 2006). The results
348

of the experiments showed that leuprolide treatment can reduce Aβ40 levels in the
brains of guinea pigs, however the effect appears to be limited to the frontal cortex. The
concomitant trend toward increased α-APPs levels indicates that leuprolide may be
promoting the non-amyloidogenic pathway.
Testosterone reduces cerebral Aβ levels (Chapter 3) and LH increases CSF and cerebral
Aβ (Chapter 4). To explore these findings further, we tried to determine whether there
are additional benefits when these two treatments are combined, in other words, we
wished to determine if the effects are additive. Additional results from Chapter 5
suggest that there are no additional benefits with respect to Aβ levels when testosterone
treatment is combined with leuprolide treatment. However, the combined treatment may
be promoting the non-amyloidogenic pathway further, as indicated by a greater increase
in α-APPs levels. Taken together, this animal study has added further evidence of the
role of testosterone and LH on regulating Aβ. It has also shown a promising result for
future clinical study by modulating the testosterone as well as LH levels.

9.4 Effects of testosterone supplementation on blood biomarkers in testosterone
deficient men

There are lessons to be learned not only from the animal studies but also from clinical
studies which have investigated the effects of testosterone replacement therapy in men.
It is well known from the animal studies that the effects of testosterone mediated
through androgen receptors (AR) are widespread and complex, and influence certain
aspects of cognition and behaviour. Studies of exogenous testosterone administration in
men have provided mixed results. However, from studies of people with Subjective
Memory Complaints (SMC), Mild Cognitive Impairment (MCI) or AD, there does
appear to be an association between low testosterone levels and (increased) risk of AD.
A more comprehensive investigation of hormones, lipid profiles and related proteins,
such as total testosterone, dihydrotestosterone (DHT), estradiol, LH, cholesterol, LDL,
HDL, insulin, apolipoprotein E, sex-hormone binding globulin, and albumin is required
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to obtain a more complete picture of the interactions between the components of the
HPG axis, and to characterise better the effects of these interactions on Aβ metabolism.
From our clinical trial on elderly testosterone deficient men (Chapter 6), testosterone
treatment for 6 months caused a significant increase in plasma total testosterone levels,
which returned to baseline levels when the treatment was terminated. Similar results
were observed with DHT, an active testosterone metabolite, also a potent androgen that
cannot be aromatized to estrogen (Cunningham, 1989). However, a significant rise in
estradiol levels was not seen, which suggests there must have been greater conversion
of testosterone into DHT. These results are not unexpected, as the route of testosterone
administration favours this outcome: transdermal testosterone administration (as
opposed to intramuscular or by pellet) normally only raises estradiol levels slightly,
while quadrupling DHT levels, due to 5α-reductase enzymes in the skin (Swerdloff et
al., 2000). Consequently, testosterone treatment also resulted in a significant decrease in
LH levels, through the feedback mechanism on the HPG axis.
Testosterone and DHT treatment has been shown to influence lipoprotein levels, early
studies showed that both HDL and LDL levels could be lowered by transdermal DHT
treatment for 3 months (Vermuelen et al., 1985). Later studies then showed that the
effect of testosterone on lipoprotein metabolism was highly dependent on whether the
administration of testosterone resulted in physiological or supraphysiological
concentrations (Alexandersen et al., 2004). In accordance, the testosterone therapy
carried out in this study showed significant effects on HDL, such that a significant
decrease in levels was observed following testosterone treatment. However, out of the
lipoprotein components measured in these experiments, only HDL was found to change
significantly – there were no significant differences observed in cholesterol,
triglyceride, or LDL levels. In addition, testosterone treatment did not alter the
Chol/HDL or LDL/HDL ratios, recognized as major risk factors for cardiovascular
disease. The effects of testosterone treatment were not limited to lipoprotein
metabolism, insulin pathways were also affected. In accordance with previous studies
which showed that testosterone therapy can improve insulin sensitivity (Shabsigh, 2005;
Pasquali et al., 1991; Simon et al.,1992) the results from this study revealed a trend
towards increased insulin sensitivity following testosterone treatment. However, it is
important to note that the more one looks into relationships between testosterone
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replacement therapy and cholesterol, LDL, HDL, and insulin, the more complex and
variable the effects seem to be. The effects can vary due to the methods of testosterone
preparation and administration, the testosterone doses used, the duration of testosterone
treatments, and the ethnicity and age of the participants (Robert et al., 2000; Minneman
et al., 2008; Makinen et al., 2007).
In the elderly male, prostate cancer is common and its incidence increases with
increasing age (Bowen et al., 2000). Therefore a potential problem in terms of
testosterone treatment in elderly men is whether testosterone treatment increases the risk
of developing prostate cancer. The effects of testosterone treatment on the prostate are
very important when considering its safety, and for this purpose PSA (prostate specific
antigen) levels should be carefully monitored. The results in this study suggest that PSA
levels do not increase as a result of testosterone treatment, when carried out as done in
this study. Therefore, these results together with the almost unchanged lipid profile
suggest that the application of 100mg testosterone cream each day for 6 months is safe
and does not have any adverse effects.
Testosterone treatment was not found to influence plasma Aβ levels significantly. Both
Aβ40 and Aβ42 levels were measured and not found to be significantly different,
although there seemed to be a trend towards decreasing levels following testosterone
treatment.
This study hoped to estimate effects of testosterone treatment on CSF markers of AD.
The CSF biomarkers or analytes to be tested included Aβ42, total tau, phospho-tau,
tau/Aβ42, and phospho-tau/Aβ42. Unfortunately CSF collection is not a comfortable
procedure, and too few subjects were keen to have their CSF tested. The data that was
obtained

includes CSF data from three healthy (subjective memory complainer)

participants from the main clinical study and two participants who have been diagnosed
with AD from a side study (results not shown). As expected, AD participants had
significantly lower baseline CSF Aβ42 levels when compared to the healthy
participants. These low CSF Aβ42 levels reflect deposition of Aβ in plaques (Strozyk et
al., 2003; Tapiola et al., 2009). Overall, the testosterone treatment showed a trend
towards lowering CSF Aβ42 levels (although there was variation between individuals),
and raising the plasma Aβ42 levels in both the AD and non-AD participants. The
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number of participants clearly lowers the significance of these observations, yet the
observations are nevertheless encouraging. High CSF total tau and phospho-tau levels
would normally be expected in AD patients as a reflection of active axonal and neuronal
damage (Blennow et al., 1995). However, in this study, total tau and phospho-tau levels
in the AD participants were almost the same as those of the healthy (subjective memory
complainer) participants. In terms of testosterone effect on tau levels, this study
demonstrated that testosterone lowers tau (but not phospho-tau levels) in the healthy
participants, yet had no effect in the 2 AD participants (results not shown). Meanwhile,
changes in tau/Aβ42, and phospho-tau/Aβ42 were not observed.
ApoE plays an important role in the periphery as a mediator of lipoprotein metabolism
and lipid clearance. In the central nervous system, apoE plays a role in the redistribution
of lipids and cholesterol during membrane repair and it is believed to be important for
maintaining synaptic plasticity especially after neuronal injury. ApoE’s importance in
the central nervous system is underscored by the low abundance of other
apolipoproteins. ApoE has been linked to AD in many ways.

One of the first

indications that apoE might be involved in AD came from the immunochemical
localization of apoE in extracellular amyloid plaques and in neurons containing
neurofibrillary tangles (Wisniewski, 1992). It was then discovered that possession of
APOE4 alleles meant a higher risk of AD, and it was soon described as the main risk
factor for late onset AD. Many studies then found that, compared to the more common
apoE3 isoform, apoE4 enhances Aβ aggregation, increases Aβ deposition, and reduces
Aβ clearance (Schemechel, 1993; Berr et al., 1994) , whereas ApoE2 has a protective
effect (Corder et al., 1993). ApoE4 is also associated with poor neuronal repair. The
mechanism whereby apoE4 promotes AD is not yet established, it may involve more
than one of the above factors. Considerable evidence supports all of the above
mechanisms. For example, in vitro studies have also shown that all apoE isoforms
inhibit Aβ aggregation with apoE4 being less effective than apoE3 (Ma et al., 1994;
Moir et al., 1999; Sanan et al., 1994). Thus, the exact role of apoE is yet to be
elucidated.
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APOE allele status was also taken into account in this study. There were no significant
differences observed between APOE ε4 carriers and non-APOE ε4 carriers for all of the
blood measurements as well as BMI and body fat percentage. Participants with APOE
ε4 had a slightly higher BMI and body fat percentage when compared to participants not
carrying APOE ε4. Interestingly, there was no significant increase of total testosterone
levels in the APOE ε4 participants when compared with those who were non-APOE ε4.
The results suggest that APOE ε4 status might not be a determinant of testosterone
therapy response in this study. However, this result may have occurred due to the small
as well as unequal number of participants in regards to APOE ε4 allele status.
Furthermore, conflicting conclusions concerning the potential effects of APOE ε4 allele
status may also have arisen from differences in clinical study design.

9.5 Effects of testosterone supplementation on cognitive performances and quality
of life in testosterone deficient men

It has been known since the 1970s that circulating testosterone levels decline gradually
with age. More recently, the relationship between low levels of testosterone and
cognitive decline has been the subject of intense research since a number of studies
showed that hormone replacement therapy could reduce the risk of developing AD (in
men as well as in women). The results from Chapter 7 have added to the evidence
indicating that testosterone can improve cognition and quality of life in the elderly.
Cognitive function of the study participants (in general) improved with testosterone
therapy. Testosterone deficient men given testosterone treatment (in both arms of the
study) showed a significant increase in their MMSE scores. Neither age nor education
was a statistically significant factor when added as a covariate. Previous studies have
produced similar results, as high testosterone has been found to be associated with
improved performance in several cognitive tests (Barret-Connor et al., 1999), when
compared to men with lower plasma testosterone levels (Yaffe et al., 2002). For
example, testosterone supplementation in elderly men has been shown to improve
performance in working memory tasks (Janowski et al., 2000) and to improve spatial
cognition (Janowski et al., 1994). However, one study found that testosterone treatment
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had no effect on verbal memory and was negatively associated with verbal fluency in
men (Wolf et al., 2000). In line with Wolf et al., 2002, testosterone treatment in this
study have not shown an improvement in verbal memory.
In terms of quality of life, testosterone treatment was found to reduce depression
significantly in both arms of the study, as measured by Geriatric Depression Scale
(GDS). These results are in accordance with another study in which androgen depletion
by chemical castration resulted in an increase in depression (Almeida et al., 2003).
However, although testosterone treatment has been shown to improve muscle strength,
bone mineral density and some other symptoms of hypogonadism, improvements in
depression are not consistently found (Seidman, 2007) . In terms of physical health and
mental health, testosterone does not seem to have a significant effect in this study.
Overall, general cognitive screening instruments, which include the MMSE, RAVLT,
GDS, and SF36 have proven to be beneficial for monitoring effects of testosterone
treatment on cognitive function when used in a patient population with low testosterone
levels, who are at risk of cognitive impairment due to either age or the presence of
memory dysfunction.

9.6 Effects of testosterone supplementation on AD-related brain metabolites and
medial temporal structure in testosterone deficient men

Some of the more prominent early features of AD include mild memory impairment,
structural atrophy of the medial temporal lobe and changes in the levels of certain brain
metabolites such as myo-inositol (mI, thought to be a glial marker, increases in AD) and
N-acetyl aspartate (NAA, decreases in AD, interpreted as a marker of neuronal loss)
(Mizuno et al., 2000). Magnetic resonance spectroscopy (MRS) is used to detect
changes in NAA/creatine or mI/creatine, yet in our measurements summarised in
Chapter 8, it can be seen that no significant changes were detected in brain metabolite
levels following testosterone treatment. On the other hand, medial temporal atrophy
(MTA) was assessed using a standardised visual rating scale, and it was found that
testosterone treatment resulted in a reduction in atrophy by decreasing the MTA score
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by 1, regardless of sequence effect of the treatment (Chapter 8). Medial temporal lobe
atrophy seen in MRI is indeed macroscopic result of neuronal loss and synapses
(Bobinski et al., 2000)
The presence of APOE ε4 allele participants was investigated for the response to
testosterone treatment. Participants who started with high atrophy rates at their baseline
(MTA scale >2) have shown reduction of MTA scale following 6 months testosterone
treatment in both arms, even after pooling all of the participants. This effect was
observed in non-APOE ε4 carriers only but not in APOE ε4 carriers. These results may
indicate that the carriers of the APOE ε4 allele may not be responsive to testosterone
treatment in terms of modifying medial temporal atrophy. Another hypothesis is
testosterone effect on APOE ε4 participants (which have greater rates of atrophy
compared to non-APOE ε4) (Cohen et al., 2001) may only maintain the integrity of
medial temporal lobe structure, thereby preventing its atrophy rates.
In Chapter 6, a significant increase in the number of red blood cells was found to occur
following testosterone treatment. This increase in red blood cells is believed to help
regenerate stem cells proposed to stimulate hippocampal neurogenesis, which one might
assume would be reflected in an improvement in the MTA scale. However, given the
smaller potential of neurogenesis (DeCarolis, 2010), one can probably assume that the
effect of testosterone treatment as measured here is due to a reduction in brain atrophy.
In relation to cognitive performance and quality of life, testosterone treatment was
found to decrease depression to some extent, and in fact a positive correlation was
found between the reduction in medial temporal atrophy and the decrease in depression.
This supports previous studies which showed that stress or depression can damage the
hippocampus, leading to its atrophy (McEwen, 1999).
This study has demonstrated that medial temporal structure changes can be detected
even after a short time period. Such changes may allow assessment of a drug’s effect in
the prodromal phase of AD, such that any positive effects on atrophy may be
measurable prior to the appearance of detectable cognitive changes. Taken together, this
study has found that MRI, but not MRS may provide a potentially powerful biomarker
for early stages of AD.
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9.7 Conclusions

Our understanding of testosterone replacement therapy in the aging male has greatly
improved over the last 20 years. However, good randomized, double-blind, placebocontrolled clinical studies are still lacking. In Indonesia in particular, no such
testosterone clinical study as a potential approach for the prevention and treatment of
AD has been carried out till now. There is a need for longitudinal clinical studies to
help us to understand better whether testosterone replacement therapy is of value in the
prevention, delay and/or treatment of AD. This thesis has added to the growing
evidence that testosterone replacement in testosterone deficient patients (as well as in
animal models) has potential benefits with respect to brain health and cognition, and has
increased our understanding of likely side-effects. A combination of biomarkers : blood
measurements, neuropsychological assessment, CSF Aβ42 and tau measurements
(although in very limited samples), and neuroimaging tools (MRI and MRS)
investigated in this double-blind randomized placebo-controlled crossover study has
shown these markers to be most powerful tools in the early diagnosis of AD, in the
understanding of the pathophysiology of AD, and in the monitoring of AD treatment.
This study has also provided further evaluation of the safety of testosterone replacement
therapy, with results suggesting the therapy utilised here causes no increased risk of
prostate cancer or increased cardiovascular risk. Hence, if this study is initiated in the
right “critical time” following testosterone deficient men with future suggestions
applied, it will be a significant future implications for prevention as well as early
detection of AD. Taken together, the animal studies and human studies in this thesis
have demonstrated and explored further the links between testosterone, LH, and Aβ,
three main players in the pathogenesis of AD. Furthermore, this study suggests that,
with the aid of AD biomarkers mentioned above, there may be a window of opportunity
for the pre-symptomatic detection of AD, and the prevention, and/or delay of AD
symptoms in elderly testosterone deficient men using testosterone replacement therapy.
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Other potential treatments that can enhance androgen status include non-steroidal, small
molecule compounds (selective androgen receptor agonists (SARMS).These have high
affinity for the androgen receptors in the brain.There is the potential to signal through
the androgen receptor and only activate essential pathways (e.g. anabolic pathways in
the brain). SARMs are not commercially available yet, although investigations are
under way into the therapeutic implications for androgen deficient males, including
those with memory complaints. SARMS may also be safer for patients, since there is no
potential prostate stimulation. 7α-methyl-19-nor-testosterone (MENT), which is less
likely to stimulate the prostate, is 10 times more potent than testosterone.
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APPENDICES
Table 1 Individual Testosterone levels Treatment AB
Patient
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

APOE
E4 ‐
E4 ‐
E4 ‐
E4 ‐
E4 ‐
E4 ‐
E4 ‐
E4 ‐
E4 ‐
E4 ‐
E4 ‐
E4 ‐
E4 ‐
E4 ‐
E4 +
E4 +
E4 +
E4 +
E4 +
E4 +
E4 +
E4 +

T Baseline AB Mean T Testo AB Mean T Placebo AB Treatment effect AB*
9.53
24.48
8.10
16.38
14.21
32.12
18.69
13.43
25.97
37.67
23.09
14.58
19.87
18.38
15.61
2.76
17.23
16.95
14.32
2.63
23.09
26.29
17.88
8.41
17.44
23.02
19.91
3.11
20.04
25.67
15.81
9.86
17.72
30.31
18.34
11.97
11.68
9.01
10.37
‐1.35
14.42
20.31
12.78
7.53
16.33
28.83
14.89
13.94
13.24
20.03
19.23
0.80
9.85
21.56
9.78
11.78
16.75
27.58
15.36
12.22
22.09
38.73
21.54
17.18
18.34
42.33
16.64
25.69
21.67
31.76
20.19
11.57
13.83
37.56
13.12
24.44
16.09
39.05
15.56
23.50
10.82
20.05
10.27
9.77
12.07
30.43
10.09
20.34

*Treatment effect = mean Testosterone treatment – mean Placebo treatment
Only one participant had lower testosterone levels compared to placebo (yellow box).
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Table 2. Individual Testosterone levels Treatment BA
Patient
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

APOE
E4 ‐
E4 ‐
E4 ‐
E4 ‐
E4 ‐
E4 ‐
E4 ‐
E4 ‐
E4 ‐
E4 ‐
E4 ‐
E4 ‐
E4 ‐
E4 ‐
E4 ‐
E4 ‐
E4 ‐
E4 ‐
E4 +
E4 +
E4 +
E4 +

T Baseline BA Mean T Placebo BA Mean T Testo BA Treatment effect BA*
17.13
17.70
67.84
50.14
24.03
19.27
30.78
11.51
11.55
11.27
30.26
18.98
14.98
13.02
18.09
5.07
24.89
21.21
31.90
10.69
10.30
13.33
16.25
2.92
14.73
15.36
15.64
0.27
21.81
28.20
27.97
‐0.23
19.10
17.66
22.47
4.80
22.78
24.55
47.95
23.40
14.46
13.46
26.06
12.60
20.94
18.10
33.82
15.72
19.31
19.00
23.28
4.28
27.77
28.52
22.70
‐5.82
23.85
20.22
48.47
28.24
10.40
12.67
16.58
3.92
17.96
17.55
33.30
15.74
11.06
14.32
17.95
3.62
25.34
21.98
29.48
7.51
9.08
15.53
23.11
7.59
14.60
15.08
9.60
‐5.47
21.29
16.07
8.78
‐7.29

*Treatment effect = mean Testosterone treatment – mean Placebo treatment
Four participants had lower testosterone levels compared to placebo (yellow boxes).

364

Table 3. Individual DHT levels Treatment AB
Patient APOE
1 E4 ‐
2 E4 ‐
3 E4 ‐
4 E4 ‐
5 E4 ‐
6 E4 ‐
7 E4 ‐
8 E4 ‐
9 E4 ‐
10 E4 ‐
11 E4 ‐
12 E4 ‐
13 E4 ‐
14 E4 ‐
15 E4 +
16 E4 +
17 E4 +
18 E4 +
19 E4 +
20 E4 +
21 E4 +
22 E4 +

DHT Baseline AB Mean DHT Testo AB Mean DHT Placebo AB Treatment effect AB*
0.90
7.06
1.17
5.89
2.53
11.75
2.59
9.16
3.57
11.93
2.38
9.55
2.43
6.58
2.02
4.55
2.36
4.30
1.35
2.95
1.04
9.03
1.29
7.74
1.59
8.71
2.87
5.84
2.57
8.96
1.40
7.56
3.05
8.77
1.81
6.96
1.42
2.40
1.76
0.64
1.59
10.01
1.62
8.39
1.59
7.87
2.07
5.80
0.60
5.27
1.71
3.56
0.62
5.48
1.55
3.92
3.22
16.77
2.32
14.45
2.08
16.81
1.58
15.23
3.16
15.19
2.92
12.26
1.77
10.86
1.51
9.34
1.53
11.82
0.26
11.56
1.18
6.78
1.14
5.63
0.67
5.15
1.05
4.10
1.03
8.40
1.02
7.37

*Treatment effect = mean Testosterone treatment – mean Placebo treatment
All participants had some increase in DHT levels, although the increase did vary
widely.
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Table 4. Individual DHT levels Treatment BA
DHT
Mean DHT Placebo Mean DHT Testo Treatment
Patient APOE Baseline BA
BA
BA
BA*
1 E4 3.50
3.43
18.8
2 E4 4.19
3.16
12.4
3 E4 1.76
1.31
7.83
4 E4 1.20
1.26
4.71
5 E4 2.04
1.42
3.31
6 E4 1.07
1.82
7.06
7 E4 3.27
1.38
7.39
8 E4 2.95
3.13
4.90
9 E4 1.66
1.87
6.47
10 E4 2.79
2.57
13.1
11 E4 1.57
1.61
8.55
12 E4 1.96
1.52
13.1
13 E4 1.80
1.11
5.61
14 E4 2.17
2.01
10.1
15 E4 1.52
1.65
13.5
16 E4 1.64
1.16
5.92
17 E4 1.21
1.12
8.51
18 E4 2.32
0.98
10.6
19 E4 +
2.57
2.17
14.1
20 E4 +
0.51
3.35
6.95
21 E4 +
1.92
1.92
3.16
22 E4 +
2.04
1.79
4.94

*Treatment effect = mean Testosterone treatment – mean Placebo treatment
All participants had some increase in DHT levels, although the increase did vary
widely.
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effect
15.4
9.28
6.52
3.45
1.88
5.23
6.01
1.76
4.59
10.5
6.93
11.6
4.50
8.10
11.8
4.76
7.38
9.65
11.9
3.60
1.23
3.15

Table 5. Individual Estradiol levels Treatment AB

Patient APOE
1
E4 2
E4 3
E4 4
E4 5
E4 6
E4 7
E4 8
E4 9
E4 10
E4 11
E4 12
E4 13
E4 14
E4 15
E4 +
16
E4 +
17
E4 +
18
E4 +
19
E4 +
20
E4 +
21
E4 +
22
E4 +

E
Baseline
AB
60
60
80
80
50
60
100
100
80
90
80
140
90
50
90
60
50
120
90
90
80
80

Mean E Testo
AB
101.7
103.3
93.3
56.7
43.3
53.3
86.7
75
66.7
93.3
93.3
145
91. 7
45
90
50
120
118.3
83.3
76.7
80
121.7

Mean E
Placebo AB
70
86. 7
80
73.3
46. 7
70
96. 7
83.3
96. 7
86. 7
56.7
133.3
130
60
73.3
70
86. 7
93.3
110
56. 7
90
83.3

Treatment effect
AB*
31.7
16.7
13.3
-16. 7
-3.33
-16.7
-10
-8.33
-30
6.67
36.7
11.7
-38.3
-15
16.7
-20
33.3
25
-26.7
20
-10
38.3

*Treatment effect = mean Testosterone treatment – mean Placebo treatment
11 participants had lower estradiol levels compared to placebo (yellow boxes), 2
participants started with high estradiol levels at baseline.
Normal reference range = 10-82 pg/mL
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Table 6. Individual Estradiol levels Treatment BA
Patient
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

APOE
E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 +
E4 +
E4 +
E4 +

E
Baseline Mean E Placebo
Treatment
BA
BA
Mean E Testo BA effect BA*
70
80
210
130
88.3
106.7
18.3
130
100
88.3
106.7
18.3
40
41.6
40
-1.67
50
46.7
53.3
6.67
40
45
46.7
1.67
50
53.3
46.7
-6.67
80
80
60
-20
100
83.3
83.3
0
50
60
100
40
100
105
96.7
-8.33
70
66.7
130
63.3
90
66.7
70
3.33
90
51.6
63.3
11.7
90
68.3
75
143.3
60
65
66.7
1.67
173
210
36.6
130
40
43.3
60
16.6
80
80
83.33
3.33
70
58.3
83.3
25
110
91.6
73.3
-18.3
93.3
93.3
0
120

*Treatment effect = mean Testosterone treatment – mean Placebo treatment
5 participants had lower estradiol levels compared to placebo (yellow boxes), 3
participants started with high estradiol levels at baseline.
Normal reference range = 10-82 pg/mL
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Table 7. Individual Body Mass Index (BMI) Treatment AB
Patient
ID

APO BMI Baseline BMI The End BMI The End Treatment
E
AB
of Testo AB
of Placebo AB
AB
1 E4 23.1
25.2
27
2 E4 21.2
21
20.9
3 E4 23.9
24.9
24.9
4 E4 23.1
23.3
23.3
5 E4 29.8
29.1
28.4
6 E4 30
28.5
29.7
7 E4 25.6
25.4
25.2
8 E4 25.7
27
27.4
9 E4 23.7
24.1
23.8
10 E4 28.2
29.5
29.4
11 E4 27.1
27.2
27.5
12 E4 23
24.2
23.7
13 E4 25.8
25.1
25.6
14 E4 24.6
24.4
24
15 E4 +
21.8
23.9
24.2
16 E4 +
24.4
24.1
23.8
17 E4 +
28.7
27.1
27.2
18 E4 +
26.6
26.2
25.7
19 E4 +
21.8
21.9
21.7
20 E4 +
32.4
32.5
32.3
21 E4 +
33.9
34.1
33.2
22 E4 +
32.6
32.4
32.5
*Treatment effect = mean Testosterone treatment – mean Placebo treatment
8 participants had lower BMI compared to placebo (yellow boxes), 8 participants were
obese, 11 participants were overweight and 3 participants were underweight at baseline.
Normal reference range = 16-19 kg/m2, cut off score of 22 kg/m2 considered to be
overweight, 27 kg/m2 as obese (WHO).
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effect
-2.1
0.1
0
0
0.7
-1.2
0.2
-0.4
0.3
0.1
-0.3
0.5
-0.5
0.4
-0.3
0.3
-0.1
0.5
0.2
0.2
0.9
-0.1

Table 8. Individual Body Mass Index (BMI) Treatment BA
Patien
t ID
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

AP
OE
E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4
+
E4
+
E4
+
E4
+

BMI
Baseline
BMI The End of BMI The End of Treatment
BA
Placebo BA
Testo BA
effect BA
25.3
26
26.4
0.4
22.4
21.5
20.9
-0.6
-1
28.2
28.7
27.7
24.5
24.8
23.8
-1
22.4
22.6
23.6
1
26.5
-2
27.8
28.5
21.1
20.1
20
-0.1
22.4
22.3
21.8
-0.5
25.5
25.2
25.7
0.5
13.6
14.8
14
-0.8
26.9
26.7
-0.7
27.4
26.4
26.1
26
-0.1
21.6
20.3
19.6
-0.7
24.2
25.6
24.6
-1
19.3
18.8
19.4
0.6
26.6
25.9
25.2
-0.7
0.4
31
31
31.4
26.1
26.4
26.2
-0.2
23.7

23.9

24.2

0.3

30.1

30.3

29.4

-0.9

20.9

23.3

24

0.7

23.5

24.2

24.6

0.4

*Treatment effect = mean Testosterone treatment – mean Placebo treatment
14 participants had lower BMI compared to placebo (yellow boxes), 4 participants were
obese, 13 participants were overweight, and 5 participants were underweight at baseline.
Normal reference range = 16-19 kg/m2, cut off score of 22 kg/m2 considered to be
overweight, 27 kg/m2 as obese (WHO)

370

Table 9. Individual Body Fat Percentage Treatment AB
BF
AP Baseline
BF The End of BF The End of Treatment
OE AB
Testo AB
Placebo AB
effect AB*
E4 25.4
24.7
25.4
-0.7
E4 17
15.8
17
-1.2
E4 19.3
20.7
21.5
-0.8
E4 18.1
18.5
20
-1.5
E4 0.8
33.1
32.5
31.7
E4 0.2
27.3
28.1
27.9
E4 21.5
20.6
21.8
-1.2
E4 20.2
23.6
22.1
1.5
E4 22.4
21.3
21.8
-0.5
E4 27
0.8
28.2
27.4
E4 26.2
26.8
-2.3
29.1
E4 19.9
21.2
20.1
1.1
E4 22.3
19.7
19.8
-0.1
E4 22.3
23.2
23.1
0.1
E4
15
+
14.5
18.7
19.4
-0.7
E4
16
+
24.6
23.9
23
0.9
E4
17
+
19.8
20.2
17.3
2.9
E4
18
+
23.1
23.5
24.3
-0.8
E4
19
+
22.2
21.5
21.1
0.4
E4
20
+
-2.2
32.5
32
34.2
E4
21
+
2.4
35.4
32.8
30.4
E4
22
+
1.5
32.5
29.5
28
*Treatment effect = mean Testosterone treatment – mean Placebo treatment
Patien
t ID
1
2
3
4
5
6
7
8
9
10
11
12
13
14

11 participants had a lower body fat percentage compared to placebo (yellow boxes), 5
participants were obese at baseline.
Cut off score of 27% considered as obese (Gallagher et al. Am J Clin Nut 2000;
72:694-701)
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Table 10. Individual Body Fat Percentage Treatment BA
BF
AP Baseline
BF The End of BF The End of Treatment
OE BA
Placebo BA
Testo BA
effect BA*
E4 20.7
21.5
22.7
1.2
E4 19.5
19.1
17.5
-1.6
E4 -0.1
27.3
27.9
27.8
E4 22.3
23
21.7
-1.3
E4 15.9
16.6
19.2
2.6
E4 25.1
-6.2
29.1
31.3
E4 17.6
15.6
14.3
-1.3
E4 15.7
15.9
14.8
-1.1
E4 26.2
24.9
3.9
28.8
E4 2.5
5.7
3.6
-2.1
E4 25.4
26.6
-2.2
28.8
E4 20.5
22.2
19.8
-2.4
E4 15.8
15.4
13.5
-1.9
E4 21.9
23.2
23.4
0.2
E4 13.8
13
14.4
1.4
E4 27
0.5
28.8
27.5
E4 -1.7
27.9
28.9
27.2
E4 25.3
25.5
26.4
0.9
E4
19
+
22.9
22.9
25.6
2.7
E4
20
+
-0.3
28.6
29.2
28.9
E4
21
+
19.1
19.6
17.8
-1.8
E4
22
+
22.2
23.7
24.1
0.4
*Treatment effect = mean Testosterone treatment – mean Placebo treatment
Patien
t ID
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

13 participants had a lower body fat percentage compared to placebo (yellow boxes), 5
participants were obese at baseline.
Cut off score of 27% considered as obese (Gallagher et al. Am J Clin Nut 2000;
72:694-701)
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Lipid profile classification based on Total Cholesterol baseline threshold levels
Treatment AB
HDL :
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LDL :
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Total Cholesterol :
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Lipid profile classification based on Total Cholesterol baseline threshold levels
Treatment BA
HDL :

376

LDL :

Total Cholesterol :
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378

Total Cholesterol Treshold levels (at Baseline) :
< 4.6 mmol/L = low
4.6 – 5.2 mmol/L = desirable
5.3 – 6.2 mmol/L = moderate
> 6.2 mmol/L = high

All of the participants in the two arms of the study started with low, desirable, or
moderate levels of total cholesterol levels at baseline.
From the graphs above, in treatment arm AB, we can see that those who started off
with higher than normal (desirable) levels of total cholesterol showed significant
decreases in total cholesterol, LDL, and HDL following testosterone treatment. For
those who started off with low and desirable total cholesterol levels at baseline, it may
be that the treatment was not able to reduce levels further, because the body’s
metabolism compensated and produced cholesterol to maintain cholesterol levels above
a certain minimum level. Therefore, these people were not likely to show any change.
Thus, the results from the participants who started off with low and normal levels of
total cholesterol may have masked any significant changes in partipants who started off
with moderate total cholesterol. Meanwhile, in treatment arm BA, no significant
changes were observed in those participants who started off with moderate total
cholesterol levels. This may be due to the small number of participants, which was only
4. No significant changes were observed in those participants with low or moderate
starting total cholesterol levels (as observed in the previous arm).
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